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ABSTRACT

Pancreatic adenocarcinoma (PDAC) remains one of the most lethal cancer types, with
92% of patients succumbing to the disease within five years. One of the hallmarks of
this intractable disease is its nearly universal resistance to chemotherapeutic
intervention. The deoxycytidine analog gemcitabine persists as the primary
chemotherapy for advanced PDAC patients despite little improvement to its toxicity
and tenuous efficacy over the past two decades. Plant‐based drug discovery has a
longstanding history and has led to some of the most significant drugs of the modern
era, including some chemotherapeutic agents like paclitaxel and camptothecin. Our
study analyzed the potential inhibitory effects of herbal extracts against pancreatic
cancer cells. We selected a panel of extracts based on their history of pancreas‐specific
action and their current use in clinics which employ traditional Chinese medicine
(TCM). Initial data indicated that the extract of Anemarrhena asphodeloides (AA) exhibited
a significant dose‐dependent decrease in PDAC cell viability. The potentially cytotoxic
effects of AA had not previously been examined in pancreatic cancer prior to our study.
We examined the effects of AA and one of its constituents, timosaponin‐AIII (TAIII), as
viii

well as AA or TAIII plus gemcitabine on PDAC cell viability via MTT assay. Flow
cytometric analysis revealed dysfunctional cell cycle progression in PDAC cells treated
with AA and TAIII alone and in combination with gemcitabine. We utilized a magnetic
bead‐based multiplex assay to determine the effects of these treatments on the
expression and activation of Akt signaling pathway members and observed a marked
decrease in anti‐apoptotic protein activation along with an increase in the activation of
pro‐apoptotic proteins compared to cells treated with gemcitabine alone. The effect of
AA and TAIII on gemcitabine sensitivity in PDAC cells was elucidated through the
determination of transcriptional and protein expression of gemcitabine uptake and
metabolism mechanisms. Finally, a luminescent‐based kinase assay revealed that
activity of the rate‐limiting kinase in gemcitabine activation, deoxycytidine kinase
(dCK), was notably increased in the cells treated with AA or TAIII compared to
gemcitabine. Taken together, the results of our present study implicates AA as a
significant inhibitor of PDAC cell progression as well as a potential adjunctive
therapeutic agent which can enhance gemcitabine efficacy within advanced pancreatic
cancer.
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CHAPTER ONE:
INTRODUCTION

1. Pancreatic Cancer
1.1. Epidemiology
Cancer of the pancreas is one of the most lethal cancers with nearly equal incidence and
mortality rates. Currently the fourth leading cause of cancer‐related deaths in men and
women in the United States, pancreatic cancer is projected to become the second
leading cause of cancer deaths by the year 2030 [1, 2]. The classification of pancreatic
cancer is bifurcated into distinct categories based on the cells from which the primary
tumor arises. The pancreas is a complex organ with endocrine and exocrine functions
responsible for the regulation of several processes within the body including glucose
homeostasis and digestion. The pancreas is primarily comprised of exocrine cells and as
such, exocrine pancreatic cancers are appreciably more common than endocrine‐
derived tumors. Pancreatic adenocarcinoma accounts for approximately 95% of all
exocrine pancreatic cancers; henceforth, the term “pancreatic cancer” will refer to
pancreatic adenocarcinoma (PDAC). The acute lethality associated with pancreatic

1

cancer is due to an amalgam of circumstances which impede early detection and
intervention such as non‐specific symptoms, a lack of screening methods, and
ineffective treatment options. Over half of all pancreatic cancer diagnoses are made
when the disease has already spread to distant sites, for which the 5‐year survival rate
is 3% [2]. Metastases can occur in several sites throughout the body but are commonly
found in the liver, lungs, peritoneum, and adrenal glands [3]. Even among those
patients whose disease is detected early enough and undergo pancreatic head resection,
the overall 5‐year survival rate remains dismally low at a range of 10‐25% [4, 5].

1.2. Etiology
The precise causes of pancreatic cancer have not yet been elucidated, but studies have
identified risk factors that may potentially increase the chance of developing pancreatic
cancer. Those at high risk of developing pancreatic cancer, due to multiple first‐order
relatives diagnosed with pancreatic cancer or certain inheritable conditions like Peutz‐
Jeghers syndrome and hereditary pancreatitis syndrome, where the risk of developing
PDAC is increased 132‐ and 26.3‐fold, respectively, are urged to receive genetic testing
and undergo screening protocols that are not recommended for the general public [6, 7].
Other risk factors include smoking, obesity, and chronic pancreatitis [8]. It is important
to note, however, that while these factors have been associated with an increased risk of
developing pancreatic cancer compared to the general population, the majority of
2

diagnosed patients do not have any of the listed risk factors. The current model of
pancreatic tumorigenesis proposes three distinct types of precursor lesions whose
stepwise progression can lead to the development of invasive carcinoma (Fig. 1) [9]. The
most common among them is the small pancreatic intraepithelial neoplasia (PanIN).
PanINs range in degree with increasing severity from PanIN‐1A and 1B, which are
common and seldom malignant, to PanIN‐3 which are considerably rarer, however,
typically lead to invasive carcinoma. The other two types of precursor lesions,
Intraductal Papillary Mucinous Neoplasm (IPMN) and Mucinous Cystic Neoplasm
(MCN), are larger, fluid‐filled, and also vary in degree from low‐ to high‐grade
dysplasia. If an IPMN or MCN is detected, the decision to surgically remove it is
subjective and predicated on the location and size of the lesion, as well as the patient’s
age and genetic predisposition for pancreatic cancer [10]. Adding to the enigmatic
nature of the disease, there is ambiguity regarding the cell of origin for PDAC tumors.
Since it is classified as a ductal adenocarcinoma the logical conclusion would be that
ductal cells are the cells of origin; however, studies have demonstrated that targeted
expression of mutant KRAS in ductal cells fails to induce the formation of PanINs or
PDAC while mutant KRAS‐expressing acinar cells in mice can become reprogrammed
into ductal cells leading to PanIN formation (Fig. 2) [11‐14].
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1.3. Clinical Characteristics
One of the contributing factors to pancreatic cancer’s lethality is the fact that it is
difficult to detect and diagnose before it has reached late stages. Indeed, only
approximately 15‐20% of patients present with a resectable disease at the time of
diagnosis [15]. This is in part because in its early stages, pancreatic cancer is generally
asymptomatic and any symptoms that may arise in later stages such as abdomen and
back pain, jaundice, weight loss, nausea, loss of appetite, changes in bowel movements,
pancreatitis, and recent‐onset of diabetes can often be misinterpreted as symptoms of
other, more common ailments. These symptoms are usually caused by physical changes
to the pancreas due to the tumor. Pain in the abdomen or back may be due to the tumor
putting pressure on nearby nerves or organs; jaundice can result when the tumor
enlarges and obstructs the common bile duct and causes an accumulation of bilirubin in
the body; recent‐onset type 2 diabetes can occur if the growing tumor damages
endocrine cells and prevents them from producing or utilizing insulin.

1.4. Detection and Diagnosis
1.4.1. Clinical Diagnosis
Physical examination of the pancreas is hindered by its location behind the stomach,
and there are currently no screening or biomarker tests available for the early detection
of pancreatic cancer. Blood tests for certain tumor markers such as carbohydrate antigen
4

19‐9 (CA 19‐9) and carcinoembryonic antigen (CEA) were once hailed as potential
diagnostic indicators for the detection of pancreatic cancer; however, subsequent
studies have repeatedly shown that neither marker is specific to pancreatic cancer nor
sensitive enough to prevent false positives [16‐18]. Additional limitations render these
markers inadequate as diagnostic implements, still CA 19‐9 and CEA levels are
sometimes monitored and used as a prognostic indicator of treatment efficacy or tumor
progression in select subsets of diagnosed patients. Detection and diagnosis of
pancreatic cancer are performed using a combination of assessments including several
imaging techniques, physical examination, medical history, blood chemistry tests, and
biopsy. Upon diagnosis, a classification system is used to determine the stage based on
the extent of the tumor’s size, spread to local lymph nodes, and existence of distant
metastases (Fig. 3). The stage generally dictates what treatment options are to be used,
though there can be variability among patients whose tumors are in the same stage.

1.4.2. Early Detection and Biomarker Studies
Detection of the disease at early stages when the tumor is more responsive to
intervention offers the greatest chance of increasing survivability for pancreatic cancer
patients. Analysis of the genetic evolution of PDAC tumors indicates a span of at least
fifteen years between the initiating mutational event and eventual dissemination,
providing an opportunity for early detection and potentially curative measures [19].
5

Various biological molecules such as proteins, circulating tumor DNA (ctDNA),
miRNA, epigenetic modifications, circulating tumor cells (CTCs), and extracellular
vesicles like exosomes can be used as biomarkers. A successful biomarker should be
non‐ or minimally invasive, highly sensitive and specific, and able to differentiate
between dysplasia and cancer [20]. Specificity is of particular importance since a
positive result may lead to invasive measures, which carry their own risk of morbidity
and mortality. In addition to these criteria, an effective pancreatic cancer biomarker
requires the capacity to distinguish the presence of pancreatic cancer from that of other
conditions including pancreatitis, diabetes, and other gastrointestinal cancers. The
Recalcitrant Cancer Research Act, which calls on the NCI to develop frameworks
specifically for pancreatic, lung, and other highly lethal cancers with a 5‐year survival
rate less than 20%, was signed into law in 2013. One of the initiatives created under the
Act is the Pancreatic Cancer Detection Consortium (PCDC). The PCDC was formed
under the NCI’s Division of Cancer Prevention with the main objective of developing
and testing novel molecular and imaging biomarkers that will improve the early
detection of PDAC and its precursor lesions. Also in response to the Recalcitrant Cancer
Research Act, several cancer centers and research universities have launched pancreatic
cancer early detection research platforms with the intent of developing novel
biomarkers, blood tests, and therapeutic strategies. Several challenges have historically
impeded progress toward effective pancreatic cancer biomarkers and early detection
6

modalities which efforts like the PCDC and pancreatic cancer early detection initiatives
seek to address through new paradigms of innovation, collaboration, and scale. Access
to a range of well‐characterized tumor specimens which can be utilized for biomarker
identification and validation has been limited. Late stage diagnosis and the rapid
deterioration of patients have led to a lack of well‐annotated specimens, particularly
those from early or premalignant stages. Additionally, very few resections are
performed in locations which characterize and store the specimens for research
purposes. Adequate funding for biomarker development has also been lacking under
traditional funding mechanisms. Finally, the inability of researchers to utilize existing
resources within institutions and universities to assist in the identification and
validation of biomarkers has also hindered advancement in the field. The goal of all of
these programs is to create a vast network of researchers and repositories to develop
new and innovative approaches to detection and treatment so that tumors can be
identified and patients can receive intervention at a potentially curable stage.

1.5. Molecular Characteristics
1.5.1. Mutational Landscape
1.5.1.1. Driver mutations
Genomic analysis has revealed that the mutational landscape of pancreatic cancer is a
complex compendium of inherited and acquired mutations that accumulate during the
7

evolution from precursor lesions to invasive disease. Drastic genetic variability exists
between pancreatic cancer patients; however, characteristic driver mutations resulting
in the oncogenic activation of Kirsten rat sarcoma viral oncogene homolog (KRAS) and
inactivation of cyclin dependent kinase inhibitor 2A (CDK2NA), tumor protein 53
(TP53), and SMAD family member 4 (SMAD4) tumor suppressor genes have been
demonstrated in 92‐100%, 74‐83%, 31‐33%, and 35‐75% of analyzed tumor specimens,
respectively [21]. Indeed, the generation of genetically engineered mouse models which
spontaneously acquire pancreatic cancer required the accumulation of specific driver
mutations. In 2005, Higorani et al. interbred conditional LSL‐Trp53R172H/+, LSL‐KrasG12D/+,
and Pdx‐1‐Cre mice strains to obtain triple mutant KPC mice [22]. Conditional targeting
of point mutations in KRAS and TP53, specifically in the pancreas via the Pdx‐1
promoter, leads to PanIN formation and progression to invasive and metastatic
pancreatic cancer in triple mutant KPC mice which mirrors the human disease in its
clinical, histopathological, and genomic instability patterns. Since the progression of
pancreatic cancer in the KPC mouse represents the human disease so closely, it is one of
the most relevant preclinical models of PDAC available [23]. The tumors that develop in
KPC mice are generally gemcitabine‐resistant, further solidifying the model as a genetic
and phenotypic representative of the human malignancy [24]. Genomic analyses
continue to support the basic progression model in which these characteristic mutations
drive the progression and invasiveness of pancreatic cancer, and numerous studies
8

have been performed to elucidate whether they may potentially serve as prognostic
biomarkers in patients. While the discovery of these driver mutations helped advance
our understanding of the enigmatic disease, improvements in diagnostic and
therapeutic strategies based on this information still did not lead to significant advances
in patient outcome [25]. In addition to the classic driver mutations, advances in
genome‐wide sequencing have revealed the presence of several other frequently altered
genes, signaling pathways, and structural and epigenetic variations in patient
specimens and murine models that characterize pancreatic cancer.

1.5.1.1.1 KRAS
Activated KRAS is particularly significant in pancreatic tumorigenesis as it is found in
nearly all patients and is the predominant initiating genetic alteration in low‐grade
precursor lesions [26‐28]. The KRAS gene encodes the KRAS protein, a small GTPase
which facilitates signal transduction across the cell membrane and interacts with several
cell growth signaling networks such as the Rat sarcoma (RAS)/mitogen‐activated
protein kinases (MAPK) and phosphatidylinositiol 3‐kinase (PI3K) pathways. Under
normal conditions, KRAS is bound to GDP in its inactive state and becomes activated
when bound by GTP. Since it is a GTPase, KRAS can inactivate itself by hydrolyzing
GTP, however additional GTPase‐activating proteins such as guanine‐nucleotide
exchange factors are usually required to facilitate efficient inactivation [29]. Oncogenic
9

activation of KRAS is typically achieved through a point mutation on codon 12 in which
glycine is replaced by aspartic acid, valine, arginine, or serine. Mutations can also occur
on codons 13 and 61, though these are far less common [30]. This glycine substitution
leads to impaired intrinsic GTPase activity and prevents the ability to bind to GTPase‐
activating proteins, resulting in a perpetual state of active KRAS [31]. The crucial role of
oncogenic KRAS in pancreatic cancer tumorigenesis and progression has led to
tremendous efforts to therapeutically target its activity. However, several failed clinical
attempts have demonstrated that direct targeting is not feasible due to cross activation
of up‐ and downstream effector molecules within the pathway. For instance, since the
KRAS protein requires farnesylation to interact with its activating proteins within the
plasma membrane, farnesyltransferase inhibitors (FTIs) were clinically evaluated for
their ability to target oncogenic KRAS activity [32, 33]. A phase III study compared the
overall survival of advanced, unresectable PDAC patients treated with gemcitabine
plus the FTI tipifarnib to those treated with gemcitabine plus a placebo and found no
advantage in overall survival [34]. Additionally, clinical trials testing the efficacy of
MEK1/2 inhibitors resulted in no significant difference in overall survival [35]. Rigorous
attempts have since been made to elucidate therapeutic combinations that may be able
to suppress multiple members of the complex signaling network [36].
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1.5.1.1.2 CDKN2A
CDKN2A encodes two proteins due to alternative reading frames, the p16INK4A and
p14ARF tumor suppressors, and is inactivated in up to 95% of PDAC tumors making it
the most frequently inactivated tumor suppressor gene in PDAC [37]. Modifications in
CDKN2A gene function can occur through loss of heterozygosity, homozygous deletion,
or promoter silencing. Functional p16INK4A arrests cell proliferation by inhibiting cyclin
D‐dependent kinases CDK4 and CDK6 and prevents entry into S‐phase of the cell cycle
by obstructing the phosphorylation of the retinoblastoma protein (Rb) [38]. The p14ARF
protein also negatively regulates cell growth and functions by inhibiting p53
ubiquitination and degradation induced by MDM2 [39]. Approximately 40% of p16INK4A
inactivation is due to homozygous deletion of the CDKN2A gene, which consequently
also inactivates p14ARF [40].

1.5.1.1.3 TP53
TP53 is a gene encoding the p53 tumor suppressor transcription factor which regulates
numerous critical cellular operations and represents one of the most frequent mutations
in the progression of pancreatic tumors [41, 42]. While the sum of its amino acid
residues is 43.7 kDa, p53 was so named due to its apparent mass of 53 kDa when run on
SDS‐polyacrylamide gels [43]. Mutations and deletions in TP53 occur in more than 50%
of all human cancers and is one of the most widely studied tumor suppressors. In
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recognition of its central role in regulating cell growth, DNA repair, and apoptosis, p53
has been aptly termed the “guardian of the genome” and “cellular gatekeeper” [44, 45].
Under normal conditions, levels of p53 are tightly regulated and remain low to limit cell
survival and proliferation. When a cellular stress induces its activation, p53 is stabilized
either via amino‐terminal phosphorylation which disrupts MDM2‐mediated
ubiquitination or through the antagonism of the MDM2‐p53 complex by p14ARF, causing
its cellular levels to rise [46, 47]. Active p53 then binds to specific DNA sequences to
activate or repress the expression of its target genes. Once the appropriate cellular
functions have been performed, the kinase responsible for activating p53 becomes
inactive. This leads to an accumulation of non‐phosphorylated p53 which forms a
complex with MDM2 and subsequently undergoes ubiquitin‐mediated degradation.
Mutations in TP53 commonly occur as missense point mutations in regions which affect
DNA binding and lead to the loss of p53 transcription factor function [48]. The p53
tumor suppressor represents a rare departure from the classic two‐hit hypothesis in
which tumor suppressors require biallelic mutations. Because p53 functions as a
tetramer, mutations in a single allele result in a dominant‐negative influence over the
expressed WT p53 allele [49]. Unlike CDKN2A inactivation which occurs in early and
intermediate PanIN stages, the loss of p53 function happens late in the development of
PDAC tumors [50]. The appearance of TP53 mutations late in pancreatic tumor
development suggests its role in the evolution to an advanced, metastatic disease state.
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Indeed, aberrant p53 expression is correlated with a poor prognosis and higher rate of
metastasis in pancreatic cancer patients [51, 52].

1.5.1.1.4 SMAD4
The SMAD4 gene encodes the SMAD4 tumor suppressor protein and is inactivated in
approximately 50% of pancreatic cancers, often as a late event in its progression [50, 53,
54]. Functional SMAD4 forms a heterotrimeric complex with SMAD2 and SMAD3
proteins upon activation by TGF‐β receptor kinases. This complex then translocates to
the nucleus where it acts as a transcription factor by regulating the expression of its
target genes through interaction with DNA and DNA‐binding proteins [55, 56].
Inactivation of SMAD4 contributes to tumor promotion due to its role as a mediator of
TGF‐β signaling‐induced cell cycle arrest, apoptosis, and genomic integrity preservation
[57].

1.5.1.2. Other genomic variations
Genome analysis has supported the findings that the characteristic driver mutations like
oncogenic KRAS and inactivation of TP53, CDKN2A, and SMAD4 occur at high rates as
well as a small portion of persistent mutations in genes related to DNA repair,
chromatin remodeling, and other promoters of tumorigenesis account for the vast
majority of mutations detected in pancreatic cancer. It was also realized, however, that
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the data includes an extensive list of infrequently mutated genes which contributes to a
substantial degree of interpatient heterogeneity [58]. Several forms of structural
variations such as point mutations, copy number variations (CNVs), chromosomal
aberrations, and insertions and deletions have been detected in pancreatic cancer. Point
mutations occur frequently throughout the development of pancreatic cancer; indeed
the key mutational events in its tumorigenesis are the point mutations in KRAS and the
TP53, CDKN2A, and SMAD4 tumor suppressors. The number and types of genetic
alterations varies greatly between patients with the average number of mutations per
patient ranging from 21 to 857, of which approximately 75% are not silent [58‐61].
Chromosomal aberrations are commonly observed in pancreatic cancer and can cause
atypical gene expression such as inactivation through deletion or rearrangement,
activation through copy number gain or amplification, or oncogenic gene products
through gene fusions [58, 62]. Another genetic alteration frequently observed in PDAC
is telomere shortening. Telomeres are a region of repetitive nucleotide sequences
located at the end of each chromosome which help maintain genomic stability by
preventing chromosome ends from deteriorating and fusing with other chromosomes.
Telomere shortening has been observed throughout the stages of PDAC development
and progression, and may even precede KRAS mutations as evidenced by a higher
frequency of detection in low‐grade PanINs [63]. Under physiologic conditions,
telomere shortening eventually results in a crisis state for the cell requiring repair
14

mechanisms or cell death, but in pancreatic and other cancer cells chromosome
maintenance is altered and a process called breakage‐fusion‐bridge cycles allows them
to survive and evade apoptosis [64].

1.5.1.3. Epigenetic alterations
Most genome‐wide sequencing analyses of precursor lesions and pancreatic cancer
specimens have been primarily focused on driver mutations and other frequently
altered genes and signaling pathway proteins; however, recent evidence has
demonstrated that many of the genetic modifications detected target epigenetic
regulators and epigenetic alterations are a commonly found influence on pancreatic
tumor progression [65]. Epigenetics refers to the heritable, and in some cases reversible,
variations in gene expression which are not a result of changes to the underlying DNA
sequence [66]. Epigenetic alterations include DNA methylation, chromatin remodeling,
non‐coding RNAs, and histone methylation, acetylation, and ubiquitination. DNA
methylation is the process of adding a methyl (CH3) residue to a cytosine preceding a
guanosine, or CpG dinucleotide, and is a key mechanism of epigenetic modification.
DNA methylation is commonly encountered within gene promoters, resulting in
restricted transcription, whereas methylation within the body of the gene may lead to
enhanced transcription or alternative splicing [67]. Aberrant DNA methylation and
silencing of tumor suppressor gene promoters is considered one of the primary
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epigenetic mechanisms in the development and progression of many cancer types,
including PDAC [68‐70]. Some tumor suppressor genes such as CDKN2A can be
inactivated through either mutation or epigenetic silencing whereas others like Ras
association domain family member 1 (RASSF1A), suppressor of cytokine signaling 1
(SOCS‐1), and APC, WNT signaling pathway regulator (APC) are found to be silenced
solely through promoter hypermethylation in pancreatic cancer [71‐75]. CpG
hypermethylation has been reported to varying degrees in PanINs and IPMNs,
indicating this event happens early and its occurrence has been shown to increase
though progression of disease [76]. In addition to hypermethylation leading to gene
suppression, hypomethylation has also been found within genes associated with
overexpression in pancreatic cancer including claudin‐4 (CLDN4), mesothelin (MSLN),
and prostate stem cell antigen (PSCA) [77].

1.5.1.4. Key signaling pathways
In addition to the frequently observed mutations in the driver oncogenes and tumor
suppressor genes, several other key cellular signaling pathways accumulate mutations
during pancreatic tumorigenesis and progression. Several independent investigations
have revealed through whole exome or genome sequencing analysis of hundreds of
PDAC tumor specimens a set of core cellular regulatory processes and signaling
pathways with a high frequency of genetically altered components [59, 60, 78]. These
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pathways and mechanisms include transforming growth factor β (TGF‐β), Wnt,
neurogenic locus notch homolog protein (Notch), Hedgehog (Hh), roundabout homolog
(ROBO)/slit homolog protein (SLIT) signaling, G1/S phase transition, DNA repair,
chromatin modifications, and RNA processing.

1.5.2. Genetic Subtypes
Recent large‐scale genomic investigations have led to a characterization of pancreatic
cancer subtypes based on their genetic profile in the hopes of creating a standard
stratification model of the disease which can help direct more effective treatment
strategies as is the case for some other solid cancers including breast, colorectal, and
prostate. Great advances have been made in the understanding of PDAC development
and the existence of distinct subtypes, but a consensus has yet to be reached regarding
strict definitions of the subtypes given the tremendous heterogeneity of the mutational
spectrum of PDAC tumors and technical challenges. In 2011, Collisson and colleagues
provided the first major analysis of molecular PDAC subtypes based on transcriptional
profiling of microdissected neoplastic epithelium and concluded that there were three
classifications: classical, quasimesenchymal, and exocrine‐like [79]. They also found that
the classical subtype was more sensitive to erlotinib, while the quasimesenchymal
subtype was more sensitive to gemcitabine. Later, in 2015 when Moffitt, et al. analyzed
molecular subtypes of PDAC they characterized two subtypes which they named
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classical and basal [80]. These classifications roughly matched Collisson’s classical and
quasimesenchymal subtypes; however an exocrine‐like profile was not defined on the
basis that pancreatic exocrine transcripts were to be considered an artifact from normal
pancreatic tissue and excluded from analysis. Also in 2015, Waddell et al. characterized
PDAC subtypes based on their structural variation rather than transcriptome and
classified four subtypes: stable, locally rearranged, scattered, and unstable [58]. In 2016,
Bailey, et al. identified four subtypes, squamous, pancreatic progenitor, immunogenic,
and aberrantly differentiated endocrine exocrine (ADEX), according to the differential
expression of transcription factors and their respective targets [60]. While the technical
methodology and computational analysis has yet to be standardized to determine a
universal consensus of subtypes, information gathered by these studies have confirmed
the validity of defining molecular signatures within PDAC tumors for improved
therapeutic benefit and may lead to the creation of biomarkers for diagnostic and
predictive purposes.

1.5.3. Tumor Microenvironment
One of the hallmarks of pancreatic cancer is the presence of substantial desmoplasia, the
profuse fibrotic stroma that envelops the tumor, which can comprise as much as 80% of
the tumor mass. While its presence was known for decades, it was only after 1998 when
pancreatic stellate cells (PSCs) were cultivated and studied in experimental settings
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when researchers began to understand that this inordinately dense stromal tissue is not
simply an idle feature of PDAC tumors but rather an integral component which can
potentially contribute to drug resistance, proliferation, and metastasis [81‐83]. Activated
pancreatic stroma is a complex structure with several distinct cell types including
stellate cells, endothelial cells, nerve cells, immune cells, fibroblasts, myofibroblasts,
extra cellular matrix (ECM), as well as blood and lymphatic vessels. This mass of stroma
is so dense that it leads to impaired vasculature and contributes to limited drug
delivery to the tumor parenchyma [84]. Production of the stroma is stimulated by
activated oncogenic receptor‐mediated signaling pathways including transforming
growth factor β (TGFβ), hepatocyte growth factor (HGF), fibroblast growth factors
(FGFs), insulin‐like growth factor 1 (IGF‐1), and epidermal growth factor (EGF) [85, 86].
It was long believed that this high grade desmoplasia was unique to the primary tumor;
however, a recent study found that a considerable amount of stromal tissue exists in the
metastatic lesions of pancreatic cancer patients and that there was no significant
difference between the degree of desmoplasia in the primary tumor compared to the
metastases [87]. A complex relationship exists between the tumor cells and those of the
surrounding stromal matrix in which the concerted activity of various components
promote tumor progression, migration, metastasis, and drug resistance [88]. Due to the
prominent role that desmoplasia plays throughout the development and progression of
pancreatic cancer, several attempts have been made to exploit some aspect of the stroma
19

for therapeutic benefit. However, multiple studies demonstrated that eradication of the
stromal complex actually amplified tumor aggressiveness and resulted in decreased
overall survival [89, 90]. This unforeseen result confirmed the complex nature of the
relationship between tumor and stroma and contradicted the notion that the dense
microenvironment served a solely tumor‐protective function. Still, our understanding of
this multifaceted component continues to grow and individual pathways as well as
crosstalk mechanisms within the stroma remain targets of clinical investigation for
therapeutic potential.

1.6. Treatment Strategies
1.6.1. Traditional Therapeutic Options
1.6.1.1. Stages I and II
Surgical resection remains the only potentially curative intervention for local, stage I
and II pancreatic cancer. However, only a small population of patients (15‐20%) are
eligible for resection and the 5‐year survival rate is a mere 18‐24% [91]. Pancreatic
resection surgery can entail the Whipple procedure (also referred to as
pancreaticoduodenal resection), distal pancreatectomy for tumors located in the
pancreas body and tail, or total pancreatectomy. While surgery can lead to a complete
eradication of the disease in some patients, for most the prognosis remains poor due to
a high rate of recurrence. The use of postoperative interventions including
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chemotherapy (gemcitabine or 5‐fluorouracil (5‐FU)) and chemoradiation (5‐FU and
radiation) therapy is controversial due to conflicting results among clinical trial data
[92‐95].
1.6.1.2. Stages III and IV
Standard treatment options for patients with stages III and IV pancreatic cancer include
chemotherapy, chemoradiation, palliative surgery to alleviate symptoms of a biliary
obstruction, and palliative therapy for pain relief. Chemotherapy is the primary
treatment option for advanced pancreatic cancer and gemcitabine has been the standard
regimen for over two decades, though the efficacy of new combination regimens has
been studied in recent years. Such combinations include gemcitabine plus erlotinib,
gemcitabine plus nab‐paclitaxel, and FOLFIRINOX (oxaliplatin, irinotecan, leucovorin,
and 5‐FU), though most clinical trials investigating these regimens have revealed them
to exert either a moderate improvement of overall survival or highly toxic side effects
compared to gemcitabine treatment. Chemoradiation for locally advanced, stage III
pancreatic cancer patients is controversial due to flawed clinical trial design and
analysis as well as the discovery that approximately 30% of patients with stage III
pancreatic cancer have no evidence of distant metastases at the time of death [96].
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1.6.2. Experimental Therapeutics
1.6.2.1. Immunotherapy
The goal of immunotherapy is to either stimulate or suppress specific aspects of the
patient’s immune system to treat not only the primary tumor, but also to target any
microsatellite metastases that may exist throughout the body [97]. Immunosuppression
by tumor‐associated macrophages, myeloid‐derived suppressor cells (MDSCs), and
regulatory T cells (Tregs) has been observed in early stage precursor lesions and
throughout the progression of PDAC in vivo [98]. Such early and continued
immunomodulation presents potential therapeutic targets. Indeed, the interference of
Treg migration led to reduced tumor size in mice harboring pancreatic tumors
compared to the control cohort [99]. There is an abundance of regulatory pathways
which are critical for managing the delicate balance and magnitude of the immune
response, termed immune checkpoints. Because these regulatory processes are
manipulated in many types of cancer, including PDAC, immune checkpoint inhibitors
represent a large class of immunotherapeutic agents currently under evaluation in
clinical trials [97, 100]. Cancer vaccines designed to elicit an immune response through
the delivery of tumor‐specific antigens, monoclonal antibodies engineered to
specifically target tumor cells, and adoptive cell transfer in which the patient’s immune
cells are modified and returned are also classes of immunotherapy currently under
investigation for the treatment of pancreatic cancer [101]. Still, there remains a great
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deal left to understand about the complex nature of the immune response to PDAC
initiation and progression, as well as the efficacy and systemic consequences of
immunotherapeutic intervention in patients which requires further investigation.

1.6.2.2. Targeted therapy
Traditional chemotherapy inhibits the growth of continuously proliferating cells
regardless of their function which results in systemic toxicity and side effects as some
normal cells like those in hair follicles, intestinal lining, and bone marrow also divide
rapidly. Targeted therapy refers to treatment which is used to directly affect specific
pathways, proteins, or receptors whose aberrant activity is critical for disease
pathogenesis and progression in the hopes that the malignant cells will be primarily, if
not solely, affected. The first, and only currently FDA‐approved, targeted therapy for
the treatment of pancreatic cancer was erlotinib, a HER1/EGFR tyrosine kinase inhibitor
originally approved for non‐small cell lung cancer (NSCLC) patients, in combination
with gemcitabine. However, the advantage in median patient survival compared to
those receiving only gemcitabine in its first phase‐III trial was modest (6.24 and 5.91
months, respectively) [102]. Targeted therapy has led to vastly improved patient
survival and prognosis in other cancer types, but unfortunately there has been no such
breakthrough in pancreatic cancer. This is likely due in part to the heterogeneity and
wide array of cellular processes that are altered in pancreatic cancer. Still, the data
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obtained through large‐scale genomic, proteomic, and transcriptomic analysis over the
past decade has led to several clinical trials evaluating drugs that target these malignant
aberrations.

1.6.2.3. Gene therapy
Another therapeutic strategy currently under clinical investigation for the effective
treatment of this intractable disease is gene therapy. The concept of gene therapy
encompasses various approaches with the goal of altering specific gene expression to
affect tumor cells and not healthy cells. Such approaches include the restoration of
tumor suppressor gene expression through the delivery of wild type‐carrying vector,
inhibition of oncogene expression through the delivery of RNA interference or a
dominant negative version of the gene, and the delivery of a suicide gene which can
conditionally induce cell death in the presence of an otherwise non‐toxic drug [103,
104]. Investigations evaluating these approaches have had success in preclinical studies,
but clinical studies have been far less fruitful [102].

1.7. Gemcitabine
Gemcitabine (2’,2’‐difluoro 2’‐deoxycytidine; dFdC) is a deoxycytidine analog and has
been the standard chemotherapeutic agent for the treatment of advanced pancreatic
cancer since a pivotal study in 1997 determined its superiority over 5‐FU in overall
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patient survival [105]. Gemcitabine is structurally similar to the first cytidine analog,
cytosine arabinoside (Ara‐C), however it has distinct cellular pharmacology,
metabolism, and mechanisms of action. While the FOLFIRINOX regimen has emerged
as the most efficacious first line treatment option for patients with metastatic PDAC, its
effectiveness is often dwarfed by its intolerable side effects. Still, gemcitabine remains
one of the most prevalent chemotherapies used to treat pancreatic cancer, usually in
combination with either nab‐paclitaxel or erlotinib [106].

1.7.1. Metabolism
1.7.1.1. Cellular uptake
Gemcitabine is a prodrug that requires facilitated transport and multiple intracellular
phosphorylation steps to become the active diphosphate (dFdCDP) and triphosphate
(dFdCTP) forms (Fig. 4). Cellular uptake mechanisms are vital to gemcitabine’s efficacy
as it is hydrophilic and requires human nucleoside transporters (hNTs) for passage into
the cell. Members of the energy‐independent human equilibrative nucleoside
transporters and cation‐dependent human concentrative nucleoside transporters
(hENTs and hCNTs, respectively) mediate the transport of gemcitabine into cells. The
hENT family allows bidirectional nucleoside transport across the cell membrane while
hCNT family members are sodium‐dependent and permit unidirectional transport
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[107]. Most gemcitabine uptake is mediated by hENT1, though hENT2, hCNT1, and
hCNT3 have also demonstrated some activity [108, 109].

1.7.1.2. Metabolite activation
After it has been transported into the cell, gemcitabine is rapidly phosphorylated by
deoxycytidine kinase (dCK) to become gemcitabine monophosphate (dFdCMP). This
initial phosphorylation event is considered the rate‐limiting step in gemcitabine
activation. Pyrimidine nucleoside monophosphate kinase (UMP‐CMP kinase) then
phosphorylates dFdCMP to create the diphosphate form (dFdCDP) which subsequently
becomes gemcitabine triphosphate after the final phosphorylation by nucleoside‐
diphosphate kinase (NDPK) [110].

1.7.1.3. Metabolite inactivation
Gemcitabine and its metabolites can become inactivated by various processes. The
monophosphate form dFdCMP can be dephosphorylated by 5’‐nucleotidases (5’‐NTs).
Gemcitabine can also be deaminated in reactions catalyzed by deoxycytidylate
deaminase (dCTD) and cytidine deaminase (CDA). Deamination of dFdCMP by dCTD
results in 2’‐deoxy‐2’,2’‐difluorouridine monophosphate (dFdUMP) and by CDA results
in difluorodeoxyuridine (dFdU). While substantial inter‐patient variability regarding its
clearance exists, only a fraction of gemcitabine is converted to its active metabolites
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upon injection as the majority rapidly undergoes deamination by CDA. Generally,
within one week, more than 90% of the administered dose is recovered, primarily in the
urine, as either dFdU (99%) or the parent gemcitabine (1%) [111].

1.7.2. Mechanisms of Action
1.7.2.1. DNA synthesis inhibition
The primary gemcitabine metabolite, dFdCTP, acts as a competitive substrate of
deoxycytidine triphosphate (dCTP) which allows it to be incorporated into DNA during
replication. In a process known as “masked chain termination”, a single endogenous
deoxynucleotide triphosphate (dNTP) is subsequently integrated into the growing
strand which prevents the excision of dFdCTP and DNA repair by 3’5’‐exonuclease
(Fig. 5A) [112]. DNA elongation is then halted, leading to S‐phase cell cycle arrest and
eventually apoptosis [112]. dFdCTP can also be incorporated into RNA, resulting in
RNA synthesis inhibition [113]. Furthermore, dFdCDP impedes DNA synthesis by
directly inhibiting the M1 subunit ribonucleotide reductase (RRM1), the critical enzyme
responsible for maintaining the pool of dNTPs available for DNA replication, by
binding to its active site [114].
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1.7.2.2. Self‐potentiation
Gemcitabine possesses the ability to self‐potentiate by impeding deoxynucleotide
metabolism. Deoxycytidylate deaminase (dCTD) is an enzyme which contributes to the
de novo biosynthesis of deoxythymidine triphosphate (dTTP) and is directly inhibited
by dFdCTP. The availability of deoxynucleotides positively regulates dCTD activity and
since dFdCDP depletes the deoxynucleotide pool by inhibiting RR activity, it also
indirectly inhibits dCTD, thereby reducing the deamination of dFdCMP. Additionally,
dCK activity is negatively regulated by dCTP, therefore the reduced deoxynucleotide
pool leads to an increase in dCK activity and a subsequent increase in dFdC
phosphorylation. This culminates in an increased dFdCTP to dCTP ratio, making
dFdCTP more likely to be incorporated into DNA during replication (Fig. 5B) [115].

1.7.3. Gemcitabine Resistance in Pancreatic Cancer
1.7.3.1. Uptake and metabolism
Unsurprisingly, alterations in the transport and metabolism of gemcitabine are some of
the primary mechanisms by which the cells become resistant. Owing to its central role
in gemcitabine activation, loss of deoxycytidine kinase (dCK) activity through
posttranscriptional and posttranslational modification plays a major role in gemcitabine
resistance in PDAC cell lines and tumors, and its expression is tightly correlated with
gemcitabine sensitivity and overall survival in vitro and in vivo [116‐120]. Similarly,
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hENT1 is also correlated with gemcitabine resistance, as reduced hENT1 expression
leads to significantly impaired influx of gemcitabine. However, regression analysis of
protein expression of several gemcitabine uptake and metabolism regulators concluded
that while hENT1 expression was linked to IC50 in response to gemcitabine treatment in‐
vitro, only dCK concentration was highly correlated with both IC50 and progression‐free
survival in PDAC cell lines and tissues, respectively [118]. An additional study found
that downregulation of hENT1 by siRNA had no effect on gemcitabine sensitivity or cell
proliferation [117]. This may be due to the availability of other nucleoside transporters
which can import gemcitabine in the absence of hENT1, while dCK is solely responsible
for initially phosphorylating intracellular gemcitabine [121]. The RNA binding protein
Human antigen R (HuR) upregulates dCK at the transcriptional level and studies have
shown increased survival in patients with high cytoplasmic HuR expression [122, 123].
Reduced hCNT1 expression in response to MUC4 regulation is also correlated with
decreased gemcitabine sensitivity in pancreatic cancer cell lines [124]. Deamination of
dFdCMP by CDA and dephosphorylation by 5’‐NTs are robust methods of gemcitabine
inactivation and clearance, and as such their expression is also linked to gemcitabine
sensitivity. Targeting CDA activity with tetrahydrouridine led to a significant increase
in gemcitabine efficacy in vivo, and siRNA targeting of 5’‐nucleotidase III induced
greater gemcitabine sensitivity in both pancreatic and breast cancer cell lines [125‐127].
While not directly responsible for gemcitabine’s metabolism, upregulation of the two
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subunits RRM1 and RRM2 that comprise ribonucleotide reductase are also contribute to
gemcitabine resistance in pancreatic and other cancers [128, 129]. Indeed, targeting
RRM2 expression by siRNA improved gemcitabine sensitivity in‐vivo and in‐vitro
[130]. Another study found that apart from increased expression, posttranslational
modifications which cleave RRM1 can also lead to gemcitabine resistance in pancreatic
cancer [131].

1.7.3.2. Exosomes
Interest surrounding exosomes and their multifaceted influence on pancreatic cancer
has increased substantially in recent years. While their precise roles have yet to be fully
elucidated studies have demonstrated their potential use as biomarkers and drug
delivery vehicles as well as their effects on tumorigenesis, tumor progression,
immunosuppression, migration, and therapeutic resistance [132]. The ability of
exosomes to readily shuttle biological molecules between cells throughout the body
allow them to influence a wide range of physiological factors. Treatment with
gemcitabine resulted in amplified production of exosomes containing increased levels
of the chemoresistance‐promoting transcription factor Snail and its downstream target
miR‐146a in PDAC cancer associated fibroblasts (CAFs) [133]. Furthermore, conditioned
media containing these exosomes conferred increased gemcitabine resistance and
proliferation to epithelial and PDAC cells lines. This exosome‐specific effect was
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validated when the CAFs exhibited decreased survival after they were treated with
GW4869, which impedes exosome release by inhibiting the inward budding of
multivesicular bodies mediated by ceramide [133, 134]. Increased secretion of exosomes
containing high levels miR‐155 and miR‐365 have also been shown to be highly
expressed and transported by PDAC cells in response to gemcitabine treatment [135,
136]. Exosomes with elevated quantities of miR‐155 induced a positive feedback loop in
which more exosomes overexpressing miR‐155 were released [136]. miR‐155 expression
is associated with decreased gemcitabine sensitivity by inhibiting DCK and activating
anti‐apoptotic genes, and its overexpression in patients treated with gemcitabine is
correlated with poor prognosis [136, 137]. Exosomes derived from macrophages
containing increased miR‐365 significantly increased gemcitabine resistance in PDAC
cells and tumor‐bearing mice [135].

1.7.3.3. Signaling pathways
Dysfunctional cellular regulatory and signaling pathways are characteristic features of
pancreatic cancer throughout its initiation and progression, including those which incur
resistance to chemotherapeutic intervention. Aberrant expression of the nuclear factor‐
κB (NF‐κB) transcription factor has been associated with gemcitabine‐resistant
pancreatic cancer cells [138]. Due to its role in numerous cellular signaling pathways,
several mechanisms for the gemcitabine resistance ascribed to increased NF‐κB levels
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have been proposed. Inhibition of apurinic/apyrimidic endonuclease 1/redox factor‐1
(APE1/Ref‐1), an activator of NF‐ κB, was shown to increase gemcitabine efficacy in
PDAC cells [139, 140]. High expression of MUC4 was shown to negatively regulate
hCNT1 expression in pancreatic cancer cells, and thus gemcitabine sensitivity, via NF‐
κB signaling [141]. Hypoxia inducible factor‐1α (HIF‐1α) activity has also demonstrated
a multifaceted role in promoting gemcitabine resistance in pancreatic cancer. Increased
levels of active HIF‐1α in response to MUC1 stabilization is associated with gemcitabine
resistance, and inhibition of HIF‐1α enhanced sensitivity [142]. Upregulation of the C‐X‐
C chemokine receptor 4 (CXCR4) mediated by HIF‐1α and NF‐κB also precipitates
gemcitabine resistance and invasive properties in PDAC cells [143]. Collectively, these
studies demonstrate once more how the extensive heterogeneity of PDAC tumors
affects their distinctive properties and contributes to a diverse array of mechanisms that
allow them to evade chemotherapeutically induced apoptosis.

Just as tumor heterogeneity and the presence of abundant desmoplastic stroma are
hallmark characteristics of pancreatic cancer, so too is the nearly universal recalcitrance
to and evasion of chemotherapeutic intervention. Thus, the studies detailed herein seek
to identify a novel adjunctive agent which can selectively target and ameliorate
gemcitabine efficacy in pancreatic cancer cells.
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2. Plants as Sources of Novel Drugs
Natural products are an essential component of drug discovery and have been utilized
for medicinal purposes for thousands of years [144]. While sources of natural products
include plants, marine organisms, minerals, and microorganisms, botanicals have
particular importance in the history of traditional medicine with written records of their
use dating as far back as 2600 BCE in Mesopotamia [145]. In 1985, the World Health
Organization (WHO) estimated that plant‐derived traditional medicine was the
principal source of medical care for approximately 65% of the global population [146]. It
was also found that of the 122 structurally defined, purified plant‐based compounds
used as drugs, 80% were utilized in accordance with the traditional ethnomedical
purpose. In the context of drug discovery, natural products typically refer to secondary
metabolites; these are compounds which, unlike primary metabolites such as fats,
carbohydrates, and nucleic acids, are not essential for an organism’s survival and
reproduction but serve as defense mechanisms against other organisms [147]. These
secondary metabolites serve as potential sources of drugs either in their stable, purified
form or as a lead compound which can be used as a model for semisynthetic modalities
with more targeted or less toxic effects. Two of the best‐known instances of drug
discovery from natural products are the isolation of morphine from opium by Friedrich
Wilhelm Sertürner and the generation of the semi‐synthetic drug aspirin based on
salicin isolated from Salix alba. Additional examples of the numerous plant derived
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compounds that became models for future, more effective drugs include khellin
isolated from Ammi visnaga (L.) Lamk., papaverine isolated from Papaver somniferum L.,
and galegine isolated from Galega officinalis L. [148]. Khellin was originally used as a
bronchodilator until side effects such as nausea and vomiting were associated with
prolonged use. The search for synthetic analogs of khellin that would remain
biologically active with fewer side effects led to the discovery of chromolyn and
subsequently the synthesis of amiodarone. The structure of papaverine, traditionally
used as a smooth muscle relaxant, was used in the creation of the anti‐hypertension
drug verapamil. Galegine was isolated and used as a hyperglycemic agent as the
ethnomedical use of Galega officinalis L. was to treat diabetes. Galegine was eventually
the molecular basis for the synthesis of metformin, which remains one of the most
extensively used medications in the treatment of type 2 diabetes. The introduction of
synthetic small molecules and implementation of strict definitions regarding the
validity of potential drug candidates by pharmaceutical companies led to a decline in
the interest of natural products; however, plants and other sources of natural products
have distinct advantages regarding biologically active compounds in drug discovery
[149]. Natural products are complementary to synthetic compounds as they are vastly
diverse in both their chemical and structural diversity, and approximately 40% of the
chemical structures in natural products are not found in modern drug chemistry [150,
151]. The development of an effective drug requires the ability to interact with other
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molecules and natural products have the distinct advantage of a biological history since
they are continuously enzymatically modulated. Furthermore, the native activity of
these metabolites often includes interacting with other proteins, which is interpreted by
some as a form of biological validation [152]. While the biodiversity and complexity of
natural products provides an advantage over synthetic compounds, the drawback of
such a vast pool of potential leads is the sheer volume there is to be explored. Of the
estimated 300,000 higher plant species that exist, a mere 6% have been screened for
bioactivity, and the phytochemical profiles of roughly just 15% have been investigated
[153]. This indicates that the potentially limitless trove of medically relevant biological
lead compounds has been scarcely evaluated and with the urgent need for new
pharmaceuticals to treat a myriad of human diseases, not the least of which are
recalcitrant cancers, the search for bioactive compounds from natural sources has only
just begun.

2.1. Plant‐Based Drug Development and Cancer
The exploration of plants as sources of chemotherapeutic agents has been active since
the discovery of the vinca alkaloids vinblastine and vincristine isolated from the
Madagascar periwinkle, Catharanthus roseus, and of epipodophyllotoxin which became
the basis of the semisynthetic derivatives etoposide and teniposide [145, 154]. In 1960,
the National Cancer Institute (NCI) and United States Department of Agriculture
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(USDA) initiated a program to collect and screen a broad taxonomic range of plant
extracts from species‐rich, temperate environments in recognition of the chemical
diversity of secondary metabolites such environments would induce in its flora [155].
Between 1960 and 1981, over 114,000 extracts of 35,000 plants were screened against
various cancer types. One of the most significant findings from the program was the
discovery in 1964 that extracts from the bark of the Pacific yew tree, Taxus brevifolia,
were toxic to oral epidermoid carcinoma (KB) cells. The primary cytotoxic compound
within the extracts was eventually isolated and named paclitaxel (Taxol®) [156]. One of
the characteristics that made paclitaxel so remarkable and intriguing to researchers was
its mechanism of action. Whereas other chemotherapeutic agents at the time functioned
by inhibiting tubulin polymerization, paclitaxel was discovered to stimulate extensive
tubulin polymerization which renders cells unable to direct cell division and ultimately
leads to apoptosis. Today, paclitaxel is an essential chemotherapeutic drug and along
with its analogues is used to treat a range of cancers including breast, ovarian,
pancreatic, non‐small cell lung cancer, and Kaposi sarcoma. The path to its blockbuster
status was arduous, however. Three decades passed between paclitaxel’s initial
discovery and its FDA approval for the treatment of refractory ovarian cancer due to
the complexity of its molecular structure, low availability within the nonrenewable bark
of the Pacific yew tree, and lack of aqueous solubility [157]. Another notable discovery
made during this initiative was that of camptothecin, isolated in 1966 from the Chinese
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ornamental tree, Camptotheca acuminata Decne [158]. Studies investigating
camptothecin’s antitumor efficacy revealed a distinctive mechanism of action in which
topoisomerase I is trapped in a complex with DNA and the catalytic activity of
topoisomerase I is inhibited [159]. Clinical trials for camptothecin were discontinued in
the 1970s due to bladder toxicity; however, three semisynthetic analogs belotecan,
irinotecan, and topotecan were successfully developed and have been approved for use
against lung, breast, colorectal, and ovarian cancers [145, 160]. Of the 136 small
molecule anticancer drugs approved between 1981 and 2014, 83% are either natural
products or derivatives thereof [161]. The essentiality of natural products for
chemotherapeutic drug discovery and development cannot be overlooked as the
potential for previously unknown chemical scaffolds and mechanisms of action within
them may continue to lead to significant advances in modern medicine.

2.2. Anemarrhena asphodeloides
The rhizome of Anemarrhena asphodeloides Bunge (AA) (Fig. 6) has been a significant
fixture in Traditional Chinese Medicine (TCM) for thousands of years. AA is the only
species in its genus and is a perennial herb native to China, Korea, and Mongolia.
Known as Zhi Mu in TCM, AA is classified by the Chinese Materia Medica as a heat‐
clearing herb that treats ailments such as febrile diseases with dire thirst and the
internal heat caused by diabetes. As of 2014, 108 compounds have been isolated and
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identified from AA [162]. The primary chemical components are steroidal saponins,
flavonoids, phenylpropanoids, alkaloids, steroids, organic acids, and anthraquinones.
Most abundant among its identified constituents are steroidal saponins. There has been
great interest in recent years in investigating the pharmacological activities of secondary
metabolites isolated from AA, with the findings as varied as the compounds
themselves. Some of the pharmacological properties of compounds found in AA
include neuroprotective, anti‐diabetic, anti‐inflammatory, and anti‐tumorigenic
responses [162]. Although recent interest in AA and its constituents has led to many
potentially significant findings, what remains unknown about its prospective use in
human diseases warrants further investigation, particularly regarding such intractable
malignancies as pancreatic cancer.

2.3. Timosaponin‐AIII
Among studies evaluating AA, both as a crude extract and its individual components,
the most prominent anti‐cancer compound is timosaponin‐AIII (TAIII), a steroidal
saponin first isolated from AA by Kawasaki et al. in 1963. Saponins are vastly diverse
both in their chemical structure and biological function. At high concentrations, greater
than 100 μM, saponins permeabilize cell membranes and become indiscriminately
cytotoxic. However, some saponins have recently garnered interest for their ability to
induce selective cytotoxicity within cancerous cells at much lower concentrations [163].
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TAIII has demonstrated pro‐apoptotic and anti‐metastatic efficacy against non‐small
cell lung cancer, melanoma, colorectal carcinoma, and breast cancer [162]. While the
cytotoxic effects of TAIII have been assessed in some cancer types, prior to our study its
potential activity against pancreatic cancer had not been tested.
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Figure 1: Genetic progression of pancreatic cancer precursor lesions. Pancreatic
intraepithelial neoplasia (PanIN), mucinous cystic neoplasm (MCN), and intraductal
papillary mucinous neoplasm (IPMN) are the three distinct precursor lesions which
give rise to invasive exocrine pancreas tumors.
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Figure 2: Progression model of pancreatic cancer from initiation to late stage. Note:
Reprinted from “KRAS, Hedgehog, Wnt and the twisted developmental biology of
pancreatic ductal adenocarcinoma” by J. Morris, S. Wang, & M. Hebrok, 2010, Nature
Reviews Cancer, 10, p. 686. Copyright 2010 by Springer Nature. Reprinted with
permission.
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Figure 3: Pancreatic cancer staging definitions. Note: From the American Joint
Committee on Cancer (AJCC) 7th Edition Staging Poster. Reprinted with permission.
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Figure 4: Overview of gemcitabine uptake and metabolism. Gemcitabine (dFdC) is
transported across the cell membrane by a nucleoside transporter where it undergoes
sequential phosphorylation to become its monophosphate (dFdCMP), diphosphate
(dFdCDP), and triphosphate (dFdCTP) forms. dCK: deoxycytidine kinase; 5’NT: 5’
nucleotidase; CDA: cytidine deaminase; dFdU: 2’,2’‐difluoro‐2’‐deoxyuridine; dFdUMP:
2’,2’‐difluoro‐2’‐deoxyuridine monophosphate; dCTD: deoxycytidylate deaminase;
NDPK: nucleoside diphosphate kinase. RR: ribonucleotide reductase; NDP:
ribonucleoside diphosphate; dNDP: deoxyribonucleoside diphosphate; dNTP:
deoxynucleotide triphosphate.
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Figure 5: Primary gemcitabine mechanisms of action. (A) In a process called “masked
chain termination,” gemcitabine triphosphate (dFdCTP) is incorporated into the
growing DNA strand, followed by a single dNTP, and halts elongation. (B) Gemcitabine
prompts self‐potentiation as dFdCDP binds to and inhibits the activity of RR, thereby
reducing the pool of dNTPs available for DNA replication and increasing the rate of
dFdC phosphorylation.
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Figure 5 continued.
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Figure 6: Anemarrhena asphodeloides (Bunge). Rhizome, whole plant, and flowers of
Anemarrhena asphodeloides. Note: Reprinted from “The genus Anemarrhena Bunge: A
review on ethnopharmacology, phytochemistry and pharmacology” by Y. Wang, Y.
Dan, D. Yang, Y. Hu, L. Zhang, C. Zhang, H. Zhu, Z. Cui, M. Li, Y. Liu, 2014, Journal of
Ethnopharmacology, 153, p. 44. Copyright 2014 by Elsevier. Reprinted with permission.
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CHAPTER TWO:
EXPLORATION OF TRADITIONAL CHINESE HERBAL EXTRACTS AS NOVEL,
NATURALLY DERIVED THERAPEUTICS FOR THE TREATMENT OF
ADVANCED PANCREATIC CANCER

1. Introduction
1.1. Background and Rationale
The premise of the current study is the result of an enquiry regarding the cytological
impact of select herbal extracts summarized in Table 1, as well as a proprietary
combination of eight extracts referred to in this study as “8‐mix”. The original
hypothesis stated that the extracts induce pancreatic beta cell proliferation and enhance
glucose sensitivity, and was formulated in collaboration with Clare Zhang, Ph.D.,
MAcOM, who utilizes these herb extracts for patients with type 2 diabetes in her
integrative Oriental medicine practice. In addition to demonstrating clinical efficacy, the
extracts we selected had been previously studied for their ability to affect metabolic
consequences of type 2 diabetes such as lowering blood glucose levels, improving lipid
metabolism, and increasing insulin sensitivity [164‐168], but their molecular
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mechanisms of action had not yet been explicated, which our study sought to
accomplish. To overcome complications related to the procurement and experimental
manipulation of primary pancreatic islets, we utilized the 1.1B4 cell line, created in 2011
by electrofusion of primary human pancreatic beta cells with PANC‐1 cells. These
innovative cells exhibit functional characteristics reminiscent of primary pancreatic beta
cells such as insulin secretion and glucose sensitivity while also providing the
advantages of an immortalized cell line [169].

1.2. Experimental Overview
To elucidate the molecular mechanisms responsible for the effects observed on
pancreatic beta cell and glycemic regulation by the extracts, we first examined the
viability of 1.1B4 cells in response to each extract at a range of concentrations to
determine if there was an increase in beta cell proliferation. Upon initial examination, a
biphasic trend was noted in the cells treated with 8‐mix in which lower concentrations
did in fact result in increased viability, while a conspicuous decrease was observed in
those treated with higher concentrations of 8‐mix. This unexpected finding prompted
us to determine whether the extract mix also elicited a decrease in viability of pancreatic
cancer cells, and whether the individual extracts that comprise 8‐mix exhibited effects
similar to the mixture. The results of the ensuing analyses precipitated our subsequent
investigation into the cytotoxicity of Anemarrhena asphodeloides rhizome extract and its
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potential bioactive compounds which, prior to our study described in succeeding
chapters, had never been tested in pancreatic cancer.

2. Materials and Methods
2.1. Cell Culture
1.1B4, BxPC‐3, and PANC‐1 cells were cultured in growth medium (RPMI‐1640 with L‐
glutamine for 1.1B4 and BxPC‐3 cells and DMEM with L‐glutamine for PANC‐1)
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin‐streptomycin (100
units/mL penicillin and 100 μg/mL streptomycin). 1.1B4 cells were purchased from the
European Collection of Authenticated Cell Cultures (ECACC; Cat. No. 10012801).
PANC‐1 and BxPC‐3 cells were generously supplied by Dr. Meera Nanjundan. Both cell
lines were independently authenticated via STR profiling (Promega) and confirmed to
be an exact match to the indicated cell line by ATCC (STR12699 and STR12675). Cells
were maintained in a humidified incubator in 5% CO2 at 37°C.

2.2. Preparation of Extracts
Dried extract granules were originally obtained from Tianjiang Pharmaceutical Co.,
Aloha Medicinals, Inc., or Min Tong Pharmaceutical Co., Ltd. and kindly provided to us
by Dr. Clare Zhang. Each extract, with the exception of AG which was already in an
aqueous solution, was reconstituted in sterile mQ water at a ratio of 1:4 w/v and mixed
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on a rocker at room temperature for 72 hours. Each solution was centrifuged at 2000 x g
for 10 min to separate undissolved particles and sterilized using a 0.2 μm PEM filter.
Total protein content within the extract stocks was determined using the Pierce BCA
protein assay (Thermo Fisher Scientific Inc.). Stocks were stored at 4°C and diluted with
sterile mQ water to the indicated concentration prior to each experiment.

2.3. Cell Viability Assays
Cell viability was assessed via modified 3‐(4,5‐dimethylthiazol‐2‐yl)−2,5‐
diphenyltetrazolium bromide (MTT) assay using the CellTiter 96® Non‐Radioactive cell
proliferation assay (Promega). Briefly, cells were seeded at 8 x 104 cells in 400μL in a 24‐
well plate and allowed to attach overnight. The cells were then treated with each extract
at the indicated concentrations or sterile mQ water as the vehicle control for 12, 24, or 48
hours. Absorbance was measured as optical density (OD) at a wavelength of 570 nm
using the VersaMax microplate reader (Molecular Devices). The OD of vehicle‐treated
control cells represented 100% viability. Viability of treated cells was expressed as a
percentage of vehicle‐treated control cells.

2.4. Caspase‐3/7 Activity Assay
Active caspase‐3 and ‐7 activity was measured in BxPC‐3 cells treated with AA, SC, and
8‐mix using the Caspase‐Glo® 3/7 assay (Promega). Cells were seeded at 6 x 104 cells in
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400μL in each well of a 24‐well plate and allowed to attach overnight. The cells were
then treated with various concentrations of AA, SC, 8‐mix, or sterile mQ water and
incubated for 12 hours. Equal volume of Caspase‐Glo reagent was added to each well
and the reaction incubated at RT for 1 hour. The luminescence of each sample was
measured in relative light units (RLU) using the BD Monolight™ 3010 luminometer
according to its manual. The luminescence of the vehicle‐treated cells was used as the
blank.

2.5. Statistical Analysis
Results are presented as mean ± SE of the number of indicated independent
experiments. Statistical significance was determined by performing one‐way analysis of
variance (ANOVA) followed by Dunnett’s multiple comparison post‐test with the
vehicle‐treated cells as the control in GraphPad Prism 5.01.

3. Results
3.1. Effects of CS, AG, and 8‐mix on 1.1B4 Cell Proliferation
To determine the effects of CS, AG, and 8‐mix on pancreatic beta cells proliferation, we
tested each extract at concentrations from 10 to 1000 μg/mL for 12 hours. The results of
three independent experiments are shown in Figure 7. Interestingly, the data shows that
while the lower concentrations of 8‐mix do exert a proliferative effect on the 1.1B4 cells,
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there is a subsequent dose‐dependent decrease in viability at concentrations greater
than 100 μg/mL. This observation prompted our investigation into the potential growth
inhibition of pancreatic cancer cells by the extracts.

3.2. Viability of PANC‐1 and BxPC‐3 Cells Treated with CS, AG, and 8‐mix
We then treated PANC‐1 and BxPC‐3 cells with CS, AG, and 8‐mix for 12 hours. The
data in Figure 8 and Figure 9 show similar trends to that of the 1.1B4 cells in both
PANC‐1 and BxPC‐3 cell lines whereby lower doses of the 8‐mix extract leads to
increased proliferation while higher concentrations ultimately inhibits the cells’
viability.

3.3. Viability of PANC‐1 and BxPC‐3 Cells Treated with Individual Extracts from 8‐mix
We next investigated whether the individual extracts that comprise 8‐mix had a similar
inhibitory effect or if the observed suppression of pancreatic cancer cell viability
required their combination. Figure 10 shows a robust divergence in the viability of
PANC‐1 cells treated with AA, SC, and PO from that of PANC‐1 cells treated with CF,
PH, RG, AP, GF, and 8‐mix at concentrations exceeding 500 μg/mL. The data from the
treated BxPC‐3 cells also demonstrates that AA, SC, and PO inhibit cell viability while
the remaining individual extracts and 8‐mix lead to either no significant change or an
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increase in viability, though the point at which they deviate is not as distinct as is seen
in PANC‐1 cells (Fig. 11).

3.4. Validation of Inhibition by AA, SC, and PO Extracts
To confirm the observed inhibitory effects of AA, SC, and PO, we obtained new batches
of the dried extracts and created a new stock solution of each. We then repeated the
viability tests on PANC‐1 cells to determine whether the effects we observed were
batch‐specific. Remarkably, treatment with AA and SC produced results consistent with
the prior experiments while PO did not (Fig. 12). The average percent viability of
PANC‐1 cells treated with 1250 μg/mL of the original AA, PO, and SC stocks was 55.7,
33.72, and 14.65, respectively (Fig. 10) whereas treatment with the new stocks resulted
in an average of 40.38, 73.1, and 15.5 percent viability, respectively (Fig. 12). We
postulated that the extraction process could have been inconsistent between batches or
that the bioactive component(s) responsible for the inhibitory effects we initially
observed was unstable or inconsistent. In any case, we continued our investigation with
AA and SC.

3.5. Viability of 1.1B4 Cells Treated with AA, SC, and 8‐mix
To determine the specificity of the inhibitory effect of AA and SC regarding cancerous
and normal cells, we measured the viability of 1.1B4 cells in response to their treatment.
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Figure 13 shows that SC and 8‐mix, but not AA, significantly inhibit proliferation after
24 hours of treatment at concentrations as low as 300 and 500 μg/mL, respectively. This
finding is significant because an ideal adjuvant chemotherapeutic agent would target
malignant cells and exert little to no toxicity on neighboring healthy cells.

3.6. Caspase‐3/7 Activity of BxPC‐3 Cells Treated with AA, SC, and 8‐mix
While AA and SC clearly demonstrate a dose‐ and time‐dependent inhibition of PANC‐
1 and BxPC‐3 cell viability, we aimed to define the method by which the extracts inhibit
the cells and whether caspase‐dependent apoptosis was initiated. To determine this, we
utilized a luciferase‐based assay to measure the activation of caspase‐3 and ‐7 which are
essential for caspase‐dependent apoptosis induction. Figure 14 shows that BxPC‐3 cells
treated with AA exhibit greater caspase‐3 and ‐7 activity than any other treatment by
far, while the caspase‐3 and ‐7 activity of those treated with 8‐mix is analogous to the
control cells. Conspicuously, cells treated with 200 and 400 μg/mL of SC express
caspase activity similar to the control cells whereas higher concentrations result in
negligible caspase activity. Based on further scrutiny of the caspase and viability data,
in addition to the morphological distinctions between PANC‐1 and BxPC‐3 cells treated
with SC compared to those treated with AA (Fig. 15‐18), we suspected that the growth
inhibition exerted by SC is more likely a result of necrotic or other injury than caspase‐
dependent apoptosis. Therefore, we chose to focus our investigation on AA and its
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potential bioactive compounds against pancreatic cancer cell proliferation and drug
resistance.

4. Discussion
Pancreatic cancer is one of the leading causes of cancer‐related deaths owing to a
compendium of hallmarks, including non‐specific symptoms which lead to primarily
late stage diagnoses, extensive tumor heterogeneity, and lack of therapeutic options due
to resistance. The exact mechanisms that afford pancreatic tumors to so deftly
circumvent chemotherapeutic intervention are still incompletely understood;
consequently, even after two decades of research into therapeutic options more effective
than the standard gemcitabine, progress has been scant. This search for improved
therapeutic efficacy is made even more desperate by the dismally low survival rate [2].
Plant and natural product‐based treatment options are an especially advantageous
resource for such an urgent need as their native activity generally requires them to
readily interact with other proteins and undergo enzymatic modulation [150‐152].
While it cannot be denied that the outcome of the present study could not have been
predicted based on its inceptive premise, what has materialized is the genesis of an
equally intriguing notion; a potential novel, naturally derived therapeutic agent for the
treatment of advanced pancreatic cancer may exist in the extract of Anemarrhena
asphodeloides.
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In this study, we screened several herbal extracts utilized in traditional medicine for
their potential growth inhibitory effects on pancreatic cancer cells. We chose to
investigate these readily available, well tolerated extracts based on their current clinical
efficacy against pancreas‐specific disorders. We measured the viability response of cells
treated with a range of concentrations of each extract to discern whether any were able
to inhibit the proliferation of PDAC cells. Effector caspase activity was also evaluated in
response to the two extracts most effective in impeding cell viability to determine if the
observed growth inhibition was caused by programmed cell death via apoptosis.
Finally, we identified AA as the only extract which consistently affected PDAC cell
growth through stimulating caspase‐dependent apoptosis mechanisms. Prior to this
study AA and some of its secondary metabolites such as flavonoids, saponins, and
sapogenins had been shown to elicit varying degrees of cytotoxic and anti‐tumorigenic
properties in models of leukemia, ovarian, and colon cancer models, but it had not been
examined in pancreatic cancer [170‐173]. Thus, our findings from this preliminary study
warranted further probing into the molecular mechanisms by which AA inhibit
proliferation and induce apoptosis in pancreatic cancer cells, which is detailed in the
ensuing chapters.
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Table 1: List of selected extracts and their source.
Common
Name

TCM
Name

Scientific Name

Commercial
Source

Batch/
Lot No.

Natural
Source

Astragalus
(AP)1

Huang
Qi

Astragalus propinquus
Schischkin

Tianjiang
Pharmaceutical
Co., Ltd.

0501319

Root

Pseudostellaria Tai Zi
(PH)1
Shen

Pseudostellaria
heterophylla (Miq.) Pax

0900318

Root

Gypsum
fibrosum (GF)1

Shi Gao

N/A

0307018

Mineral

Rehmannia
(RG)1

Sheng
Di

Rehmannia glutinosa
(Gaertn.) DC.

0914919

Root

Anemarrhena
(AA)1

Zhi Mu

Anemarrhena
asphodeloides Bunge

1005417
0515417

Rhizome

Cornus fruit
(CF)1

Shan
Zhu Yu

Cornus officinalis
Siebold & Zucc.

43120201

Fruit

Schisandra
(SC)1

Wu
Wei Zi

Schisandra chinensis
(Turcz.) Baill.

33104801
42104801

Fruit

Solomon’s Seal
(PO)1

Yu Zhu

Polygonatum odoratum
(Mill.) Druce

31107501
43107501

Rhizome

Cordyceps
(CS)

Cordyceps sinensis
Dong
(Berk.) Sacc.
Chong
Xia Cao
Xi Yang Panax quinquefolius L.
Shen

Tianjiang
Pharmaceutical
Co., Ltd.
Tianjiang
Pharmaceutical
Co., Ltd.
Tianjiang
Pharmaceutical
Co., Ltd.
Tianjiang
Pharmaceutical
Co., Ltd.
Min Tong
Pharmaceutical
Co., Ltd.
Min Tong
Pharmaceutical
Co., Ltd.
Min Tong
Pharmaceutical
Co., Ltd.
Aloha
Medicinals, Inc.

071013‐
CS

Fungus

404775

Root

American
ginseng (AG)
1

denotes extracts which comprise “8‐mix”.
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Figure 7: Viability of 1.1B4 cells treated with CS, AG, and 8‐mix. 1.1B4 cells were
treated with the indicated concentrations of CS, AG, 8‐mix, or vehicle for 12 hours. Data
from three independent experiments are expressed as mean ± SE. Viability was
calculated as a percentage of the vehicle‐treated control cells. Statistical significance is
indicated where viability was inhibited compared to the control cells and calculated by
one‐way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001).
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Figure 8: Viability of PANC‐1 cells treated with CS, AG, and 8‐mix. PANC‐1 cells
were treated with the indicated concentrations of CS, AG, 8‐mix, or vehicle for 12 hours.
Data from two independent experiments are expressed as mean ± SE. Viability was
calculated as a percentage of the vehicle‐treated control cells. Statistical significance is
indicated where viability was inhibited compared to the control cells and calculated by
one‐way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001).
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Figure 9: Viability of BxPC‐3 cells treated with CS, AG, and 8‐mix. BxPC‐3 cells were
treated with the indicated concentrations of CS, AG, 8‐mix, or vehicle for 12 hours. Data
from two independent experiments are expressed as mean ± SE. Viability was
calculated as a percentage of the vehicle‐treated control cells. Statistical significance is
indicated where viability was inhibited compared to the control cells and calculated by
one‐way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001).
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Figure 10: PANC‐1 cells treated with individual extracts from 8‐mix. PANC‐1 cells
were treated with the indicated concentrations of AA, AP, CF, GF, PH, PO, RG, SC, 8‐
mix, or vehicle for 24 (A) or 48 (B) hours. Data from three independent experiments are
expressed as mean ± SE. Viability was calculated as a percentage of the vehicle‐treated
control cells. Statistical significance is indicated where viability was inhibited compared
to the control cells and calculated by one‐way ANOVA (*p < 0.05, **p < 0.01, ***p <
0.001).
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Figure 10: continued.
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Figure 11: BxPC‐3 cells treated with individual extracts from 8‐mix. BxPC‐3 cells were
treated with the indicated concentrations of AA, AP, CF, GF, PH, PO, RG, SC, 8‐mix, or
vehicle for 24 (A) or 48 (B) hours. Data from three independent experiments are
expressed as mean ± SE. Viability was calculated as a percentage of the vehicle‐treated
control cells. Statistical significance is indicated where viability was inhibited compared
to the control cells and calculated by one‐way ANOVA (*p < 0.05, **p < 0.01, ***p <
0.001).
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Figure 11: continued.
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Figure 12: Batch validation of AA, PO, and SC. PANC‐1 cells were treated for 24 hours
with the indicated concentrations of AA, PO, and SC extracts from the new batch. Data
from three independent experiments are expressed as mean ± SE. Viability was
calculated as a percentage of the vehicle‐treated control cells.
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Figure 13: 1.1B4 cells treated with AA, SC, and 8‐mix. 1.1B4 cells were treated with the
indicated concentrations of AA, SC, or 8‐mix for 24 hours. Data from two independent
experiments are expressed as mean ± SE. Viability was calculated as a percentage of the
vehicle‐treated control cells. Statistical significance is indicated where viability was
inhibited compared to the control cells and calculated by one‐way ANOVA (*p < 0.05,
**p < 0.01, ***p < 0.001). Note: Data reprinted with permission from original author,
Arielle Sharp.
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Figure 14: Caspase‐3/7 activity in BxPC‐3 cells treated with AA, SC, and 8‐mix. Levels
of active caspase‐3 and ‐7 were determined via luciferase assay. Relative activity
compared to vehicle‐treated control cells.
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Figure 15: Morphology of BxPC‐3 cells treated with AA. BxPC‐3 cells were treated
with vehicle control (A), 250 μg/mL AA (B), 750 μg/mL AA (C), or 1250 μg/mL AA (D)
for 24 hours. Images shown at 40x magnification.
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Figure 16: Morphology of BxPC‐3 cells treated with SC. BxPC‐3 cells were treated with
vehicle control (A), 250 μg/mL SC (B), 750 μg/mL SC (C), or 1250 μg/mL SC (D) for 24
hours. Images shown at 40x magnification.
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Figure 17: Morphology of PANC‐1 cells treated with AA. PANC‐1 cells were treated
with vehicle control (A), 250 μg/mL AA (B), 750 μg/mL AA (C), or 1250 μg/mL AA (D)
for 24 hours. Images shown at 40x magnification.
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Figure 18: Morphology of PANC‐1 cells treated with SC. PANC‐1 cells were treated
with vehicle control (A), 250 μg/mL SC (B), 750 μg/mL SC (C), or 1250 μg/mL SC (D) for
24 hours. Images shown at 40x magnification.
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CHAPTER THREE:
ANEMARRHENA ASPHODELOIDES BUNGE AND ITS CONSTITUENT
TIMOSAPONIN‐AIII INDUCE CELL CYCLE ARREST AND APOPTOSIS IN
PANCREATIC CANCER CELLS
Note to Reader
Portions of this chapter have been previously published in FEBS Open Bio, 2018, 8(7):
1155‐1166, and have been reproduced with permission from Wiley. Catherine B.
MarElia conceived and designed the study, performed experiments and data analysis,
and wrote the manuscript. Arielle E. Sharp and Tiffany A. Shemwell assisted with data
acquisition. Y. Clare Zhang conceived and designed the study. Brant R. Burkhardt
conceived and designed the study, interpreted data, and contributed to manuscript
writing. All authors read and approved the final manuscript.

1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers with nearly
equal incidence and mortality rates due to a combination of factors including a lack of
early detection methods, limited surgical options, and ineffective treatment options due
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to drug and apoptotic resistance [174]. Surgery remains the only potential curative
therapeutic approach but is not a viable option for most patients as more than 80% are
already in an advanced disease state at the time of detection [175]. Relapse of the
disease is common in patients whose tumors are initially resectable, rendering
chemotherapy a necessity even after surgical intervention. Standard chemotherapy for
advanced PDAC since 1997 has been the deoxycytidine analog gemcitabine alone or in
combination with nab‐Paclitaxel or 5‐fluorouracil [105]. However, the prognosis in
these patients remains poor due to chemoresistance resulting in substantial treatment
failure in addition to debilitating side effects [176].

Mutations within a concerted network of several core cellular signaling pathways can
be found throughout the progression of PDAC [177]. Phosphatidylinositol‐3 kinase
(PI3K)/Akt signaling represents one of the most frequently altered pathways in PDAC
and regulates the activity of a litany of substrates involved in cell survival, proliferation,
growth, and motility. Increased activity of the serine/threonine kinase Akt promotes cell
survival and evasion of apoptosis through the inhibition of pro‐apoptotic proteins
including Bcl‐2‐associated death promoter (BAD) and the activation of pro‐survival
substrates and has been observed in several types of cancers [178, 179]. One of the
primary negative regulators of PI3K/Akt activity is phosphatase and tensin homologue
deleted on chromosome ten (PTEN); inactivating mutations within PTEN contribute to
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the hyperactive state of the PI3K/Akt pathway and progression of PDAC [180].
Glycogen synthase kinase‐3 (GSK‐3α/β) plays a critical role in controlling several cell
cycle regulators and transcription factors which affect cell fate. Akt catalyzes the
inhibition of GSK‐3 via phosphorylation at Ser21 and Ser9 (on GSK‐3α and GSK‐3β,
respectively) [181]. The mammalian target of rapamycin (mTOR) signaling pathway is
also affected by mutational Akt activity through phosphorylation and activation of the
mTORC1 complex. Phosphorylated mTOR promotes cell growth by enhancing the
transcription of growth factor mRNAs via the activation of several substrates, including
p70 S6 kinase 1 [182].

The exploration of plants as a source of chemotherapeutic agents in Western medicine
has been active since the 1950s with the discovery of the vinca alkaloids vinblastine and
vincristine isolated from Catharanthus roseus and the isolation of cytotoxic
podophyllotoxins [183]. The rhizome of Anemarrhena asphodeloides Bunge (AA) has been
a significant fixture in Traditional Chinese Medicine (TCM) for thousands of years and
is the only species in the genus. Its primary chemical components are steroidal
saponins, flavonoids, phenylpropanoids, alkaloids, steroids, organic acids, and
anthraquinones. Most abundant among the identified constituents are steroidal
saponins. Timosaponin‐AIII (TAIII), a steroidal saponin first isolated from AA by
Kawasaki et al. in 1963, has exhibited pro‐apoptotic and anti‐metastatic efficacy against
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non‐small cell lung cancer, melanoma, colorectal carcinoma, and breast cancer in vitro
[171, 184‐187]. Although recent studies suggest AA and its constituents may possess
potent antitumor properties, its prospective use in the treatment of refractory pancreatic
cancer has yet to be elucidated. In this study we identified the inhibitory effects of AA
and TAIII on PDAC cell lines in part through modulation of PI3K/Akt pathway
proteins.

2. Materials and Methods
2.1. Chemicals and Reagents
Timosaponin‐AIII (TAIII) (CAS registry number: 41059‐79‐4) was purchased from Santa
Cruz Biotechnology. HPLC analysis by the manufacturer determined the purity was
greater than 98%. Gemcitabine hydrochloride (CAS registry number: 122111‐03‐9) was
purchased from Sigma‐Aldrich. HPLC analysis by the manufacturer determined a
purity greater than 98%. Rabbit monoclonal antibodies against cleaved caspase‐3
(Asp175; Cat. 9664), mouse monoclonal antibody against β‐actin (Cat. 3700), and HRP‐
linked secondary antibodies were purchased from Cell Signaling Technology.

2.2. Preparation of AA Extract and TAIII Stock
AA extract stock was prepared as previously described in Chapter Two. A stock
solution of 8 mM TAIII was prepared in dimethyl sulfoxide (DMSO) then diluted with
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sterile mQ water to a final concentration of 0.5% DMSO for each treatment condition.
Stock solution was stored at ‐20°C.

2.3. Determination of TAIII Content in AA Extract via LC‐MS‐TOF
LC‐MS analysis was performed using Agilent 1200 series/6230 TOF liquid
chromatography/mass spectrometer with a SynergiTM 4 μm Hydro‐RP LC column (250 x
4.6 mm) with 80 Å pore size. Samples of AA (0.5 mg/mL) and TAIII (0.1 mg/mL) were
run in positive mode at a flow rate of 1 mL per min using a 14 min gradient of 0‐98%
ACN in 0.05% formic acid. TAIII content in the AA extract was determined by
comparison to reference sample.

2.4. Cell Viability Assay
Viability of PANC‐1 and BxPC‐3 cells was assessed as described in Chapter Two with
the exception of using 10,000 cells per well in a 96‐well plate. After attaching overnight,
the cells were treated with equal volumes of various concentrations of AA and TAIII,
with and without 1 mM gemcitabine, 1 mM gemcitabine alone, and sterile mQ water or
0.5% DMSO vehicle control for 24 or 48 hours.
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2.5. Flow Cytometric Analysis of Cell Cycle Distribution
Cell cycle distribution was determined using propidium iodide (PI) cellular DNA
staining. BxPC‐3 cells were seeded at a density of 1.25x106 cells in 5 mL in 25 cm2 flasks
and allowed to attach overnight. The media was then replaced with fresh media
containing each treatment condition. After 24 hours the cells were harvested and
washed then re‐suspended in cold PBS. The cells were added dropwise to cold 70%
ethanol and fixed overnight at ‐20°C. Fixed cells were washed in cold PBS and filtered
through a 40 μM nylon cell strainer to remove aggregates. The cells were stained at a
density of 1x106 cells in 500 μL staining solution (0.1% Triton X‐100, 20 μg/mL PI, and
0.2 mg/mL DNase‐free RNase A in PBS) and incubated at RT in the dark for 30 min.
Intracellular DNA data was acquired by a BD Accuri C6 cytometer. Debris and doublets
were excluded by gating on forward vs. side scatter‐area and forward scatter‐area vs.
forward scatter‐height. Gates were performed on the control sample and uniformly
applied to each sample. At least 10,000 gated events were used for analysis and the
resulting cell cycle distribution was determined using FCS Express 6 software (De Novo
Software).

2.6. Protein Extraction and Western Blot Analysis
PANC‐1 cells were seeded at a density of 1.25x106 cells in 5 mL in 25 cm2 flasks and
treated as indicated above. After collection, standard lysis buffer supplemented with 1x
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Halt Protease Inhibitor Cocktail (Thermo Fisher Scientific Inc.) was used to obtain
whole cell lysate. The samples were sonicated and protein concentrations were
determined using the BCA Protein Assay. Equivalent protein content was loaded into
each lane, separated by SDS‐PAGE (Mini‐PROTEAN TGX Pre‐Cast gels, 4‐20%), and
transferred to PVDF membranes. Membranes were blocked with 5% non‐fat dry milk in
tris‐buffered saline with 0.05% Tween‐20 (TBST) and probed with primary antibodies
against indicated proteins diluted in 5% non‐fat dry milk or BSA in TBST overnight at
4°C. Blots were then incubated with a horseradish peroxidase (HRP)‐conjugated
secondary antibody specific to the primary antibody in 5% non‐fat dry milk in TBST at
RT for 1 hour. Signal was detected using SuperSignal West Pico PLUS
Chemiluminescent Substrate (Pierce). Blots were imaged and analyzed using the
Amersham Imager 600 and the accompanying ImageQuant TL 8.1 software (GE
Healthcare Life Sciences).

2.7. Analysis of PI3K/Akt Pathway Signaling Activity via Bead‐based Multiplex Assay
Phosphorylated forms of Akt (Ser473), mTOR (Ser2248), BAD (Ser136), p70 S6 kinase (Thr389),
GSK‐3α/β (Ser21/Ser9), and PTEN (Ser380) were detected in the lysate of PANC‐1 cells
treated under the aforementioned conditions using the Bio‐Plex Pro cell signaling Akt
panel (Bio Rad). The only deviation from the given protocol was the use of 1x Halt
Protease Inhibitor Cocktail in place of phenylmethylsulfonyl fluoride in the cell lysis
78

buffer. Analysis was performed using the Luminex MAGPIX. Percent median
fluorescence intensity (MFI) of each analyte is expressed as a percentage of the MFI
corresponding to the vehicle control‐treated sample.

2.8. Statistical Analysis
Results are presented as mean ± SE of the number of indicated independent
experiments. Statistical significance was determined by performing a two‐tailed,
unpaired Student’s t‐test or one‐way analysis of variance (ANOVA) followed by
Tukey’s multiple comparison post‐test in GraphPad Prism 5.01.

3. Results
3.1. TAIII Content in AA Extract via LC‐MS‐TOF Analysis
Since TAIII is one of the chemical signatures of AA, and in order to relatively compare
the activity of the whole extract with TAIII as a single compound, we first wanted to
confirm the presence of TAIII in our AA extract. We employed LC‐MS‐TOF to compare
the ESI‐MS spectra of the extract (Fig. 19A; RT: 11.24) to that of the TAIII reference
standard (Fig. 19B; RT: 11.23). Analysis of the standard TAIII sample and the AA
extract showed the protonated molecule at m/z 741.44. Furthermore, fragment ions at
m/z 579.38 [MH ‐ Glu]+ and 417.34 [MH ‐ Glu ‐ Gal]+ characteristic of TAIII are present
in both ESI‐MS spectra [188].
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3.2. AA Enhances Inhibition of Pancreatic Cancer Cells by Gemcitabine
PANC‐1 and BxPC‐3 cells are resistant to gemcitabine to varying degrees, with PANC‐1
cells exhibiting less sensitivity than BxPC‐3 cells [189]. To determine the effect of AA
alone and in the presence of gemcitabine on the viability of pancreatic cancer cells, we
treated PANC‐1 and BxPC‐3 cells for 24 and 48 hours with increasing concentrations of
AA or AA and 1 mM gemcitabine. As shown in Figure 20, AA exhibited a dose‐
dependent decrease in viability of both cell lines. The viability of PANC‐1 cells exposed
to 750, 1000, and 1250 μg/mL AA alone and with gemcitabine for 24 and 48 hours was
substantially decreased compared to those treated with only gemcitabine (p <
0.001)(Fig. 20A‐B). Co‐treatment of 1000 and 1250 μg/mL AA plus gemcitabine for 24
hours was significantly more effective at inhibiting viability than the same
concentration of AA alone (p < 0.05 or p < 0.01)(Fig. 20A). A marked decrease in cell
proliferation was seen in BxPC‐3 cells treated with AA alone and with gemcitabine at
concentrations greater than 500 μg/mL (p < 0.05 or p < 0.001)(Fig. 20C‐D). BxPC‐3 cells
treated for 24 hours with 500, 750, and 1000 μg/mL AA plus gemcitabine exhibited
significantly less viability than those treated with the same concentration of AA (p <
0.05 or p < 0.01). Taken together, these data suggest that AA not only inhibits the
viability of PANC‐1 and BxPC‐3 cells but it also appreciably enhances the effect of
gemcitabine in a dose‐dependent manner.
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3.3. Effects of TAIII on Viability of Pancreatic Cancer Cell Lines
We next wanted to examine the effect of the single compound TAIII on the viability of
PANC‐1 and BxPC‐3 cells. As shown in Figure 21, TAIII dose‐dependently inhibited
PANC‐1 cells (Fig. 21A‐B), with the highest dose reducing the viability after 24 and 48
hours to approximately 25% and 19%, respectively. Viability of PANC‐1 cells treated for
24 hours with 5, 10, and 20 μM TAIII was significantly less than in those treated with
gemcitabine alone (p < 0.05 or p < 0.001). Simultaneous exposure of TAIII with
gemcitabine also resulted in significant inhibition of PANC‐1 cells compared to
gemcitabine, though not to the same degree as the TAIII‐only samples. BxPC‐3 cells
treated for 24 hours with 10 and 20 μM TAIII alone and 10 μM TAIII with gemcitabine
also exhibited significantly reduced viability compared to gemcitabine treatment (p <
0.05 or p < 0.01)(Fig. 21C). There was no significant difference observed in BxPC‐3 cells
treated for 48 hours with TAIII alone or with gemcitabine compared to gemcitabine
alone (Fig. 21D).

3.4. BxPC‐3 Cell Cycle Progression is Inhibited by AA and Arrested in G1 Phase by
TAIII
To elucidate the effect of AA and TAIII treatment on the progression of the cell cycle,
BxPC‐3 cells treated with increasing concentrations of either AA or TAIII for 24 hours
were fixed and stained with propidium iodide (PI) and their DNA content was
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analyzed by flow cytometry. As shown in Figure 22A, AA markedly disrupts the cell
cycle. At 250 μg/mL AA, there is a greater population of cells in G1 phase compared to
the control sample (73.90% and 47.17%, respectively), allowing fewer cells to reach S
and G2/M phases. At 750 and 1250 μg/mL AA, the cells exhibit a drastic shift in the cycle
resulting in a large portion of the cells stalling in the sub‐G1 phase (37.68% and 78.90%,
respectively) compared to the control (1.89%). Exposure to increasing concentrations of
TAIII for 24 hours resulted in a marked increase in the population of cells in G1 phase
(50.06%, 72.92%, and 72.86%) and a subsequent decrease in the S and G2/M phase
populations compared to the control (Fig. 22B). Cells treated with 20 μM TAIII exhibit a
notable increase in the sub‐G1 population compared to the control group (9.29% and
1.89%, respectively).

3.5. AA and TAIII Enhance Disruption of BxPC‐3 Cell Cycle by Gemcitabine
Pancreatic cancer is frequently resistant to gemcitabine, which can be due to several
possible mechanisms including efflux from the cell, downregulation of gemcitabine‐
activating proteins, and upregulation of gemcitabine‐inactivating proteins [115]. We
therefore wanted to determine if either AA or TAIII co‐treatment with gemcitabine
could have a greater effect on cell cycle progression than gemcitabine alone. Exposure
to AA and gemcitabine dramatically increased the portion of cells in the sub‐G1 phase
when compared to gemcitabine alone (Fig. 23A). The co‐treated cells also resulted in a
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more dramatic shift from the G1 to sub‐G1 populations than those treated with the
corresponding concentration of AA alone (Fig. 22A). TAIII plus gemcitabine resulted in
a dose‐dependent arrest in G1 phase and subsequent increase in the sub‐G1 population
compared to the gemcitabine‐only treated cells (Fig. 23B). As with AA, co‐treatment
with TAIII and gemcitabine resulted in a greater population of cells in the sub‐G1 phase
than those treated with TAIII alone (Fig. 22B). These results indicate that co‐treatment
of AA or TAIII and gemcitabine is more effective at inducing BxPC‐3 cell cycle arrest
than treatment with AA, TAIII, or gemcitabine as a single agent.

3.6. AA and TAIII Modulate Activation of PI3K/Akt Pathway Members
To determine the effect of AA and TAIII on the activation of PI3K/Akt pathway
proteins, PANC‐1 cells were treated for 24 hours as described above and evaluated for
phosphorylated Akt pathway proteins using the Bio‐Plex pro cell signaling Akt panel.
Activation via phosphorylation of the pro‐survival proteins mTOR and p70 S6 kinase
was significantly decreased in PANC‐1 cells treated with AA alone and with
gemcitabine compared to those in which only gemcitabine was administered (p <
0.001)(Fig. 24D‐E). Inhibitory phosphorylation of the pro‐apoptotic proteins PTEN and
BAD was also significantly decreased in PANC‐1 cells treated with AA alone and in
combination with gemcitabine compared to cells treated with gemcitabine alone (p <
0.01 or p < 0.001)(Fig. 24B‐C). While the differences in the expression levels of
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phosphorylated Akt, PTEN, mTOR, BAD, and GSK‐3 between cells treated with AA
and those treated with AA in the presence of gemcitabine did not reach statistical
significance, there is a clear stepwise and dose‐dependent decrease. This may indicate
that even subtle differences in the activity of these efficient proteins result in a biological
effect before reaching levels of statistical consequence. In the instance of
phosphorylated p70 S6 kinase, expression does not appear to differ between cells
treated with AA alone and with AA in the presence of gemcitabine. It is possible that
AA alters the expression of some cellular targets in such a drastic manner that it eclipses
any effect gemcitabine may have had. Phosphorylation of BAD, mTOR, and p70 S6
kinase was significantly decreased in cells treated with 20μM TAIII alone and with
gemcitabine compared to gemcitabine alone (p < 0.05 or p < 0.01)(Fig. 24C‐E). Similar to
the effect seen between treatment with AA and with AA plus gemcitabine, the levels of
phosphorylated BAD between cells treated with 20μM TAIII with and without
gemcitabine do not differ statistically, though there may still be a biologically
significant variance. Additionally, there may still be other causative proteins targeted
by AA and TAIII that we have yet to identify.

3.7. AA and TAIII Induce Caspase‐Dependent Apoptosis in PANC‐1 Cells
Based on the combined results of the viability, cell cycle, and multiplex analysis, we
suspected AA and TAIII elicit a caspase‐dependent apoptotic cascade. To investigate
84

this, the lysates of PANC‐1 cells treated with AA or TAIII alone and in the presence of
gemcitabine were examined by Western blot analysis for activated caspase‐3. The
results showed a clear dose‐dependent increase in active caspase‐3 in PANC‐1 cells
treated with AA compared to the vehicle‐treated control cells and those treated with
only gemcitabine. There is a similar trend in the cells treated with increasing
concentrations of TAIII, albeit to a lesser degree. Interestingly, the level of active
caspase‐3 in the cells treated with TAIII is slightly greater than in the cells treated with
both TAIII and gemcitabine which mirrors the cell viability data seen in Figure 21;
again this suggests that the presence of gemcitabine affects the activity of TAIII within
the cells. These results indicate that AA and TAIII initiate apoptosis in PANC‐1 cells via
a caspase‐dependent mechanism.

4. Discussion
Pancreatic ductal adenocarcinoma (PDAC) is one of the most highly lethal cancers and
its incidence rate is currently on the rise. Due to a lack of sensitive and accurate
detection methods, a propensity for metastasis, and nearly universal drug resistance,
the 5‐year survival rate among patients whose tumors have disseminated at the time of
detection is among the lowest of any cancer [2, 174]. In the three decades since the
landmark study that led to gemcitabine as the primary chemotherapeutic agent for
PDAC, progress toward a more effective and less toxic treatment has been scant. Recent
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treatment regimens such as gemcitabine + nab‐Paclitaxel and FOLFIRINOX (5‐
fluorouracil, leucovorin, irinotecan, oxaliplatin) have offered only modest
improvements to overall survival or debilitating side effects, therefore the dire need for
effective treatment with low toxicity still remains [190, 191].

In recent years, interest in natural products such as herbal extracts as anti‐cancer agents
has gained significant traction as they offer a multitude of active compounds and the
potential for significant reduction of the toxicity associated with traditional
chemotherapy. The extract of Anemarrhena asphodeloides Bunge (AA) as well as its
bioactive compound timosaponin‐AIII (TAIII) have demonstrated anti‐cancer effects in
a number of cancer types, however neither have been investigated for efficacy against
PDAC cell growth and gemcitabine resistance which we have done in our present
study. Our results demonstrate that AA and TAIII markedly inhibit the growth of
PANC‐1 and BxPC‐3 cells and induce caspase‐dependent apoptosis by modulating the
activity of PI3K/Akt pathway proteins involved in cell cycle and proliferation. As seen
in Figure 20, treatment of PANC‐1 and BxPC‐3 cells with AA exhibits a hormetic‐like,
biphasic dose response wherein there is a low dose stimulatory effect and subsequent
inhibition with increasing doses. This dose response phenomenon frequently occurs
across biological models as low concentrations of a particular substance elicit a
protective stress response within the cells while higher doses overwhelm normal repair
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mechanisms and are able to affect the intended receptor or signaling pathway [192,
193]. A similar biphasic dose response can be seen in the results of our multiplex
analysis examining the expression of phosphorylated Akt and PTEN (Fig. 24A‐B).
Notably, both AA and TAIII exhibit a greater degree of inhibition in the PANC‐1 cells
which harbor an activating G12D KRAS mutation than in the BxPC‐3 cells which
express wild‐type KRAS [194]. The results also reveal that PANC‐1 cells subjected to
TAIII with gemcitabine exhibit less inhibition and modulation of PI3K/Akt pathway
proteins than those treated with TAIII alone. The opposite trend is true for AA, where
treatment with AA in the presence of gemcitabine is more effective than with AA alone.
This could indicate that one or more of the processes by which these cells resist
gemcitabine also, at least partially, affects TAIII. Several mechanisms of gemcitabine
resistance have been demonstrated in PDAC cells and tumors, including highly efficient
efflux of the drug due to increased expression of multidrug resistant (MDR) and ATP‐
binding cassette (ABC) transporters which could potentially also affect levels of TAIII
within the cells [195, 196].

Regulation of the cell cycle involves a delicate balance of several concerted processes
whose disruption is a hallmark of tumor proliferation and drug resistance. Thus,
chemotherapeutic agents that can force cancer cells into an arrested cell cycle and
eventually induce apoptosis are of great interest. Our results show that AA causes the
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cells to steadily decrease S and G2 phase populations, while the majority of cells enter a
sub‐G1 phase. Treatment with TAIII leads to a dose‐dependent decrease in S and G2
phase populations and increased G1 populations, resulting in G1 arrest. Multiplex
analysis also revealed that treatment with AA led to a significant decrease in
phosphorylated GSK‐3α/β and, along with TAIII (20 μM), significantly reduced
phosphorylation of p70 S6 kinase in PANC‐1 cells compared to treatment with
gemcitabine. p70 S6 kinase is activated by phosphorylation and one of its major
functions is regulation of cell growth and it is required for progression through the G1
phase [197]. GSK‐3 is a critical downstream kinase in the PI3K/Akt pathway and can be
inhibited via Akt‐mediated phosphorylation at Ser21 (GSK‐3α) and Ser9 (GSK‐3β) [181].
Under normal conditions, GSK‐3β regulates cyclin D1 turnover and subsequently the
transition from G1 phase to S phase by phosphorylation, however the role of GSK‐3α/β
in PDAC remains a topic of controversy as it has demonstrated both tumor suppressor
and oncogenic effects [198]. The activities of GSK‐3 are also highly dependent upon
whether it is located in the cytoplasm or nucleus [199]. Taken together, these data
indicate that AA and TAIII disrupt PDAC cell cycle progression, are concordant with
the viability assay data shown in Figure 20 and Figure 21, and suggest the possibility of
distinct mechanisms of action between AA and TAIII.
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In addition to aberrant cell cycle and growth regulation, PDAC is highly adept at
circumventing apoptosis induction by both intracellular mechanisms and
chemotherapeutic agents. It has been repeatedly demonstrated that over‐activation of
the PI3K/Akt pathway contributes to proliferation and drug resistance in PDAC. Thus,
this pathway is an attractive target in the search for vulnerabilities within PDAC cells to
attenuate resistance and induce apoptosis. Our results indicate that while the combined
effect is not synergistic, both AA and TAIII singularly and with gemcitabine are able to
inhibit the phosphorylation of PI3K/Akt pathway proteins and promote apoptosis in
PDAC cells to a much greater extent than gemcitabine alone.

In summary, the results of our study demonstrate that the extract of Anemarrhena
asphodeloides Bunge and its constituent timosaponin‐AIII modulate the activity of
PI3K/Akt pathway proteins and are potent inhibitors of PDAC cell proliferation. These
findings demonstrate the importance of further investigation into the potential anti‐
tumorigenic and gemcitabine‐sensitizing properties of AA and TAIII in treating
advanced pancreatic cancer.

89

A.

Figure 19: TAIII present in AA extract. The presence of timosaponin‐AIII in our AA
extract was determined by comparing the LC‐MS‐TOF ESI spectra of the whole extract
(A) to that of the TAIII reference sample (B).
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B.

Figure 19: continued.
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Figure 20. AA inhibits viability of PDAC cell lines and potentiates gemcitabine
efficacy. PANC‐1 (A‐B) and BxPC‐3 (C‐D) cells were incubated with the indicated
concentrations of AA, with and without 1 mM gemcitabine, 1 mM gemcitabine alone, or
vehicle for 24 (A, C) or 48 (B, D) hours. Data from three independent experiments are
expressed as mean ± SE. Viability was calculated as a percentage of the vehicle‐treated
control cells. Statistically significant inhibition was determined compared to cells
treated with gemcitabine alone (*p < 0.05, **p < 0.01, ***p < 0.001) and between treatment
with AA alone and AA + gemcitabine (#p < 0.05, # #p < 0.01).
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Figure 20: continued.
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Figure 20: continued.
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Figure 20: continued.
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Figure 21: Effect of TAIII on PANC‐1 and BxPC‐3 cell viability. PANC‐1 (A‐B) and
BxPC‐3 (C‐D) cells were incubated with the indicated concentrations of TAIII, with and
without 1 mM gemcitabine, 1 mM gemcitabine alone, or vehicle for 24 (A, C) or 48 (B,
D) hours. Data from three independent experiments are expressed as mean ± SE.
Viability was calculated as a percentage of the vehicle‐treated control cells. Statistically
significant inhibition was determined compared to cells treated with gemcitabine alone
(*p < 0.05, **p < 0.01, ***p < 0.001).
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Figure 21: continued.
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Figure 21: continued.
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Figure 21: continued.
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Figure 22: AA and TAIII induce cell cycle arrest and dysfunction in BxPC‐3 cells.
Flow cytometric analysis of BxPC‐3 cells treated with the indicated concentrations of
AA (A), TAIII (B), or 0.5% DMSO for 24 hours. Cell cycle distribution was determined
by staining intracellular DNA with PI. At least 10,000 gated cells used for analysis of
each sample. Data shown are representative of three independent experiments.
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Figure 22: continued.
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Figure 23: Co‐treatment with AA or TAIII enhances ability of gemcitabine to impede
BxPC‐3 cell cycle progression. Flow cytometric analysis of BxPC‐3 cells treated with the
indicated concentrations of AA + 1 mM gemcitabine (A), TAIII + 1 mM gemcitabine (B),
or 1 mM gemcitabine alone for 24 hours. Cell cycle distribution was determined by
staining intracellular DNA with PI. At least 10,000 gated cells used for analysis of each
sample. Data shown are representative of three independent experiments.
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Figure 23: continued.
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Figure 24: AA and TAIII in the presence and absence of gemcitabine modulate the
activity of Akt signaling pathway members. PANC‐1 cells were treated with 1 mM
gemcitabine, AA or TAIII (250, 750, or 1250 μg/mL and 5, 10, or 20 μM, respectively)
alone or with 1 mM gemcitabine, or vehicle for 24 hours. Phosphorylation of several
Akt pathway members (A‐F) was measured by the magnetic based cell signaling
multiplex assay. Results from two independent experiments are expressed as the
relative percent median fluorescence intensity (MFI) compared to the vehicle‐treated
control for each analyte. Significant differences from the gemcitabine‐only treatment are
indicated (*p < 0.05, **p < 0.01, ***p < 0.001).
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Figure 24: continued.
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Figure 24: continued.
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Figure 24: continued.
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Figure 24: continued.
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Figure 24: continued.
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Figure 25: Caspase‐3 activation in PANC‐1 cells treated with AA or TAIII and
gemcitabine. The expression of activated caspase‐3 was examined by Western blot
analysis of PANC‐1 cells treated with AA or TAIII, alone or in combination with 1 mM
gemcitabine, 1 mM gemcitabine alone, or vehicle. Expression of β‐Actin used as a
loading control. Data shown are representative of three independent experiments.
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Figure 26: Schematic of AA and TAIII mechanism of action against PDAC cells.
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CHAPTER FOUR:
ANEMARRHENA ASPHODELOIDES AND TIMOSAPONIN‐AIII ENHANCE
GEMCITABINE SENSITIVITY IN PDAC CELLS BY MODULATING THE
EXPRESSION AND ACTIVITY OF KEY METABOLIC COMPONENTS

1. Abstract
The purpose of our present study was to identify the mechanisms by which AA and
TAIII ameliorate gemcitabine sensitivity in PDAC cells. Gemcitabine is a prodrug which
requires nucleoside transporters for cellular uptake and a series of sequential
phosphorylation events to produce its active metabolites. Aberrant expression and
activity of these transporters and metabolic enzymes have been demonstrated to cause
gemcitabine resistance in PDAC cell lines and tumors. Western blot and RT‐qPCR
analysis revealed differential expression of gemcitabine transport and metabolism
components, most notably increased activity of the primary gemcitabine‐activating
catalyst deoxycytidine kinase (dCK), in cells treated with AA or TAIII in combination
with gemcitabine compared to those treated with gemcitabine alone. This finding is
significant because the initial phosphorylation of gemcitabine by dCK is considered the
rate limiting step in gemcitabine activation and a strong correlation between dCK
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expression levels and gemcitabine sensitivity in vitro and in vivo has been established.
Further investigation into how AA and TAIII induce dCK expression to overcome
gemcitabine resistance in PDAC could provide a novel, complimentary therapeutic
agent which can not only inhibit PDAC progression but also mitigate gemcitabine
resistance within the highly recalcitrant malignancy.

2. Materials and Methods
2.1. Protein and RNA Extraction
Protein and RNA were isolated and extracted from cells under each treatment or control
condition using the TRIzol Plus RNA Purification Kit from Invitrogen. The
accompanying protocol was adhered to with the exception of the final protein
resuspension. In lieu of resuspending the pelleted proteins in a solution of 1% SDS, we
solubilized the pellet in an optimized buffer (100mM Tris‐HCl [pH 8.0] 20mM EDTA,
140mM NaCl, 5% SDS supplemented with 1x HALT Protease and Phosphatase inhibitor
cocktail [Thermo Fisher Scientific]) at 50°C for 2 hours [200].
Total protein and RNA concentration for each sample was measured by BCA assay and
Nanodrop, respectively. Protein was stored at ‐20°C and RNA was stored at ‐80°C.
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2.2. RT‐qPCR
To determine the transcriptional expression levels of several components of
intracellular gemcitabine metabolism, we utilized quantitative reverse transcription
polymerase chain reaction (RT‐qPCR). RT‐qPCR was performed using custom TaqMan®
Array Plates (Life Technologies) according to the manufacturer’s protocol. Expression
levels of solute carrier family 29 member 1 (SLC29A1) which encodes the equilibrative
nucleoside transporter 1 (ENT1) protein (Assay ID: Hs01085706_m1), solute carrier
family 29 member 2 (SLC29A2) which encodes the equilibrative nucleoside transporter 2
(ENT2) protein (Assay ID: Hs01546959_g1), deoxycytidine kinase (DCK) (Assay ID:
Hs01040726_m1), ribonucleotide reductase catalytic subunit M1 (RRM1) (Assay ID:
Hs01040698_m1), ribonucleotide reductase catalytic subunit M2 (RRM2) (Assay ID:
Hs00357247_g1), mucin 1 (MUC1) (Assay ID: Hs00159357_m1), mucin 4 (MUC4) (Assay
ID: Hs00366414_m1), ATP binding cassette subfamily C member 1 (ABCC1) which
encodes the multidrug resistance‐associated protein 1 (MRP1) protein (Assay ID:
Hs01561483_m1), and ATP binding cassette subfamily C member 3 (ABCC3) which
encodes the multidrug resistance‐associated protein 3 (MRP3) (Assay ID:
Hs00978452_m1) were determined with 18S (Assay ID: Hs99999901_s1), defender
against cell death 1 (DAD1) (Assay ID: Hs00154671_m1), optineurin (OPTN) (Assay ID:
Hs00184221_m1), and glyceraldehyde‐3‐phosphate dehydrogenase (GAPDH) (Assay
ID: Hs02786624_g1) used as endogenous controls. Briefly, total RNA from PANC‐1 cells
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treated as outlined in the previous chapter was first transcribed into complimentary
DNA (cDNA) using the High‐Capacity RNA‐to‐cDNA™ Kit (Life Technologies). The
cDNA from each sample was then used to perform real‐time PCR using the Applied
Biosystems Step One Plus Real Time PCR System (Life Technologies). Relative
expression levels of each gene of interest were normalized to the averaged endogenous
controls using the 2‐ΔΔCt method from three independent experiments with each sample
run in duplicate.

2.3. Western Blot Analysis
Equivalent total protein (20μg) from each sample were separated by SDS‐PAGE,
transferred to PVDF membranes, and probed for the indicated proteins as described in
Chapter Three. Blots were imaged and analyzed using the Amersham Imager 600 and
the accompanying ImageQuant TL 8.1 software (GE Healthcare Life Sciences).
Expression of each protein of interest was normalized to GAPDH.

2.4. dCK Activity Assay
Endogenous dCK activity was measured using the Kinase‐Glo® Luminescent Kinase
Assay. Since the rate‐limiting step in gemcitabine activation is phosphorylation by dCK
in the cytoplasm, cytoplasmic protein was utilized for this assay. Nuclear and
cytoplasmic protein fractions were isolated from PANC‐1 cells treated as described
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previously using NE‐PER™ Nuclear and Cytoplasmic Extraction Reagents (Thermo
Scientific). Protein content within each fraction was determined by BCA protein assay.
Cytoplasmic protein from each sample (20μg) was incubated with a dCK substrate,
10μM Cytarabine or 10μM deoxycytidine, in 25μL reaction buffer (50mM Tris‐HCl [pH
7.6], 5mM MgCl2, 0.5mM DTT, 1mg/mL BSA) containing 1μM ATP at RT for 30 min.
After 30 min, equal volume of Kinase‐Glo® reagent was added to each sample and
incubated for 10 min. Luminescence was recorded as relative light unit (RLU) using a
BD Monolight™ 3010 luminometer.

3. Results
3.1. AA and TAIII Modulate Gemcitabine Uptake and Metabolism Gene Expression
To elucidate whether treatment with AA or TAIII in combination with gemcitabine
elicited differences in the expression of several transcripts related to gemcitabine
metabolism and resistance in PANC‐1 cells compared to those treated with gemcitabine
alone, we performed qRT‐PCR on RNA obtained from the treated cells. We observed a
discernable decrease in the expression of a number of genes whose overexpression
contributes to gemcitabine resistance, as well as an increase in genes whose decreased
expression is linked to resistance (Fig. 27). Expression of DCK was highest in the cells
treated with TAIII in combination with gemcitabine. Notably, the elevated expression of
RRM1 and RRM2 stimulated by gemcitabine treatment was markedly reduced in the
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cells co‐treated with AA and gemcitabine. Both AA and TAIII were able to reverse the
increased expression of the multidrug resistance‐associated ABC transporter 3 gene
ABCC3 detected in cells treated with gemcitabine. Additionally, levels of the nucleoside
transporter SLC29A2 was also increased by co‐treatment with each AA and TAIII.

3.2. AA Ameliorates RRM1/2 Protein Expression Changes Induced by Gemcitabine
Gemcitabine treatment has been shown to induce resistance in PDAC through several
proposed mechanisms, including an increase in expression of the RRM1 and RRM2
subunits. We observed this trend in our study where PANC‐1 cells treated with
gemcitabine exhibited a 0.92‐ and 2.42‐fold increase in RRM1 and RRM2 expression,
respectively (Fig. 28). Analysis of dCK, RRM1, and RRM2 protein levels revealed
differential expression of these proteins among those cells treated with either AA or
TAIII in combination with gemcitabine compared to gemcitabine monotreatment. Co‐
treatment of AA plus gemcitabine had the most pronounced effect on RRM1 and RRM2
expression compared to gemcitabine, while TAIII co‐treatment showed no
improvement. These results mirror the trend in RRM1 and RRM2 gene expression levels
between observed in Figure 27. Expression of dCK, the rate‐limiting enzyme in
gemcitabine activation, was increased by a factor of 1.2 and 0.22 in cells treated with
gemcitabine plus AA and TAIII, respectively, compared to the gemcitabine‐only treated
cells.
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3.3. AA and TAIII Increase dCK Activity in PANC‐1 Cells
The initial phosphorylation of gemcitabine by dCK to produce gemcitabine
monophosphate is considered the rate‐limiting step in generating gemcitabine’s active
metabolites, gemcitabine‐diphosphate and ‐triphosphate. To quantitate the amount of
dCK activity in response to each treatment, cytoplasmic protein from treated PANC‐1
cells was isolated and incubated with a substrate of dCK, cytarabine or deoxycytidine.
ATP consumption has a direct relationship with dCK activity and was determined
using a luminescent kinase assay [201]. We observed a striking increase in dCK activity
in PANC‐1 cells treated with AA alone and in combination with gemcitabine compared
to gemcitabine monotreatment (Fig. 29). When exposed to cytarabine and deoxycytidine
dCK‐containing protein from cells treated with AA plus gemcitabine exhibit a 2.49 and
3.59‐fold increase in dCK activity, respectively, over those treated with gemcitabine.
TAIII also induced increased dCK activity compared to gemcitabine treatment, though
not to the same degree as AA.

4. Discussion
Gemcitabine remains the cornerstone of chemotherapeutic regimens for patients with
advanced pancreatic cancer, however chemotherapeutic resistance is a hallmark of the
disease. The median overall survival for PDAC patients receiving gemcitabine is 6.7
months, with a 2‐year survival rate of 4% [191]. While other treatment regimens such as
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FOLFIRINOX or gemcitabine plus nab‐paclitaxel have begun to supersede gemcitabine
monotherapy in the clinics, their improvement in overall survival is either very modest
or comes at the expense of greater toxicity [190, 191]. Therefore, any treatment modality
that is well tolerated and can improve gemcitabine’s efficacy is urgently needed. The
results of our previous study demonstrate that both AA and TAIII in combination with
gemcitabine reduce viability, increase the induction of apoptosis, and modulate
PI3K/Akt pathway member activation in PDAC cells when compared to those treated
with gemcitabine alone. In the present investigation, our aim was to establish the
mechanisms by which AA and TAIII affect gemcitabine sensitivity in PDAC cells. The
elucidation of these mechanisms could potentially facilitate the development of a
therapeutic agent to ameliorate gemcitabine efficacy, thereby increasing the rate and
duration of overall survival in PDAC patients.

In this study, we determined the differential transcriptional and protein expression
levels of several genes and proteins related to the uptake, activation, and metabolism of
intracellular gemcitabine in PANC‐1 cells upon each treatment. The rate‐limiting step of
gemcitabine activation is its preliminary phosphorylation by dCK, whose expression
and activity are highly correlated with gemcitabine efficacy and overall survival in
PDAC cells and patients [116‐120]. Indeed, we discerned a significant enhancement of
the expression and activity of dCK in PANC‐1 cells treated with AA plus gemcitabine
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compared to gemcitabine. Additionally, our data demonstrates that treatment with AA
plus gemcitabine appreciably reduces the transcriptional and protein expression of
RRM1 and RRM2, whose increased expression is correlated with reduced gemcitabine
sensitivity [128, 129]. These data provide a clear mechanism for the enhanced
gemcitabine sensitivity we previously observed in PDAC cells when co‐treated with
AA.

Interestingly, the increased DCK gene expression observed in response to treatment
with TAIII plus gemcitabine did not translate to an equally substantial increase in dCK
protein expression or activation. This suggests the possibility of some posttranslational
regulation of dCK which occurs in PANC‐1 cells treated with TAIII but not AA.
Another significant difference between cells co‐treated with gemcitabine plus TAIII and
those with gemcitabine plus AA is the effect of RRM1 and RRM2 protein expression.
While AA co‐treatment substantially reverses the gemcitabine‐induced increase in
RRM1 and RRM2 expression, TAIII is unable to mitigate the augmented expression in
the presence of gemcitabine. These distinctions between co‐treatment with gemcitabine
plus AA and plus TAIII are likely indicative of the presence of additional compounds or
fractions within the entire extract which work synergistically with TAIII and are
required to subjugate the methods by which PDAC cells resist gemcitabine. This would
also explicate the reduced efficacy against PDAC proliferation when treated with TAIII
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plus gemcitabine in comparison to those treated with only TAIII as reported in the
previous chapter.
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Figure 27: Transcriptional profile of gemcitabine transport and metabolism genes in
treated PANC‐1 cells. qRT‐PCR was performed using RNA isolated from PANC‐1 cells
treated with AA (750 μg/mL), AA (750 μg/mL) plus gemcitabine (1 mM), TAIII (10 μM),
TAIII (10 μM) plus gemcitabine (1 mM), gemcitabine (1 mM), or vehicle. Gene
expression was normalized to the averaged 18S, GAPDH, DAD1, and OPTN expression.
Expression fold change calculated using the 2‐ΔΔCt method with data from three
independent experiments with each sample run in duplicate.
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Figure 28: Differential expression of gemcitabine metabolism proteins. Protein from
PANC‐1 cells treated as indicated was isolated run on SDS‐PAGE gel and probed for
dCK, RRM1, and RRM2. Relative expression normalized to GAPDH.
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Figure 29: Increased dCK activity in PANC‐1 cells treated with AA and TAIII. Active
dCK in cytosolic protein from PANC‐1 cells was quantitated via luminescent kinase
assay. Relative activity compared to vehicle‐treated control cells.
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CHAPTER FIVE:
LIMITATIONS AND FUTURE DIRECTIONS

1. Summary of Major Conclusions
The primary purpose of the study detailed in the preceding chapters was to elucidate
the potential cytotoxic effects of AA and TAIII against pancreatic cancer cells, which
had not been previously investigated. The results of Chapter Two demonstrate that AA
is, in fact, a significant inhibitor of PDAC cell viability. The data presented in Chapter
Three indicates that both AA and its constituent TAIII significantly inhibit PDAC cell
viability, cell cycle progression, and activity of survival mechanisms within the Akt
signaling network. AA and TAIII were also shown to elicit a caspase‐dependent
apoptotic response in PDAC cells. Furthermore, the results of the studies in Chapter
Four show that AA and, to a lesser degree, TAIII enhance PDAC sensitivity to
gemcitabine by modulating the transcriptional and protein expression of the key
gemcitabine metabolism proteins, dCK, RRM1, and RRM2. Additionally, the kinase
activity of dCK was shown to be increased in PDAC cells treated with AA or TAIII
compared to gemcitabine. Because pancreatic cancer remains such a recalcitrant disease
characterized in part by drug resistance, there is an urgent need to identify an
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adjunctive therapeutic which can increase gemcitabine’s efficacy within PDAC patients.
Our study demonstrates that further investigation into AA’s effect on PDAC
proliferation and gemcitabine sensitivity in vivo is warranted and may lead to the
development of such an adjunctive agent.

2. Limitations of the Studies
Throughout the studies detailed in this dissertation, we used the PANC‐1 and BxPC‐3
cell lines for our pancreatic cancer model. While the use of these cell lines is vital for
scrutinizing and gathering an understanding of cellular mechanisms affected by AA
and TAIII, the use of an in vivo PDAC model such as the genetically engineered KPC
mouse will be required to fully elucidate and confirm the effects in a physiological
setting. Furthermore, the study detailed in Chapter Four included a luciferase‐based
kinase assay to determine dCK activity in treated cells. There is currently no
commercial antibody available to probe for phosphorylated (therefore, active) dCK. The
kinase assay did provide insight into the differential dCK activity, and we can be
reasonably confident in our assumption that the ATP consumption measured
corresponds to active dCK due to the use of two dCK substrates and a consistent trend
observed with each, however without the proper antibody we cannot unequivocally
confirm our results.
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3. Future Directions
The findings of these studies described herein have provided novel insight into the
efficacy of AA and TAIII against proliferation and gemcitabine resistance within
pancreatic cancer cells. Additional questions have arisen in response to these findings,
which we hope to address in the future. Taken together, these collective results strongly
suggest the presence of complimentary compounds or fractions within AA that are
required to circumvent the chemoresistance mechanisms within the cells which TAIII
alone is unable to surmount. The next logical direction is to fractionate AA and test each
fraction in combination with TAIII in order to identify the synergistic fraction(s) or
compound(s). Moreover, AA, TAIII, and the newly identified complimentary fraction
should then be examined in the in vivo model described previously for their efficacy
against PDAC tumors and metastases. The precise mechanisms by which PDAC tumors
resist chemotherapeutic intervention are not completely understood, and by elucidating
the distinctions between AA and TAIII’s mechanisms of action we may be able to
provide further insight into the actions of this recalcitrant disease.

127

REFERENCES

1.

Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M. &
Matrisian, L. M. (2014) Projecting Cancer Incidence and Deaths to 2030: The
Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States,
Cancer Research. 74, 2913.

2.

Siegel, R. L., Miller, K. D. & Jemal, A. (2016) Cancer statistics, 2016, CA: A Cancer
Journal for Clinicians. 66, 7‐30.

3.

Mao, C., Domenico, D. R., Kim, K., Hanson, D. J. & Howard, J. M. (1995)
Observations on the developmental patterns and the consequences of pancreatic
exocrine adenocarcinoma. Findings of 154 autopsies, Archives of surgery (Chicago,
Ill : 1960). 130, 125‐34.

4.

Winter, J. M., Cameron, J. L., Campbell, K. A., Arnold, M. A., Chang, D. C.,
Coleman, J., Hodgin, M. B., Sauter, P. K., Hruban, R. H., Riall, T. S., Schulick, R.
D., Choti, M. A., Lillemoe, K. D. & Yeo, C. J. (2006) 1423
pancreaticoduodenectomies for pancreatic cancer: A single‐institution
experience, Journal of gastrointestinal surgery : official journal of the Society for
Surgery of the Alimentary Tract. 10, 1199‐210; discussion 1210‐1.

5.

Distler, M., Rückert, F., Hunger, M., Kersting, S., Pilarsky, C., Saeger, H.‐D. &
Grützmann, R. (2013) Evaluation of survival in patients after pancreatic head
resection for ductal adenocarcinoma, BMC Surgery. 13, 12‐12.

6.

Lowenfels, A. B., Maisonneuve, P., Cavallini, G., Ammann, R. W., Lankisch, P.
G., Andersen, J. R., Dimagno, E. P., Andren‐Sandberg, A. & Domellof, L. (1993)
Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study
Group, The New England journal of medicine. 328, 1433‐7.

7.

Giardiello, F. M., Brensinger, J. D., Tersmette, A. C., Goodman, S. N., Petersen, G.
M., Booker, S. V., Cruz‐Correa, M. & Offerhaus, J. A. (2000) Very high risk of
cancer in familial Peutz‐Jeghers syndrome, Gastroenterology. 119, 1447‐53.
128

8.

Lowenfels, A. B. & Maisonneuve, P. (2006) Epidemiology and risk factors for
pancreatic cancer, Best Practice & Research Clinical Gastroenterology. 20, 197‐209.

9.

Distler, M., Aust, D., Weitz, J., Pilarsky, C. & Grutzmann, R. (2014) Precursor
Lesions for Sporadic Pancreatic Cancer: PanIN, IPMN, and MCN, BioMed
Research International. 2014, 11.

10.

Hruban, R. H., Maitra, A., Kern, S. E. & Goggins, M. (2007) Precursors to
pancreatic cancer, Gastroenterology clinics of North America. 36, 831‐vi.

11.

Brembeck, F. H., Schreiber, F. S., Deramaudt, T. B., Craig, L., Rhoades, B., Swain,
G., Grippo, P., Stoffers, D. A., Silberg, D. G. & Rustgi, A. K. (2003) The mutant K‐
ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric
mucous neck cell hyperplasia in transgenic mice, Cancer Res. 63, 2005‐9.

12.

De La, O. J., Emerson, L. L., Goodman, J. L., Froebe, S. C., Illum, B. E., Curtis, A.
B. & Murtaugh, L. C. (2008) Notch and Kras reprogram pancreatic acinar cells to
ductal intraepithelial neoplasia, Proceedings of the National Academy of Sciences of
the United States of America. 105, 18907‐12.

13.

Guerra, C., Schuhmacher, A. J., Canamero, M., Grippo, P. J., Verdaguer, L.,
Perez‐Gallego, L., Dubus, P., Sandgren, E. P. & Barbacid, M. (2007) Chronic
pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K‐
Ras oncogenes in adult mice, Cancer cell. 11, 291‐302.

14.

Habbe, N., Shi, G., Meguid, R. A., Fendrich, V., Esni, F., Chen, H., Feldmann, G.,
Stoffers, D. A., Konieczny, S. F., Leach, S. D. & Maitra, A. (2008) Spontaneous
induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell
targeting of oncogenic Kras in adult mice, Proceedings of the National Academy of
Sciences of the United States of America. 105, 18913‐8.

15.

Li, D., Xie, K., Wolff, R. & Abbruzzese, J. L. (2004) Pancreatic cancer, The Lancet.
363, 1049‐1057.

16.

Brody, J. R., Witkiewicz, A. K. & Yeo, C. J. (2011) The Past, Present, and Future of
Biomarkers: A Need for Molecular Beacons for the Clinical Management of
Pancreatic Cancer, Advances in Surgery. 45, 301‐321.

17.

Poruk, K. E., Gay, D. Z., Brown, K., Mulvihill, J. D., Boucher, K. M., Scaife, C. L.,
Firpo, M. A. & Mulvihill, S. J. (2013) The Clinical Utility of CA 19‐9 in Pancreatic
Adenocarcinoma: Diagnostic and Prognostic Updates, Current molecular medicine.
13, 340‐351.
129

18.

Wu, E., Zhou, S., Bhat, K. & Ma, Q. (2013) CA 19‐9 and Pancreatic Cancer, Clinical
advances in hematology & oncology : H&O. 11, 53‐55.

19.

Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M.,
Hruban, R. H., Eshleman, J. R., Nowak, M. A., Velculescu, V. E., Kinzler, K. W.,
Vogelstein, B. & Iacobuzio‐Donahue, C. A. (2010) Distant metastasis occurs late
during the genetic evolution of pancreatic cancer, Nature. 467, 1114‐7.

20.

Herreros‐Villanueva, M. & Bujanda, L. (2016) Non‐invasive biomarkers in
pancreatic cancer diagnosis: what we need versus what we have, Annals of
translational medicine. 4, 134.

21.

Du, Y., Zhao, B., Liu, Z., Ren, X., Zhao, W., Li, Z., You, L. & Zhao, Y. (2017)
Molecular Subtyping of Pancreatic Cancer: Translating Genomics and
Transcriptomics into the Clinic, Journal of Cancer. 8, 513‐522.

22.

Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban,
R. H., Rustgi, A. K., Chang, S. & Tuveson, D. A. (2005) Trp53R172H and
KrasG12D cooperate to promote chromosomal instability and widely metastatic
pancreatic ductal adenocarcinoma in mice, Cancer Cell. 7, 469‐483.

23.

Schütte, U., Bisht, S., Brossart, P. & Feldmann, G. (2011) Recent developments of
transgenic and xenograft mouse models of pancreatic cancer for translational
research, Expert opinion on drug discovery. 6, 33‐48.

24.

Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D.,
Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., Frese, K.
K., DeNicola, G., Feig, C., Combs, C., Winter, S. P., Ireland‐Zecchini, H., Reichelt,
S., Howat, W. J., Chang, A., Dhara, M., Wang, L., Rückert, F., Grützmann, R.,
Pilarsky, C., Izeradjene, K., Hingorani, S. R., Huang, P., Davies, S. E., Plunkett,
W., Egorin, M., Hruban, R. H., Whitebread, N., McGovern, K., Adams, J.,
Iacobuzio‐Donahue, C., Griffiths, J. & Tuveson, D. A. (2009) Inhibition of
Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of
Pancreatic Cancer, Science. 324, 1457‐1461.

25.

Maitra, A. & Hruban, R. H. (2008) Pancreatic Cancer, Annual review of pathology.
3, 157‐188.

26.

Kanda, M., Matthaei, H., Wu, J., Hong, S. M., Yu, J., Borges, M., Hruban, R. H.,
Maitra, A., Kinzler, K., Vogelstein, B. & Goggins, M. (2012) Presence of somatic
mutations in most early‐stage pancreatic intraepithelial neoplasia,
Gastroenterology. 142, 730‐733.e9.
130

27.

Lohr, M., Kloppel, G., Maisonneuve, P., Lowenfels, A. B. & Luttges, J. (2005)
Frequency of K‐ras mutations in pancreatic intraductal neoplasias associated
with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta‐analysis,
Neoplasia (New York, NY). 7, 17‐23.

28.

Moskaluk, C. A., Hruban, R. H. & Kern, S. E. (1997) p16 and K‐ras gene
mutations in the intraductal precursors of human pancreatic adenocarcinoma,
Cancer Res. 57, 2140‐3.

29.

Cowan, R. W. & Maitra, A. (2014) Genetic progression of pancreatic cancer,
Cancer journal (Sudbury, Mass). 20, 80‐4.

30.

Schultz, N. A., Roslind, A., Christensen, I. J., Horn, T., Hogdall, E., Pedersen, L.
N., Kruhoffer, M., Burcharth, F., Wojdemann, M. & Johansen, J. S. (2012)
Frequencies and prognostic role of KRAS and BRAF mutations in patients with
localized pancreatic and ampullary adenocarcinomas, Pancreas. 41, 759‐66.

31.

Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A.,
Schmitz, F. & Wittinghofer, A. (1997) The Ras‐RasGAP Complex: Structural Basis
for GTPase Activation and Its Loss in Oncogenic Ras Mutants, Science. 277, 333.

32.

Choi, M., Bien, H., Mofunanya, A. & Powers, S. (2017) Challenges in Ras
therapeutics in pancreatic cancer, Seminars in cancer biology.

33.

Heimbrook, D. C. & Oliff, A. (1998) Therapeutic intervention and signaling,
Current opinion in cell biology. 10, 284‐8.

34.

Van Cutsem, E., van de Velde, H., Karasek, P., Oettle, H., Vervenne, W. L.,
Szawlowski, A., Schoffski, P., Post, S., Verslype, C., Neumann, H., Safran, H.,
Humblet, Y., Perez Ruixo, J., Ma, Y. & Von Hoff, D. (2004) Phase III trial of
gemcitabine plus tipifarnib compared with gemcitabine plus placebo in
advanced pancreatic cancer, Journal of clinical oncology : official journal of the
American Society of Clinical Oncology. 22, 1430‐8.

35.

Amanam, I. & Chung, V. (2018) Targeted Therapies for Pancreatic Cancer,
Cancers (Basel). 10.

36.

Zeitouni, D., Pylayeva‐Gupta, Y., Der, C. J. & Bryant, K. L. (2016) KRAS Mutant
Pancreatic Cancer: No Lone Path to an Effective Treatment, Cancers (Basel). 8.

37.

Schutte, M., Hruban, R. H., Geradts, J., Maynard, R., Hilgers, W., Rabindran, S.
K., Moskaluk, C. A., Hahn, S. A., Schwarte‐Waldhoff, I., Schmiegel, W., Baylin, S.
131

B., Kern, S. E. & Herman, J. G. (1997) Abrogation of the Rb/p16 tumor‐
suppressive pathway in virtually all pancreatic carcinomas, Cancer Res. 57, 3126‐
30.
38.

Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G.
& Bartek, J. (1995) Retinoblastoma‐protein‐dependent cell‐cycle inhibition by the
tumour suppressor p16, Nature. 375, 503‐6.

39.

Pomerantz, J., Schreiber‐Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin,
L., Potes, J., Chen, K., Orlow, I., Lee, H.‐W., Cordon‐Cardo, C. & DePinho, R. A.
(1998) The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2
and Neutralizes MDM2ʹs Inhibition of p53, Cell. 92, 713‐723.

40.

Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A.
B., Weinstein, C. L., Hruban, R. H., Yeo, C. J. & Kern, S. E. (1994) Frequent
somatic mutations and homozygous deletions of the p16 (MTS1) gene in
pancreatic adenocarcinoma, Nature genetics. 8, 27‐32.

41.

Scarpa, A., Capelli, P., Mukai, K., Zamboni, G., Oda, T., Iacono, C. & Hirohashi,
S. (1993) Pancreatic adenocarcinomas frequently show p53 gene mutations, Am J
Pathol. 142, 1534‐43.

42.

Nag, S., Qin, J., Srivenugopal, K. S., Wang, M. & Zhang, R. (2013) The MDM2‐p53
pathway revisited, Journal of Biomedical Research. 27, 254‐271.

43.

Levine, A. J. & Oren, M. (2009) The first 30 years of p53: growing ever more
complex, Nature reviews Cancer. 9, 749‐758.

44.

Lane, D. P. (1992) Cancer. p53, guardian of the genome, Nature. 358, 15‐6.

45.

Levine, A. J. (1997) p53, the cellular gatekeeper for growth and division, Cell. 88,
323‐31.

46.

Appella, E. & Anderson, C. W. (2001) Post‐translational modifications and
activation of p53 by genotoxic stresses, European journal of biochemistry. 268, 2764‐
72.

47.

Sherr, C. J. (2006) Divorcing ARF and p53: an unsettled case, Nat Rev Cancer. 6,
663‐73.

48.

Joerger, A. C. & Fersht, A. R. (2008) Structural biology of the tumor suppressor
p53, Annual review of biochemistry. 77, 557‐82.
132

49.

Brosh, R. & Rotter, V. (2009) When mutants gain new powers: news from the
mutant p53 field, Nat Rev Cancer. 9, 701‐13.

50.

Maitra, A., Adsay, N. V., Argani, P., Iacobuzio‐Donahue, C., De Marzo, A.,
Cameron, J. L., Yeo, C. J. & Hruban, R. H. (2003) Multicomponent analysis of the
pancreatic adenocarcinoma progression model using a pancreatic intraepithelial
neoplasia tissue microarray, Modern pathology : an official journal of the United
States and Canadian Academy of Pathology, Inc. 16, 902‐12.

51.

Grochola, L. F., Taubert, H., Greither, T., Bhanot, U., Udelnow, A. & Wurl, P.
(2011) Elevated transcript levels from the MDM2 P1 promoter and low p53
transcript levels are associated with poor prognosis in human pancreatic ductal
adenocarcinoma, Pancreas. 40, 265‐70.

52.

Weissmueller, S., Manchado, E., Saborowski, M., Morris, J. P. t., Wagenblast, E.,
Davis, C. A., Moon, S. H., Pfister, N. T., Tschaharganeh, D. F., Kitzing, T., Aust,
D., Markert, E. K., Wu, J., Grimmond, S. M., Pilarsky, C., Prives, C., Biankin, A.
V. & Lowe, S. W. (2014) Mutant p53 drives pancreatic cancer metastasis through
cell‐autonomous PDGF receptor beta signaling, Cell. 157, 382‐394.

53.

Schutte, M., Hruban, R. H., Hedrick, L., Cho, K. R., Nadasdy, G. M., Weinstein,
C. L., Bova, G. S., Isaacs, W. B., Cairns, P., Nawroz, H., Sidransky, D., Casero, R.
A., Jr., Meltzer, P. S., Hahn, S. A. & Kern, S. E. (1996) DPC4 gene in various tumor
types, Cancer Res. 56, 2527‐30.

54.

Hahn, S. A., Schutte, M., Hoque, A. T., Moskaluk, C. A., da Costa, L. T.,
Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H. & Kern, S.
E. (1996) DPC4, a candidate tumor suppressor gene at human chromosome
18q21.1, Science. 271, 350‐3.

55.

Chen, Y., Lebrun, J. J. & Vale, W. (1996) Regulation of transforming growth factor
beta‐ and activin‐induced transcription by mammalian Mad proteins, Proceedings
of the National Academy of Sciences of the United States of America. 93, 12992‐7.

56.

Zhang, Y., Feng, X. H. & Derynck, R. (1998) Smad3 and Smad4 cooperate with c‐
Jun/c‐Fos to mediate TGF‐beta‐induced transcription, Nature. 394, 909‐13.

57.

Derynck, R., Akhurst, R. J. & Balmain, A. (2001) TGF‐beta signaling in tumor
suppression and cancer progression, Nature genetics. 29, 117‐29.

58.

Waddell, N.Pajic, M.Patch, A.‐M.Chang, D. K.Kassahn, K. S.Bailey, P.Johns, A.
L.Miller, D.Nones, K.Quek, K.Quinn, M. C. J.Robertson, A. J.Fadlullah, M. Z.
133

H.Bruxner, T. J. C.Christ, A. N.Harliwong, I.Idrisoglu, S.Manning, S.Nourse,
C.Nourbakhsh, E.Wani, S.Wilson, P. J.Markham, E.Cloonan, N.Anderson, M.
J.Fink, J. L.Holmes, O.Kazakoff, S. H.Leonard, C.Newell, F.Poudel, B.Song,
S.Taylor, D.Waddell, N.Wood, S.Xu, Q.Wu, J.Pinese, M.Cowley, M. J.Lee, H.
C.Jones, M. D.Nagrial, A. M.Humphris, J.Chantrill, L. A.Chin, V.Steinmann, A.
M.Mawson, A.Humphrey, E. S.Colvin, E. K.Chou, A.Scarlett, C. J.Pinho, A.
V.Giry‐Laterriere, M.Rooman, I.Samra, J. S.Kench, J. G.Pettitt, J. A.Merrett, N.
D.Toon, C.Epari, K.Nguyen, N. Q.Barbour, A.Zeps, N.Jamieson, N. B.Graham, J.
S.Niclou, S. P.Bjerkvig, R.Grützmann, R.Aust, D.Hruban, R. H.Maitra,
A.Iacobuzio‐Donahue, C. A.Wolfgang, C. L.Morgan, R. A.Lawlor, R. T.Corbo,
V.Bassi, C.Falconi, M.Zamboni, G.Tortora, G.Tempero, M. A.Australian
Pancreatic Cancer Genome, I.Biankin, A. V.Johns, A. L.Mawson, A.Chang, D.
K.Scarlett, C. J.Brancato, M.‐A. L.Rowe, S. J.Simpson, S. H.Martyn‐Smith,
M.Thomas, M. T.Chantrill, L. A.Chin, V. T.Chou, A.Cowley, M. J.Humphris, J.
L.Jones, M. D.Scott Mead, R.Nagrial, A. M., et al. (2015) Whole genomes redefine
the mutational landscape of pancreatic cancer, Nature. 518, 495.
59.

Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.‐H., Leary, R. J., Angenendt, P.,
Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., Hong, S.‐M., Fu, B., Lin, M.‐T.,
Calhoun, E. S., Kamiyama, M., Walter, K., Nikolskaya, T., Nikolsky, Y., Hartigan,
J., Smith, D. R., Hidalgo, M., Leach, S. D., Klein, A. P., Jaffee, E. M., Goggins, M.,
Maitra, A., Iacobuzio‐Donahue, C., Eshleman, J. R., Kern, S. E., Hruban, R. H.,
Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., Velculescu, V. E. &
Kinzler, K. W. (2008) Core Signaling Pathways in Human Pancreatic Cancers
Revealed by Global Genomic Analyses, Science (New York, NY). 321, 1801‐1806.

60.

Bailey, P.Chang, D. K.Nones, K.Johns, A. L.Patch, A.‐M.Gingras, M.‐C.Miller, D.
K.Christ, A. N.Bruxner, T. J. C.Quinn, M. C.Nourse, C.Murtaugh, L.
C.Harliwong, I.Idrisoglu, S.Manning, S.Nourbakhsh, E.Wani, S.Fink, L.Holmes,
O.Chin, V.Anderson, M. J.Kazakoff, S.Leonard, C.Newell, F.Waddell, N.Wood,
S.Xu, Q.Wilson, P. J.Cloonan, N.Kassahn, K. S.Taylor, D.Quek, K.Robertson,
A.Pantano, L.Mincarelli, L.Sanchez, L. N.Evers, L.Wu, J.Pinese, M.Cowley, M.
J.Jones, M. D.Colvin, E. K.Nagrial, A. M.Humphrey, E. S.Chantrill, L. A.Mawson,
A.Humphris, J.Chou, A.Pajic, M.Scarlett, C. J.Pinho, A. V.Giry‐Laterriere,
M.Rooman, I.Samra, J. S.Kench, J. G.Lovell, J. A.Merrett, N. D.Toon, C. W.Epari,
K.Nguyen, N. Q.Barbour, A.Zeps, N.Moran‐Jones, K.Jamieson, N. B.Graham, J.
S.Duthie, F.Oien, K.Hair, J.Grützmann, R.Maitra, A.Iacobuzio‐Donahue, C.
A.Wolfgang, C. L.Morgan, R. A.Lawlor, R. T.Corbo, V.Bassi, C.Rusev, B.Capelli,
P.Salvia, R.Tortora, G.Mukhopadhyay, D.Petersen, G. M.Australian Pancreatic
Cancer Genome, I.Munzy, D. M.Fisher, W. E.Karim, S. A.Eshleman, J. R.Hruban,
134

R. H.Pilarsky, C.Morton, J. P.Sansom, O. J.Scarpa, A.Musgrove, E. A.Bailey, U.‐
M. H.Hofmann, O.Sutherland, R. L.Wheeler, D. A.Gill, A. J.Gibbs, R. A.Pearson,
J. V., et al. (2016) Genomic analyses identify molecular subtypes of pancreatic
cancer, Nature. 531, 47.
61.

Biankin, A. V.Waddell, N.Kassahn, K. S.Gingras, M.‐C.Muthuswamy, L. B.Johns,
A. L.Miller, D. K.Wilson, P. J.Patch, A.‐M.Wu, J.Chang, D. K.Cowley, M.
J.Gardiner, B. B.Song, S.Harliwong, I.Idrisoglu, S.Nourse, C.Nourbakhsh,
E.Manning, S.Wani, S.Gongora, M.Pajic, M.Scarlett, C. J.Gill, A. J.Pinho, A.
V.Rooman, I.Anderson, M.Holmes, O.Leonard, C.Taylor, D.Wood, S.Xu,
Q.Nones, K.Lynn Fink, J.Christ, A.Bruxner, T.Cloonan, N.Kolle, G.Newell,
F.Pinese, M.Scott Mead, R.Humphris, J. L.Kaplan, W.Jones, M. D.Colvin, E.
K.Nagrial, A. M.Humphrey, E. S.Chou, A.Chin, V. T.Chantrill, L. A.Mawson,
A.Samra, J. S.Kench, J. G.Lovell, J. A.Daly, R. J.Merrett, N. D.Toon, C.Epari,
K.Nguyen, N. Q.Barbour, A.Zeps, N.Australian Pancreatic Cancer Genome,
I.Kakkar, N.Zhao, F.Qing Wu, Y.Wang, M.Muzny, D. M.Fisher, W. E.Charles
Brunicardi, F.Hodges, S. E.Reid, J. G.Drummond, J.Chang, K.Han, Y.Lewis, L.
R.Dinh, H.Buhay, C. J.Beck, T.Timms, L.Sam, M.Begley, K.Brown, A.Pai,
D.Panchal, A.Buchner, N.De Borja, R.Denroche, R. E.Yung, C. K.Serra, S.Onetto,
N.Mukhopadhyay, D.Tsao, M.‐S.Shaw, P. A.Petersen, G. M.Gallinger, S.Hruban,
R. H.Maitra, A.Iacobuzio‐Donahue, C. A.Schulick, R. D.Wolfgang, C. L., et al.
(2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway
genes, Nature. 491, 399.

62.

Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D.,
Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M.‐L., McBride,
D. J., Varela, I., Nik‐Zainal, S. A., Leroy, C., Jia, M., Menzies, A., Butler, A. P.,
Teague, J. W., Griffin, C. A., Burton, J., Swerdlow, H., Quail, M. A., Stratton, M.
R., Iacobuzio‐Donahue, C. & Futreal, P. A. (2010) The patterns and dynamics of
genomic instability in metastatic pancreatic cancer, Nature. 467, 1109.

63.

van Heek, N. T., Meeker, A. K., Kern, S. E., Yeo, C. J., Lillemoe, K. D., Cameron, J.
L., Offerhaus, G. J. A., Hicks, J. L., Wilentz, R. E., Goggins, M. G., De Marzo, A.
M., Hruban, R. H. & Maitra, A. (2002) Telomere Shortening Is Nearly Universal
in Pancreatic Intraepithelial Neoplasia, The American Journal of Pathology. 161,
1541‐1547.

64.

Maitra, A., Kern, S. E. & Hruban, R. H. (2006) Molecular pathogenesis of
pancreatic cancer, Best practice & research Clinical gastroenterology. 20, 211‐26.

135

65.

Roy, D. M., Walsh, L. A. & Chan, T. A. (2014) Driver mutations of cancer
epigenomes, Protein & cell. 5, 265‐96.

66.

Weinhold, B. (2006) Epigenetics: The Science of Change, Environmental Health
Perspectives. 114, A160‐A167.

67.

Silverman, B. R. & Shi, J. (2016) Alterations of Epigenetic Regulators in Pancreatic
Cancer and Their Clinical Implications, International Journal of Molecular Sciences.
17, 2138.

68.

Ueki, T., Toyota, M., Skinner, H., Walter, K. M., Yeo, C. J., Issa, J. P., Hruban, R.
H. & Goggins, M. (2001) Identification and characterization of differentially
methylated CpG islands in pancreatic carcinoma, Cancer Res. 61, 8540‐6.

69.

Tan, A. C., Jimeno, A., Lin, S. H., Wheelhouse, J., Chan, F., Solomon, A.,
Rajeshkumar, N. V., Rubio‐Viqueira, B. & Hidalgo, M. (2009) Characterizing
DNA methylation patterns in pancreatic cancer genome, Molecular oncology. 3,
425‐38.

70.

Omura, N., Li, C. P., Li, A., Hong, S. M., Walter, K., Jimeno, A., Hidalgo, M. &
Goggins, M. (2008) Genome‐wide profiling of methylated promoters in
pancreatic adenocarcinoma, Cancer biology & therapy. 7, 1146‐56.

71.

Esteller, M., Sparks, A., Toyota, M., Sanchez‐Cespedes, M., Capella, G., Peinado,
M. A., Gonzalez, S., Tarafa, G., Sidransky, D., Meltzer, S. J., Baylin, S. B. &
Herman, J. G. (2000) Analysis of adenomatous polyposis coli promoter
hypermethylation in human cancer, Cancer Res. 60, 4366‐71.

72.

Klump, B., Hsieh, C. J., Nehls, O., Dette, S., Holzmann, K., Kießlich, R., Jung, M.,
Sinn, U., Ortner, M., Porschen, R. & Gregor, M. (2003) Methylation status of
p14ARF and p16INK4a as detected in pancreatic secretions, British Journal of
Cancer. 88, 217‐222.

73.

Fukushima, N., Sato, N., Sahin, F., Su, G. H., Hruban, R. H. & Goggins, M. (2003)
Aberrant methylation of suppressor of cytokine signalling‐1 (SOCS‐1) gene in
pancreatic ductal neoplasms, British Journal of Cancer. 89, 338‐343.

74.

Matsubayashi, H., Sato, N., Fukushima, N., Yeo, C. J., Walter, K. M., Brune, K.,
Sahin, F., Hruban, R. H. & Goggins, M. (2003) Methylation of cyclin D2 is
observed frequently in pancreatic cancer but is also an age‐related phenomenon
in gastrointestinal tissues, Clinical cancer research : an official journal of the American
Association for Cancer Research. 9, 1446‐52.
136

75.

Dammann, R., Schagdarsurengin, U., Liu, L., Otto, N., Gimm, O., Dralle, H.,
Boehm, B. O., Pfeifer, G. P. & Hoang‐Vu, C. (2003) Frequent RASSF1A promoter
hypermethylation and K‐ras mutations in pancreatic carcinoma, Oncogene. 22,
3806‐12.

76.

Delpu, Y., Hanoun, N., Lulka, H., Sicard, F., Selves, J., Buscail, L., Torrisani, J. &
Cordelier, P. (2011) Genetic and Epigenetic Alterations in Pancreatic
Carcinogenesis, Current Genomics. 12, 15‐24.

77.

Sato, N., Maitra, A., Fukushima, N., van Heek, N. T., Matsubayashi, H.,
Iacobuzio‐Donahue, C. A., Rosty, C. & Goggins, M. (2003) Frequent
hypomethylation of multiple genes overexpressed in pancreatic ductal
adenocarcinoma, Cancer Res. 63, 4158‐66.

78.

Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W. C., Mansour, J.,
Mollaee, M., Wagner, K. U., Koduru, P., Yopp, A., Choti, M. A., Yeo, C. J.,
McCue, P., White, M. A. & Knudsen, E. S. (2015) Whole‐exome sequencing of
pancreatic cancer defines genetic diversity and therapeutic targets, Nature
communications. 6, 6744.

79.

Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc,
J., Weinkle, J., Kim, G. E., Jakkula, L., Feiler, H. S., Ko, A. H., Olshen, A. B.,
Danenberg, K. L., Tempero, M. A., Spellman, P. T., Hanahan, D. & Gray, J. W.
(2011) Subtypes of pancreatic ductal adenocarcinoma and their differing
responses to therapy, Nature medicine. 17, 500‐3.

80.

Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G., Hoadley, K.
A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., Smyla, J. K.,
Anderson, J. M., Kim, H. J., Bentrem, D. J., Talamonti, M. S., Iacobuzio‐Donahue,
C. A., Hollingsworth, M. A. & Yeh, J. J. (2015) Virtual microdissection identifies
distinct tumor‐ and stroma‐specific subtypes of pancreatic ductal
adenocarcinoma, Nature genetics. 47, 1168‐78.

81.

Bachem, M. G., Schneider, E., Gross, H., Weidenbach, H., Schmid, R. M., Menke,
A., Siech, M., Beger, H., Grunert, A. & Adler, G. (1998) Identification, culture,
and characterization of pancreatic stellate cells in rats and humans,
Gastroenterology. 115, 421‐32.

82.

Bachem, M. G., Schunemann, M., Ramadani, M., Siech, M., Beger, H., Buck, A.,
Zhou, S., Schmid‐Kotsas, A. & Adler, G. (2005) Pancreatic carcinoma cells induce

137

fibrosis by stimulating proliferation and matrix synthesis of stellate cells,
Gastroenterology. 128, 907‐21.
83.

Apte, M., Haber, P., Applegate, T., Norton, I., McCaughan, G., Korsten, M.,
Pirola, R. & Wilson, J. (1998) Periacinar stellate shaped cells in rat pancreas:
identification, isolation, and culture, Gut. 43, 128‐133.

84.

Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D.,
Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., Frese, K.
K., DeNicola, G., Feig, C., Combs, C., Winter, S. P., Ireland, H., Reichelt, S.,
Howat, W. J., Chang, A., Dhara, M., Wang, L., Rückert, F., Grützmann, R.,
Pilarsky, C., Izeradjene, K., Hingorani, S. R., Huang, P., Davies, S. E., Plunkett,
W., Egorin, M., Hruban, R. H., Whitebread, N., McGovern, K., Adams, J.,
Iacobuzio‐Donahue, C., Griffiths, J. & Tuveson, D. A. (2009) Inhibition of
Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of
Pancreatic Cancer, Science.

85.

Mahadevan, D. & Von Hoff, D. D. (2007) Tumor‐stroma interactions in pancreatic
ductal adenocarcinoma, Molecular cancer therapeutics. 6, 1186‐1197.

86.

Ide, T., Kitajima, Y., Miyoshi, A., Ohtsuka, T., Mitsuno, M., Ohtaka, K., Koga, Y.
& Miyazaki, K. (2006) Tumor–stromal cell interaction under hypoxia increases
the invasiveness of pancreatic cancer cells through the hepatocyte growth
factor/c‐Met pathway, International journal of cancer. 119, 2750‐2759.

87.

Whatcott, C. J., Diep, C. H., Jiang, P., Watanabe, A., LoBello, J., Sima, C.,
Hostetter, G., Shepard, H. M., Von Hoff, D. D. & Han, H. (2015) Desmoplasia in
Primary Tumors and Metastatic Lesions of Pancreatic Cancer, Clinical Cancer
Research. 21, 3561‐3568.

88.

von Ahrens, D., Bhagat, T. D., Nagrath, D., Maitra, A. & Verma, A. (2017) The
role of stromal cancer‐associated fibroblasts in pancreatic cancer, Journal of
Hematology & Oncology. 10, 76.

89.

Özdemir, B. C., Pentcheva‐Hoang, T., Carstens, J. L., Zheng, X., Wu, C.‐C.,
Simpson, T., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., Acosta, A. D.,
Sharma, P., Heidari, P., Mahmood, U., Chin, L., Moses, H., Weaver, V., Maitra,
A., Allison, J. P., LeBleu, V. S. & Kalluri, R. (2014) Depletion of Carcinoma‐
Associated Fibroblasts and Fibrosis Induces Immunosuppression and
Accelerates Pancreas Cancer with Diminished Survival, Cancer cell. 25, 719‐734.

138

90.

Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra,
S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., Westphalen, C.
B., Kitajewski, J., Fernandez‐Barrena, M. G., Fernandez‐Zapico, M. E., Iacobuzio‐
Donahue, C., Olive, K. P. & Stanger, B. Z. (2014) Stromal elements act to restrain,
rather than support, pancreatic ductal adenocarcinoma, Cancer cell. 25, 735‐47.

91.

Yeo, C. J., Abrams, R. A., Grochow, L. B., Sohn, T. A., Ord, S. E., Hruban, R. H.,
Zahurak, M. L., Dooley, W. C., Coleman, J., Sauter, P. K., Pitt, H. A., Lillemoe, K.
D. & Cameron, J. L. (1997) Pancreaticoduodenectomy for pancreatic
adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A
prospective, single‐institution experience, Ann Surg. 225, 621‐33; discussion 633‐
6.

92.

(1987) Further evidence of effective adjuvant combined radiation and
chemotherapy following curative resection of pancreatic cancer. Gastrointestinal
Tumor Study Group, Cancer. 59, 2006‐10.

93.

Kalser, M. H. & Ellenberg, S. S. (1985) Pancreatic cancer. Adjuvant combined
radiation and chemotherapy following curative resection, Archives of surgery
(Chicago, Ill : 1960). 120, 899‐903.

94.

Neoptolemos, J. P., Dunn, J. A., Stocken, D. D., Almond, J., Link, K., Beger, H.,
Bassi, C., Falconi, M., Pederzoli, P., Dervenis, C., Fernandez‐Cruz, L., Lacaine, F.,
Pap, A., Spooner, D., Kerr, D. J., Friess, H. & Buchler, M. W. (2001) Adjuvant
chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a
randomised controlled trial, Lancet (London, England). 358, 1576‐85.

95.

Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H.,
Beger, H., Fernandez‐Cruz, L., Dervenis, C., Lacaine, F., Falconi, M., Pederzoli,
P., Pap, A., Spooner, D., Kerr, D. J. & Buchler, M. W. (2004) A randomized trial of
chemoradiotherapy and chemotherapy after resection of pancreatic cancer, The
New England journal of medicine. 350, 1200‐10.

96.

Iacobuzio‐Donahue, C. A., Fu, B., Yachida, S., Luo, M., Abe, H., Henderson, C.
M., Vilardell, F., Wang, Z., Keller, J. W., Banerjee, P., Herman, J. M., Cameron, J.
L., Yeo, C. J., Halushka, M. K., Eshleman, J. R., Raben, M., Klein, A. P., Hruban,
R. H., Hidalgo, M. & Laheru, D. (2009) DPC4 gene status of the primary
carcinoma correlates with patterns of failure in patients with pancreatic cancer,
Journal of clinical oncology : official journal of the American Society of Clinical
Oncology. 27, 1806‐13.

139

97.

Thind, K., Padrnos, L. J., Ramanathan, R. K. & Borad, M. J. (2017)
Immunotherapy in pancreatic cancer treatment: a new frontier, Therapeutic
advances in gastroenterology. 10, 168‐194.

98.

Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A. &
Vonderheide, R. H. (2007) Dynamics of the immune reaction to pancreatic cancer
from inception to invasion, Cancer Res. 67, 9518‐27.

99.

Tan, M. C., Goedegebuure, P. S., Belt, B. A., Flaherty, B., Sankpal, N., Gillanders,
W. E., Eberlein, T. J., Hsieh, C. S. & Linehan, D. C. (2009) Disruption of CCR5‐
dependent homing of regulatory T cells inhibits tumor growth in a murine
model of pancreatic cancer, Journal of immunology (Baltimore, Md : 1950). 182,
1746‐55.

100.

Pardoll, D. M. (2012) The blockade of immune checkpoints in cancer
immunotherapy, Nat Rev Cancer. 12, 252‐64.

101.

Kunk, P. R., Bauer, T. W., Slingluff, C. L. & Rahma, O. E. (2016) From bench to
bedside a comprehensive review of pancreatic cancer immunotherapy, Journal for
immunotherapy of cancer. 4, 14.

102.

Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H.
J., Murawa, P., Walde, D., Wolff, R. A., Campos, D., Lim, R., Ding, K., Clark, G.,
Voskoglou‐Nomikos, T., Ptasynski, M. & Parulekar, W. (2007) Erlotinib plus
gemcitabine compared with gemcitabine alone in patients with advanced
pancreatic cancer: a phase III trial of the National Cancer Institute of Canada
Clinical Trials Group, Journal of clinical oncology : official journal of the American
Society of Clinical Oncology. 25, 1960‐6.

103.

Rouanet, M., Lebrin, M., Gross, F., Bournet, B., Cordelier, P. & Buscail, L. (2017)
Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes, International
Journal of Molecular Sciences. 18, 1231.

104.

Dabernat, S., Lafitte, M., Bedel, A., de Verneuil, H. & Moreau‐Gaudry, F. (2013)
Gene Therapy of Pancreatic Cancer, Journal of Genetic Syndromes & Gene Therapy. ‐
4, ‐ 1‐7.

105.

Burris, H. r., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L.,
Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M. & Tarassoff, P.
(1997) Improvements in survival and clinical benefit with gemcitabine as first‐
line therapy for patients with advanced pancreas cancer: a randomized trial,
Journal of clinical oncology. 15, 2403‐2413.
140

106.

Kamisawa, T., Wood, L. D., Itoi, T. & Takaori, K. (2016) Pancreatic cancer, The
Lancet. 388, 73‐85.

107.

Young, J. D., Yao, S. Y., Baldwin, J. M., Cass, C. E. & Baldwin, S. A. (2013) The
human concentrative and equilibrative nucleoside transporter families, SLC28
and SLC29, Molecular aspects of medicine. 34, 529‐47.

108.

Ritzel, M. W. L., Ng, A. M. L., Yao, S. Y. M., Graham, K., Loewen, S. K., Smith, K.
M., Hyde, R. J., Karpinski, E., Cass, C. E., Baldwin, S. A. & Young, J. D. (2001)
Recent molecular advances in studies of the concentrative Na+‐dependent
nucleoside transporter (CNT) family: Identification and characterization of novel
human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine
and pyrimidine nucleosides (system cib), Molecular Membrane Biology. 18, 65‐72.

109.

Mackey, J. R., Mani, R. S., Selner, M., Mowles, D., Young, J. D., Belt, J. A.,
Crawford, C. R. & Cass, C. E. (1998) Functional nucleoside transporters are
required for gemcitabine influx and manifestation of toxicity in cancer cell lines,
Cancer Research. 58, 4349‐4357.

110.

Wong, A., Soo, R. A., Yong, W.‐P. & Innocenti, F. (2009) Clinical pharmacology
and pharmacogenetics of gemcitabine, Drug Metabolism Reviews. 41, 77‐88.

111.

Peters, G. J., Clavel, M., Noordhuis, P., Geyssen, G. J., Laan, A. C., Guastalla, J.,
Edzes, H. T. & Vermorken, J. B. (2007) Clinical phase I and pharmacology study
of gemcitabine (2ʹ, 2ʹ‐difluorodeoxycytidine) administered in a two‐weekly
schedule, Journal of chemotherapy (Florence, Italy). 19, 212‐21.

112.

Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B. & Plunkett, W. (1991) Action
of 2ʹ,2ʹ‐difluorodeoxycytidine on DNA synthesis, Cancer Res. 51, 6110‐7.

113.

Ruiz van Haperen, V. W., Veerman, G., Vermorken, J. B. & Peters, G. J. (1993)
2ʹ,2ʹ‐Difluoro‐deoxycytidine (gemcitabine) incorporation into RNA and DNA of
tumour cell lines, Biochemical pharmacology. 46, 762‐6.

114.

Heinemann, V., Xu, Y. Z., Chubb, S., Sen, A., Hertel, L. W., Grindey, G. B. &
Plunkett, W. (1990) Inhibition of ribonucleotide reduction in CCRF‐CEM cells by
2&#039;,2&#039;‐difluorodeoxycytidine, Molecular Pharmacology. 38, 567.

115.

de Sousa Cavalcante, L. & Monteiro, G. (2014) Gemcitabine: Metabolism and
molecular mechanisms of action, sensitivity and chemoresistance in pancreatic
cancer, European Journal of Pharmacology. 741, 8‐16.

141

116.

Marechal, R., Mackey, J. R., Lai, R., Demetter, P., Peeters, M., Polus, M., Cass, C.
E., Salmon, I., Deviere, J. & Van Laethem, J. L. (2010) Deoxycitidine kinase is
associated with prolonged survival after adjuvant gemcitabine for resected
pancreatic adenocarcinoma, Cancer. 116, 5200‐6.

117.

Ohhashi, S., Ohuchida, K., Mizumoto, K., Fujita, H., Egami, T., Yu, J., Toma, H.,
Sadatomi, S., Nagai, E. & Tanaka, M. (2008) Down‐regulation of deoxycytidine
kinase enhances acquired resistance to gemcitabine in pancreatic cancer,
Anticancer research. 28, 2205‐12.

118.

Ohmine, K., Kawaguchi, K., Ohtsuki, S., Motoi, F., Ohtsuka, H., Kamiie, J., Abe,
T., Unno, M. & Terasaki, T. (2015) Quantitative Targeted Proteomics of
Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to
Progression‐Free Survival of Patients Receiving Gemcitabine Treatment,
Molecular Pharmaceutics. 12, 3282‐3291.

119.

Saiki, Y., Yoshino, Y., Fujimura, H., Manabe, T., Kudo, Y., Shimada, M., Mano,
N., Nakano, T., Lee, Y., Shimizu, S., Oba, S., Fujiwara, S., Shimizu, H., Chen, N.,
Nezhad, Z. K., Jin, G., Fukushige, S., Sunamura, M., Ishida, M., Motoi, F., Egawa,
S., Unno, M. & Horii, A. (2012) DCK is frequently inactivated in acquired
gemcitabine‐resistant human cancer cells, Biochemical and biophysical research
communications. 421, 98‐104.

120.

Tang, K., Zhang, Z., Bai, Z., Ma, X., Guo, W. & Wang, Y. (2011) Enhancement of
gemcitabine sensitivity in pancreatic cancer by co‐regulation of dCK and p8
expression, Oncol Rep. 25, 963‐70.

121.

Amrutkar, M. & Gladhaug, I. P. (2017) Pancreatic Cancer Chemoresistance to
Gemcitabine, Cancers. 9, 157.

122.

Costantino, C. L., Witkiewicz, A. K., Kuwano, Y., Cozzitorto, J. A., Kennedy, E.
P., Dasgupta, A., Keen, J. C., Yeo, C. J., Gorospe, M. & Brody, J. R. (2009) The Role
of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up‐regulates the
Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase,
Cancer Research. 69, 4567‐4572.

123.

Richards, N. G., Rittenhouse, D. W., Freydin, B., Cozzitorto, J. A., Grenda, D.,
Rui, H., Gonye, G., Kennedy, E. P., Yeo, C. J., Brody, J. R. & Witkiewicz, A. K.
(2010) HuR status is a powerful marker for prognosis and response to
gemcitabine‐based chemotherapy for resected pancreatic ductal adenocarcinoma
patients, Annals of Surgery. 252, 499‐505.
142

124.

Skrypek, N., Duchêne, B., Hebbar, M., Leteurtre, E., van Seuningen, I. &
Jonckheere, N. (2012) The MUC4 mucin mediates gemcitabine resistance of
human pancreatic cancer cells via the Concentrative Nucleoside Transporter
family, Oncogene. 32, 1714.

125.

Eda, H., Ura, M., F‐Ouchi, K., Tanaka, Y., Miwa, M. & Ishitsuka, H. (1998) The
antiproliferative activity of DMDC is modulated by inhibition of cytidine
deaminase, Cancer Research. 58, 1165‐1169.

126.

Funamizu, N., Okamoto, A., Kamata, Y., Misawa, T., Uwagawa, T., Gocho, T.,
Yanaga, K. & Manome, Y. (2010) Is the resistance of gemcitabine for pancreatic
cancer settled only by overexpression of deoxycytidine kinase?, Oncology Reports.
23, 471‐475.

127.

Li, L., Fridley, B., Kalari, K., Jenkins, G., Batzler, A., Safgren, S., Hildebrandt, M.,
Ames, M., Schaid, D. & Wang, L. (2008) Gemcitabine and Cytosine Arabinoside
Cytotoxicity: Association with Lymphoblastoid Cell Expression, Cancer Research.
68, 7050‐7058.

128.

Goan, Y. G., Zhou, B., Hu, E., Mi, S. & Yen, Y. (1999) Overexpression of
ribonucleotide reductase as a mechanism of resistance to 2,2‐
difluorodeoxycytidine in the human KB cancer cell line, Cancer Research. 59, 4204‐
4207.

129.

Nakano, Y., Tanno, S., Koizumi, K., Nishikawa, T., Nakamura, K., Minoguchi,
M., Izawa, T., Mizukami, Y., Okumura, T. & Kohgo, Y. (2007) Gemcitabine
chemoresistance and molecular markers associated with gemcitabine transport
and metabolism in human pancreatic cancer cells, British Journal Of Cancer. 96,
457.

130.

Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W. & Whang, E. E. (2003) RNA
interference targeting the M2 subunit of ribonucleotide reductase enhances
pancreatic adenocarcinoma chemosensitivity to gemcitabine, Oncogene. 23, 1539.

131.

Mann, K., Melling, J., Rogoyski, B., Shaw, V., Ghaneh, P. & Greenhalf, W. (2015)
Post‐translational modifications of ribonucleotide reductase can explain acquired
gemcitabine resistance in pancreatic cancer, Pancreatology. 15, S20.

132.

Armstrong, E. A., Beal, E. W., Chakedis, J., Paredes, A. Z., Moris, D., Pawlik, T.
M., Schmidt, C. R. & Dillhoff, M. E. (2018) Exosomes in Pancreatic Cancer: from
Early Detection to Treatment, Journal of gastrointestinal surgery : official journal of
the Society for Surgery of the Alimentary Tract. 22, 737‐750.
143

133.

Richards, K. E., Zeleniak, A. E., Fishel, M. L., Wu, J., Littlepage, L. E. & Hill, R.
(2017) Cancer‐associated fibroblast exosomes regulate survival and proliferation
of pancreatic cancer cells, Oncogene. 36, 1770‐1778.

134.

Essandoh, K., Yang, L., Wang, X., Huang, W., Qin, D., Hao, J., Wang, Y.,
Zingarelli, B., Peng, T. & Fan, G.‐C. (2015) Blockade of exosome generation with
GW4869 dampens the sepsis‐induced inflammation and cardiac dysfunction,
Biochimica et biophysica acta. 1852, 2362‐2371.

135.

Binenbaum, Y., Fridman, E., Yaari, Z., Milman, N., Schroeder, A., Ben David, G.,
Shlomi, T. & Gil, Z. (2018) Transfer of miRNA in Macrophage‐Derived Exosomes
Induces Drug Resistance in Pancreatic Adenocarcinoma, Cancer Res. 78, 5287‐
5299.

136.

Mikamori, M., Yamada, D., Eguchi, H., Hasegawa, S., Kishimoto, T., Tomimaru,
Y., Asaoka, T., Noda, T., Wada, H., Kawamoto, K., Gotoh, K., Takeda, Y.,
Tanemura, M., Mori, M. & Doki, Y. (2017) MicroRNA‐155 Controls Exosome
Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal
Adenocarcinoma, Scientific reports. 7, 42339.

137.

Patel, G. K., Khan, M. A., Bhardwaj, A., Srivastava, S. K., Zubair, H., Patton, M.
C., Singh, S., Khushman, M. & Singh, A. P. (2017) Exosomes confer
chemoresistance to pancreatic cancer cells by promoting ROS detoxification and
miR‐155‐mediated suppression of key gemcitabine‐metabolising enzyme, DCK,
Br J Cancer. 116, 609‐619.

138.

Arlt, A., Gehrz, A., Müerköster, S., Vorndamm, J., Kruse, M.‐L., Fölsch, U. R. &
Schäfer, H. (2003) Role of NF‐κB and Akt/PI3K in the resistance of pancreatic
carcinoma cell lines against gemcitabine‐induced cell death, Oncogene. 22, 3243.

139.

Lau, J. P., Weatherdon, K. L., Skalski, V. & Hedley, D. W. (2004) Effects of
gemcitabine on APE/ref‐1 endonuclease activity in pancreatic cancer cells, and
the therapeutic potential of antisense oligonucleotides, British Journal of Cancer.
91, 1166‐1173.

140.

Xiong, G. S., Sun, H. L., Wu, S. M. & Mo, J. Z. (2010) Small interfering RNA
against the apurinic or apyrimidinic endonuclease enhances the sensitivity of
human pancreatic cancer cells to gemcitabine in vitro, Journal of Digestive Diseases.
11, 224‐230.

141.

Skrypek, N., Duchêne, B., Hebbar, M., Leteurtre, E., Van Seuningen, I. &
Jonckheere, N. (2013) The MUC4 mucin mediates gemcitabine resistance of
144

human pancreatic cancer cells via the Concentrative Nucleoside Transporter
family, Oncogene. 32, 1714‐1723.
142.

Shukla, S. K., Purohit, V., Mehla, K., Gunda, V., Chaika, N. V., Vernucci, E., King,
R. J., Abrego, J., Goode, G. D., Dasgupta, A., Illies, A. L., Gebregiworgis, T., Dai,
B., Augustine, J. J., Murthy, D., Attri, K. S., Mashadova, O., Grandgenett, P. M.,
Powers, R., Ly, Q. P., Lazenby, A. J., Grem, J. L., Yu, F., Matés, J. M., Asara, J. M.,
Kim, J.‐w., Hankins, J. H., Weekes, C., Hollingsworth, M. A., Serkova, N. J.,
Sasson, A. R., Fleming, J. B., Oliveto, J. M., Lyssiotis, C. A., Cantley, L. C., Berim,
L. & Singh, P. K. (2017) MUC1 and HIF‐1alpha Signaling Crosstalk Induces
Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic
Cancer, Cancer cell. 32, 71‐87.e7.

143.

Arora, S., Bhardwaj, A., Singh, S., Srivastava, S. K., McClellan, S., Nirodi, C. S.,
Piazza, G. A., Grizzle, W. E., Owen, L. B. & Singh, A. P. (2013) An undesired
effect of chemotherapy: Gemcitabine promotes pancreatic cancer cell
invasiveness through reactive oxygen species‐dependent, nuclear factorκb‐ and
hypoxia‐inducible factor 1α‐mediated up‐regulation of CXCR4, Journal of
Biological Chemistry. 288, 21197‐21207.

144.

Butler, M. S. (2005) Natural products to drugs: natural product derived
compounds in clinical trials, Natural product reports. 22, 162‐195.

145.

Cragg, G. M. & Newman, D. J. (2013) Natural products: A continuing source of
novel drug leads, Biochimica et Biophysica Acta (BBA) ‐ General Subjects. 1830, 3670‐
3695.

146.

Farnsworth, N. R., Akerele, O., Bingel, A. S., Soejarto, D. D. & Guo, Z. (1985)
Medicinal plants in therapy, Bulletin of the World Health Organization. 63, 965‐81.

147.

Mushtaq, S., Abbasi, B. H., Uzair, B. & Abbasi, R. (2018) Natural products as
reservoirs of novel therapeutic agents, EXCLI Journal. 17, 420‐451.

148.

Fabricant, D. S. & Farnsworth, N. R. (2001) The Value of Plants Used in
Traditional Medicine for Drug Discovery, Environmental Health Perspectives. 109,
69‐75.

149.

Müller‐Kuhrt, L. (2003) Putting nature back into drug discovery, Nat Biotechnol.
21, 602.

145

150.

Henkel, T., Brunne, R. M., Müller, H. & Reichel, F. (1999) Statistical Investigation
into the Structural Complementarity of Natural Products and Synthetic
Compounds, Angewandte Chemie International Edition. 38, 643‐647.

151.

Lee, M.‐L. & Schneider, G. (2001) Scaffold Architecture and Pharmacophoric
Properties of Natural Products and Trade Drugs: Application in the Design of
Natural Product‐Based Combinatorial Libraries, Journal of Combinatorial
Chemistry. 3, 284‐289.

152.

Brohm, D., Metzger, S., Bhargava, A., Müller, O., Lieb, F. & Waldmann, H. (2002)
Natural Products Are Biologically Validated Starting Points in Structural Space
for Compound Library Development: Solid‐Phase Synthesis of Dysidiolide‐
Derived Phosphatase Inhibitors, Angewandte Chemie International Edition. 41, 307‐
311.

153.

De Luca, V., Salim, V., Atsumi, S. M. & Yu, F. (2012) Mining the Biodiversity of
Plants: A Revolution in the Making, Science. 336, 1658‐1661.

154.

Noble, R. L., Beer, C. T. & Cutts, J. H. (2006) ROLE OF CHANCE
OBSERVATIONS IN CHEMOTHERAPY: VINCA ROSEA*, Annals of the New
York Academy of Sciences. 76, 882‐894.

155.

Cragg, G. M., Boyd, M. R., Cardellina, J. H., 2nd, Newman, D. J., Snader, K. M. &
McCloud, T. G. (1994) Ethnobotany and drug discovery: the experience of the US
National Cancer Institute, Ciba Foundation symposium. 185, 178‐90; discussion 190‐
6.

156.

Wall, M. E. & Wani, M. C. (1995) Camptothecin and taxol: discovery to clinic‐‐
thirteenth Bruce F. Cain Memorial Award Lecture, Cancer Res. 55, 753‐60.

157.

Kingston, D. (2011) Taxol and Its Analogs.

158.

Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A. T. & Sim, G. A.
(1966) Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a
Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca
acuminata1,2, Journal of the American Chemical Society. 88, 3888‐3890.

159.

Hsiang, Y. H., Hertzberg, R., Hecht, S. & Liu, L. F. (1985) Camptothecin induces
protein‐linked DNA breaks via mammalian DNA topoisomerase I, The Journal of
biological chemistry. 260, 14873‐8.

146

160.

Sriram, D., Yogeeswari, P., Thirumurugan, R. & Bal, T. R. (2005) Camptothecin
and its analogues: a review on their chemotherapeutic potential, Natural product
research. 19, 393‐412.

161.

Newman, D. J. & Cragg, G. M. (2016) Natural Products as Sources of New Drugs
from 1981 to 2014, Journal of Natural Products. 79, 629‐661.

162.

Wang, Y., Dan, Y., Yang, D., Hu, Y., Zhang, L., Zhang, C., Zhu, H., Cui, Z., Li, M.
& Liu, Y. (2014) The genus Anemarrhena Bunge: A review on
ethnopharmacology, phytochemistry and pharmacology, Journal of
Ethnopharmacology. 153, 42‐60.

163.

Koczurkiewicz, P., Czyz, J., Podolak, I., Wojcik, K., Galanty, A., Janeczko, Z. &
Michalik, M. (2015) Multidirectional effects of triterpene saponins on cancer cells
‐ mini‐review of in vitro studies, Acta biochimica Polonica. 62, 383‐93.

164.

Sang, Z., Zhou, L., Fan, X. & McCrimmon, R. J. (2010) Radix astragali (huangqi)
as a treatment for defective hypoglycemia counterregulation in diabetes, The
American journal of Chinese medicine. 38, 1027‐38.

165.

Chao, M., Zou, D., Zhang, Y., Chen, Y., Wang, M., Wu, H., Ning, G. & Wang, W.
(2009) Improving insulin resistance with traditional Chinese medicine in type 2
diabetic patients, Endocrine. 36, 268‐74.

166.

Hu, J., Pang, W., chen, J., Bai, S., Zheng, Z. & Wu, X. (2013) Hypoglycemic effect
of polysaccharides with different molecular weight of Pseudostellaria
heterophylla, BMC Complementary and Alternative Medicine. 13, 267.

167.

Zhao, T., Mao, G.‐h., Zhang, M., Li, F., Zou, Y., Zhou, Y., Zheng, W., Zheng, D.‐
h., Yang, L.‐q. & Wu, X.‐y. (2013) Anti‐diabetic effects of polysaccharides from
ethanol‐insoluble residue of Schisandra chinensis (Turcz.) Baill on alloxan‐
induced diabetic mice, Chemical Research in Chinese Universities. 29, 99‐102.

168.

Zhang, R., Zhou, J., Jia, Z., Zhang, Y. & Gu, G. (2004) Hypoglycemic effect of
Rehmannia glutinosa oligosaccharide in hyperglycemic and alloxan‐induced
diabetic rats and its mechanism, Journal of ethnopharmacology. 90, 39‐43.

169.

McCluskey, J. T., Hamid, M., Guo‐Parke, H., McClenaghan, N. H., Gomis, R. &
Flatt, P. R. (2011) Development and functional characterization of insulin‐
releasing human pancreatic beta cell lines produced by electrofusion, The Journal
of biological chemistry. 286, 21982‐92.

147

170.

Shen, S., Zhang, Y., Zhang, R. & Gong, X. (2013) Sarsasapogenin induces
apoptosis via the reactive oxygen species‐mediated mitochondrial pathway and
ER stress pathway in HeLa cells, Biochemical and biophysical research
communications. 441, 519‐24.

171.

Kang, Y. J., Chung, H. J., Nam, J. W., Park, H. J., Seo, E. K., Kim, Y. S., Lee, D. &
Lee, S. K. (2011) Cytotoxic and antineoplastic activity of timosaponin A‐III for
human colon cancer cells, J Nat Prod. 74, 701‐6.

172.

Huang, H. L., Chiang, W. L., Hsiao, P. C., Chien, M. H., Chen, H. Y., Weng, W.
C., Hsieh, M. J. & Yang, S. F. (2015) Timosaponin AIII mediates caspase
activation and induces apoptosis through JNK1/2 pathway in human
promyelocytic leukemia cells, Tumour biology : the journal of the International
Society for Oncodevelopmental Biology and Medicine. 36, 3489‐97.

173.

Sy, L. K., Yan, S. C., Lok, C. N., Man, R. Y. & Che, C. M. (2008) Timosaponin A‐III
induces autophagy preceding mitochondria‐mediated apoptosis in HeLa cancer
cells, Cancer Res. 68, 10229‐37.

174.

Hidalgo, M. (2010) Pancreatic cancer, The New England journal of medicine. 362,
1605‐17.

175.

Xu, Q., Zhang, T. P. & Zhao, Y. P. (2011) Advances in early diagnosis and
therapy of pancreatic cancer, Hepatobiliary & pancreatic diseases international :
HBPD INT. 10, 128‐35.

176.

Long, J., Zhang, Y., Yu, X., Yang, J., LeBrun, D. G., Chen, C., Yao, Q. & Li, M.
(2011) Overcoming drug resistance in pancreatic cancer, Expert opinion on
therapeutic targets. 15, 817‐28.

177.

Yachida, S. & Iacobuzio‐Donahue, C. A. (2013) Evolution and dynamics of
pancreatic cancer progression, Oncogene. 32, 5253‐60.

178.

Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y. & Greenberg, M. E.
(1997) Akt phosphorylation of BAD couples survival signals to the cell‐intrinsic
death machinery, Cell. 91, 231‐41.

179.

Sun, M., Wang, G., Paciga, J. E., Feldman, R. I., Yuan, Z. Q., Ma, X. L., Shelley, S.
A., Jove, R., Tsichlis, P. N., Nicosia, S. V. & Cheng, J. Q. (2001) AKT1/PKBalpha
kinase is frequently elevated in human cancers and its constitutive activation is
required for oncogenic transformation in NIH3T3 cells, Am J Pathol. 159, 431‐7.

148

180.

Hill, R., Calvopina, J. H., Kim, C., Wang, Y., Dawson, D. W., Donahue, T. R., Dry,
S. & Wu, H. (2010) PTEN loss accelerates KrasG12D‐induced pancreatic cancer
development, Cancer Res. 70, 7114‐24.

181.

Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M. & Hemmings, B. A. (1995)
Inhibition of glycogen synthase kinase‐3 by insulin mediated by protein kinase B,
Nature. 378, 785‐9.

182.

Iriana, S., Ahmed, S., Gong, J., Annamalai, A. A., Tuli, R. & Hendifar, A. E. (2016)
Targeting mTOR in Pancreatic Ductal Adenocarcinoma, Frontiers in Oncology. 6,
99.

183.

Cragg, G. M. & Newman, D. J. (2005) Plants as a source of anti‐cancer agents,
Journal of Ethnopharmacology. 100, 72‐79.

184.

Jung, O., Lee, J., Lee, Y. J., Yun, J. M., Son, Y. J., Cho, J. Y., Ryou, C. & Lee, S. Y.
(2016) Timosaponin AIII inhibits migration and invasion of A549 human non‐
small‐cell lung cancer cells via attenuations of MMP‐2 and MMP‐9 by inhibitions
of ERK1/2, Src/FAK and beta‐catenin signaling pathways, Bioorganic & medicinal
chemistry letters. 26, 3963‐7.

185.

Kawasaki, T. & Yamauchi, T. (1963) SAPONINS OF TIMO (ANEMARRHENAE
RHIZOMA). II. STRUCTURE OF TIMOSAPONIN A‐III, Chemical &
pharmaceutical bulletin. 11, 1221‐4.

186.

Kim, K. M., Im, A. R., Kim, S. H., Hyun, J. W. & Chae, S. (2016) Timosaponin AIII
inhibits melanoma cell migration by suppressing COX‐2 and in vivo tumor
metastasis, Cancer science. 107, 181‐8.

187.

Tsai, C. H., Yang, C. W., Wang, J. Y., Tsai, Y. F., Tseng, L. M., King, K. L., Chen,
W. S., Chiu, J. H. & Shyr, Y. M. (2013) Timosaponin AIII Suppresses Hepatocyte
Growth Factor‐Induced Invasive Activity through Sustained ERK Activation in
Breast Cancer MDA‐MB‐231 Cells, Evidence‐based complementary and alternative
medicine : eCAM. 2013, 421051.

188.

Ma, C., Wang, L., Tang, Y., Fan, M., Xiao, H. & Huang, C. (2008) Identification of
major xanthones and steroidal saponins in rat urine by liquid chromatography‐
atmospheric pressure chemical ionization mass spectrometry technology
following oral administration of Rhizoma Anemarrhenae decoction, Biomedical
chromatography : BMC. 22, 1066‐83.

149

189.

Fryer, R. A., Barlett, B., Galustian, C. & Dalgleish, A. G. (2011) Mechanisms
Underlying Gemcitabine Resistance in Pancreatic Cancer and Sensitisation by the
iMiD™ Lenalidomide, Anticancer research. 31, 3747‐3756.

190.

Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., Becouarn, Y.,
Adenis, A., Raoul, J. L., Gourgou‐Bourgade, S., de la Fouchardiere, C., Bennouna,
J., Bachet, J. B., Khemissa‐Akouz, F., Pere‐Verge, D., Delbaldo, C., Assenat, E.,
Chauffert, B., Michel, P., Montoto‐Grillot, C. & Ducreux, M. (2011) FOLFIRINOX
versus gemcitabine for metastatic pancreatic cancer, The New England journal of
medicine. 364, 1817‐25.

191.

Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M.,
Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., Harris, M., Reni, M., Dowden,
S., Laheru, D., Bahary, N., Ramanathan, R. K., Tabernero, J., Hidalgo, M.,
Goldstein, D., Van Cutsem, E., Wei, X., Iglesias, J. & Renschler, M. F. (2013)
Increased survival in pancreatic cancer with nab‐paclitaxel plus gemcitabine, The
New England journal of medicine. 369, 1691‐703.

192.

Calabrese, E. J. (2013) Hormetic mechanisms, Critical reviews in toxicology. 43, 580‐
606.

193.

Calabrese, E. J. (2014) Hormesis: a fundamental concept in biology, Microbial Cell.
1, 145‐149.

194.

Deer, E. L., Gonzalez‐Hernandez, J., Coursen, J. D., Shea, J. E., Ngatia, J., Scaife,
C. L., Firpo, M. A. & Mulvihill, S. J. (2010) Phenotype and genotype of pancreatic
cancer cell lines, Pancreas. 39, 425‐35.

195.

Bergman, A. M., Pinedo, H. M., Talianidis, I., Veerman, G., Loves, W. J. P., van
der Wilt, C. L. & Peters, G. J. (2003) Increased sensitivity to gemcitabine of P‐
glycoprotein and multidrug resistance‐associated protein‐overexpressing human
cancer cell lines, British Journal of Cancer. 88, 1963‐1970.

196.

Hagmann, W., Faissner, R., Schnolzer, M., Lohr, M. & Jesnowski, R. (2011)
Membrane Drug Transporters and Chemoresistance in Human Pancreatic
Carcinoma, Cancers. 3, 106‐125.

197.

Pullen, N. & Thomas, G. (1997) The modular phosphorylation and activation of
p70s6k, FEBS letters. 410, 78‐82.

198.

Zhang, Q., Bhojani, M. S., Ben‐Josef, E., Spalding, A. C., Kuick, R., Sun, Y. &
Morgan, M. A. (2013) Glycogen Synthase Kinase 3β in Pancreatic Cancer and its
150

Implications in Chemotherapy and Radiation Therapy, Journal of carcinogenesis &
mutagenesis. 4, 147.
199.

Zhang, J. S., Herreros‐Villanueva, M., Koenig, A., Deng, Z., de Narvajas, A. A.,
Gomez, T. S., Meng, X., Bujanda, L., Ellenrieder, V., Li, X. K., Kaufmann, S. H. &
Billadeau, D. D. (2014) Differential activity of GSK‐3 isoforms regulates NF‐
kappaB and TRAIL‐ or TNFalpha induced apoptosis in pancreatic cancer cells,
Cell death & disease. 5, e1142.

200.

Kopec, A. M., Rivera, P. D., Lacagnina, M. J., Hanamsagar, R. & Bilbo, S. D.
(2017) Optimized solubilization of TRIzol‐precipitated protein permits Western
blotting analysis to maximize data available from brain tissue, Journal of
neuroscience methods. 280, 64‐76.

201.

Yu, X. C., Miranda, M., Liu, Z., Patel, S., Nguyen, N., Carson, K., Liu, Q. &
Swaffield, J. C. (2010) Novel potent inhibitors of deoxycytidine kinase identified
and compared by multiple assays, Journal of biomolecular screening. 15, 72‐9.

151

APPENDIX I:
PERMISSIONS

All previously published work contained within this dissertation was included with
copyright permissions from the respective publishers. Use of previously published
work has been noted within the text. This Appendix contains the terms and conditions
of the license agreements for each previously published work.

The following license agreements and permissions are included:
Elsevier (Journal of Ethnopharmacology)
Springer Nature (Nature Reviews Cancer)
Wiley (FEBS Open Bio)
Elsevier (Journal of Clinical & Translational Endocrinology)

152

Copyright permission for Elsevier (Journal of Ethnopharmacology):
ELSEVIER LICENSE
TERMS AND CONDITIONS
Nov 09, 2018

This Agreement between USF ‐‐ Catherine MarElia ("You") and Elsevier ("Elsevier") consists of
your license details and the terms and conditions provided by Elsevier and Copyright Clearance
Center.
License Number

4446531252129

License date

Oct 12, 2018

Licensed Content Publisher

Elsevier

Licensed Content Publication

Journal of Ethnopharmacology

Licensed Content Title

The genus Anemarrhena Bunge: A review on
ethnopharmacology, phytochemistry and pharmacology

Licensed Content Author

Yingli Wang,Yang Dan,Dawei Yang,Yuli Hu,Le
Zhang,Chunhong Zhang,Hong Zhu,Zhanhu Cui,Minhui
Li,Yanze Liu

Licensed Content Date

Apr 11, 2014

Licensed Content Volume

153

Licensed Content Issue

1

Licensed Content Pages

19

Start Page

42

End Page

60

Type of Use

reuse in a thesis/dissertation

Portion

figures/tables/illustrations

Number of
figures/tables/illustrations

1

Format

both print and electronic

Are you the author of this Elsevier
article?

No

Will you be translating?

No

Original figure numbers

Figure 1

Title of your thesis/dissertation

Investigation of Anemarrhena asphodeloides and its
constituent TAIII as novel therapeutic agents for the
treatment of advanced pancreatic cancer

Publisher of new work

University of South Florida

153

Author of new work

Brant Burkhardt

Expected completion date

Oct 2018

Estimated size (number of pages)

1

Requestor Location

USF
4202 E. Fowler Avenue
TAMPA, FL 33620
United States
Attn: Catherine MarElia

Publisher Tax ID

98-0397604

Total

0.00 USD

Terms and Conditions

INTRODUCTION
1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in
connection with completing this licensing transaction, you agree that the following terms
and conditions apply to this transaction (along with the Billing and Payment terms and
conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you
opened your Rightslink account and that are available at any time
at http://myaccount.copyright.com).
GENERAL TERMS
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject
to the terms and conditions indicated.
3. Acknowledgement: If any part of the material to be used (for example, figures) has
appeared in our publication with credit or acknowledgement to another source, permission
must also be sought from that source. If such permission is not obtained then that material
may not be included in your publication/copies. Suitable acknowledgement to the source
must be made, either as a footnote or in a reference list at the end of your publication, as
follows:
"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of
chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE
SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The
Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with
permission from Elsevier."
4. Reproduction of this material is confined to the purpose and/or media for which
permission is hereby given.
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be
altered/adapted minimally to serve your work. Any other abbreviations, additions,
deletions and/or any other alterations shall be made only with prior written authorization
of Elsevier Ltd. (Please contact Elsevier at permissions@elsevier.com). No modifications
can be made to any Lancet figures/tables and they must be reproduced in full.
6. If the permission fee for the requested use of our material is waived in this instance,
please be advised that your future requests for Elsevier materials may attract a fee.
154

7. Reservation of Rights: Publisher reserves all rights not specifically granted in the
combination of (i) the license details provided by you and accepted in the course of this
licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment
terms and conditions.
8. License Contingent Upon Payment: While you may exercise the rights licensed
immediately upon issuance of the license at the end of the licensing process for the
transaction, provided that you have disclosed complete and accurate details of your
proposed use, no license is finally effective unless and until full payment is received from
you (either by publisher or by CCC) as provided in CCC's Billing and Payment terms and
conditions. If full payment is not received on a timely basis, then any license
preliminarily granted shall be deemed automatically revoked and shall be void as if never
granted. Further, in the event that you breach any of these terms and conditions or any of
CCC's Billing and Payment terms and conditions, the license is automatically revoked and
shall be void as if never granted. Use of materials as described in a revoked license, as
well as any use of the materials beyond the scope of an unrevoked license, may constitute
copyright infringement and publisher reserves the right to take any and all action to
protect its copyright in the materials.
9. Warranties: Publisher makes no representations or warranties with respect to the
licensed material.
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and
their respective officers, directors, employees and agents, from and against any and all
claims arising out of your use of the licensed material other than as specifically authorized
pursuant to this license.
11. No Transfer of License: This license is personal to you and may not be sublicensed,
assigned, or transferred by you to any other person without publisher's written permission.
12. No Amendment Except in Writing: This license may not be amended except in a
writing signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any
purchase order, acknowledgment, check endorsement or other writing prepared by you,
which terms are inconsistent with these terms and conditions or CCC's Billing and
Payment terms and conditions. These terms and conditions, together with CCC's Billing
and Payment terms and conditions (which are incorporated herein), comprise the entire
agreement between you and publisher (and CCC) concerning this licensing transaction. In
the event of any conflict between your obligations established by these terms and
conditions and those established by CCC's Billing and Payment terms and conditions,
these terms and conditions shall control.
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions
described in this License at their sole discretion, for any reason or no reason, with a full
refund payable to you. Notice of such denial will be made using the contact information
provided by you. Failure to receive such notice will not alter or invalidate the denial. In
no event will Elsevier or Copyright Clearance Center be responsible or liable for any
costs, expenses or damage incurred by you as a result of a denial of your permission

155

request, other than a refund of the amount(s) paid by you to Elsevier and/or Copyright
Clearance Center for denied permissions.
LIMITED LICENSE
The following terms and conditions apply only to specific license types:
15. Translation: This permission is granted for non-exclusive world English rights only
unless your license was granted for translation rights. If you licensed translation rights
you may only translate this content into the languages you requested. A professional
translator must perform all translations and reproduce the content word for word
preserving the integrity of the article.
16. Posting licensed content on any Website: The following terms and conditions apply
as follows: Licensing material from an Elsevier journal: All content posted to the web site
must maintain the copyright information line on the bottom of each image; A hyper-text
must be included to the Homepage of the journal from which you are licensing
at http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for
books at http://www.elsevier.com; Central Storage: This license does not include
permission for a scanned version of the material to be stored in a central repository such
as that provided by Heron/XanEdu.
Licensing material from an Elsevier book: A hyper-text link must be included to the
Elsevier homepage at http://www.elsevier.com . All content posted to the web site must
maintain the copyright information line on the bottom of each image.
Posting licensed content on Electronic reserve: In addition to the above the following
clauses are applicable: The web site must be password-protected and made available only
to bona fide students registered on a relevant course. This permission is granted for 1 year
only. You may obtain a new license for future website posting.
17. For journal authors: the following clauses are applicable in addition to the above:
Preprints:
A preprint is an author's own write-up of research results and analysis, it has not been
peer-reviewed, nor has it had any other value added to it by a publisher (such as
formatting, copyright, technical enhancement etc.).
Authors can share their preprints anywhere at any time. Preprints should not be added to
or enhanced in any way in order to appear more like, or to substitute for, the final versions
of articles however authors can update their preprints on arXiv or RePEc with their
Accepted Author Manuscript (see below).
If accepted for publication, we encourage authors to link from the preprint to their formal
publication via its DOI. Millions of researchers have access to the formal publications on
ScienceDirect, and so links will help users to find, access, cite and use the best available
version. Please note that Cell Press, The Lancet and some society-owned have different
preprint policies. Information on these policies is available on the journal homepage.
Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an
article that has been accepted for publication and which typically includes authorincorporated changes suggested during submission, peer review and editor-author
communications.
156

Authors can share their accepted author manuscript:




immediately
o via their non‐commercial person homepage or blog
o by updating a preprint in arXiv or RePEc with the accepted manuscript
o via their research institute or institutional repository for internal institutional
uses or as part of an invitation‐only research collaboration work‐group
o directly by providing copies to their students or to research collaborators for
their personal use
o for private scholarly sharing as part of an invitation‐only work group on
commercial sites with which Elsevier has an agreement
After the embargo period
o via non‐commercial hosting platforms such as their institutional repository
o via commercial sites with which Elsevier has an agreement

In all cases accepted manuscripts should:




link to the formal publication via its DOI
bear a CC‐BY‐NC‐ND license ‐ this is easy to do
if aggregated with other manuscripts, for example in a repository or other site, be shared
in alignment with our hosting policy not be added to or enhanced in any way to appear
more like, or to substitute for, the published journal article.

Published journal article (JPA): A published journal article (PJA) is the definitive final
record of published research that appears or will appear in the journal and embodies all
value-adding publishing activities including peer review co-ordination, copy-editing,
formatting, (if relevant) pagination and online enrichment.
Policies for sharing publishing journal articles differ for subscription and gold open access
articles:
Subscription Articles: If you are an author, please share a link to your article rather than
the full-text. Millions of researchers have access to the formal publications on
ScienceDirect, and so links will help your users to find, access, cite, and use the best
available version.
Theses and dissertations which contain embedded PJAs as part of the formal submission
can be posted publicly by the awarding institution with DOI links back to the formal
publications on ScienceDirect.
If you are affiliated with a library that subscribes to ScienceDirect you have additional
private sharing rights for others' research accessed under that agreement. This includes use
for classroom teaching and internal training at the institution (including use in course
packs and courseware programs), and inclusion of the article for grant funding purposes.
Gold Open Access Articles: May be shared according to the author-selected end-user
license and should contain a CrossMark logo, the end user license, and a DOI link to the
formal publication on ScienceDirect.
Please refer to Elsevier's posting policy for further information.

157

18. For book authors the following clauses are applicable in addition to the
above: Authors are permitted to place a brief summary of their work online only. You
are not allowed to download and post the published electronic version of your chapter, nor
may you scan the printed edition to create an electronic version. Posting to a
repository: Authors are permitted to post a summary of their chapter only in their
institution's repository.
19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may
be submitted to your institution in either print or electronic form. Should your thesis be
published commercially, please reapply for permission. These requirements include
permission for the Library and Archives of Canada to supply single copies, on demand, of
the complete thesis and include permission for Proquest/UMI to supply single copies, on
demand, of the complete thesis. Should your thesis be published commercially, please
reapply for permission. Theses and dissertations which contain embedded PJAs as part of
the formal submission can be posted publicly by the awarding institution with DOI links
back to the formal publications on ScienceDirect.
Elsevier Open Access Terms and Conditions
You can publish open access with Elsevier in hundreds of open access journals or in
nearly 2000 established subscription journals that support open access publishing.
Permitted third party re-use of these open access articles is defined by the author's choice
of Creative Commons user license. See our open access license policy for more
information.
Terms & Conditions applicable to all Open Access articles published with Elsevier:
Any reuse of the article must not represent the author as endorsing the adaptation of the
article nor should the article be modified in such a way as to damage the author's honour
or reputation. If any changes have been made, such changes must be clearly indicated.
The author(s) must be appropriately credited and we ask that you include the end user
license and a DOI link to the formal publication on ScienceDirect.
If any part of the material to be used (for example, figures) has appeared in our
publication with credit or acknowledgement to another source it is the responsibility of the
user to ensure their reuse complies with the terms and conditions determined by the rights
holder.
Additional Terms & Conditions applicable to each Creative Commons user license:
CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new
works from the Article, to alter and revise the Article and to make commercial use of the
Article (including reuse and/or resale of the Article by commercial entities), provided the
user gives appropriate credit (with a link to the formal publication through the relevant
DOI), provides a link to the license, indicates if changes were made and the licensor is not
represented as endorsing the use made of the work. The full details of the license are
available at http://creativecommons.org/licenses/by/4.0.
CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts,
abstracts and new works from the Article, to alter and revise the Article, provided this is
not done for commercial purposes, and that the user gives appropriate credit (with a link
158

to the formal publication through the relevant DOI), provides a link to the license,
indicates if changes were made and the licensor is not represented as endorsing the use
made of the work. Further, any new works must be made available on the same
conditions. The full details of the license are available
at http://creativecommons.org/licenses/by-nc-sa/4.0.
CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the
Article, provided this is not done for commercial purposes and further does not permit
distribution of the Article if it is changed or edited in any way, and provided the user
gives appropriate credit (with a link to the formal publication through the relevant DOI),
provides a link to the license, and that the licensor is not represented as endorsing the use
made of the work. The full details of the license are available
at http://creativecommons.org/licenses/by-nc-nd/4.0. Any commercial reuse of Open
Access articles published with a CC BY NC SA or CC BY NC ND license requires
permission from Elsevier and will be subject to a fee.
Commercial reuse includes:





Associating advertising with the full text of the Article
Charging fees for document delivery or access
Article aggregation
Systematic distribution via e‐mail lists or share buttons

Posting or linking by commercial companies for use by customers of those companies.
20. Other Conditions:
v1.9
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.

159

Copyright permission for Springer Nature (Nature Reviews Cancer):
SPRINGER NATURE LICENSE
TERMS AND CONDITIONS
Nov 09, 2018

This Agreement between USF ‐‐ Catherine MarElia ("You") and Springer Nature ("Springer Nature")
consists of your license details and the terms and conditions provided by Springer Nature and Copyright
Clearance Center.
License Number
4395940674044
License date
Jul 25, 2018
Licensed Content Publisher
Springer Nature
Licensed Content Publication
Nature Reviews Cancer
Licensed Content Title
KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma
Licensed Content Author
John P. Morris IV, Sam C. Wang, Matthias Hebrok
Licensed Content Date
Sep 3, 2010
Licensed Content Volume
10
Licensed Content Issue
10
Type of Use
Thesis/Dissertation
Requestor type
academic/university or research institute
Format
print and electronic
Portion
figures/tables/illustrations
Number of figures/tables/illustrations
1
High-res required
no
Will you be translating?
no
Circulation/distribution
<501
Author of this Springer Nature content
no
Title
Investigation of Anemarrhena asphodeloides and its constituent TAIII as novel therapeutic agents for
the treatment of advanced pancreatic cancer
Instructor name
Brant Burkhardt
Institution name

160

University of South Florida
Expected presentation date
Oct 2018
Portions
Figure 1
Requestor Location
USF
4202 E. Fowler Avenue
TAMPA, FL 33620
United States
Attn: Catherine MarElia
Billing Type
Invoice
Billing Address
USF
4202 E. Fowler Avenue
TAMPA, FL 33620
United States
Attn: Catherine MarElia
Total
0.00 USD
Terms and Conditions

Springer Nature Terms and Conditions for RightsLink Permissions
Springer Customer Service Centre GmbH (the Licensor) hereby grants you a non-exclusive,
world-wide licence to reproduce the material and for the purpose and requirements specified in
the attached copy of your order form, and for no other use, subject to the conditions below:
1.

The Licensor warrants that it has, to the best of its knowledge, the rights to license reuse of
this material. However, you should ensure that the material you are requesting is original to
the Licensor and does not carry the copyright of another entity (as credited in the published
version).
If the credit line on any part of the material you have requested indicates that it was reprinted
or adapted with permission from another source, then you should also seek permission from
that source to reuse the material.

2.

Where print only permission has been granted for a fee, separate permission must be
obtained for any additional electronic re-use.

3.

Permission granted free of charge for material in print is also usually granted for any
electronic version of that work, provided that the material is incidental to your work as a
whole and that the electronic version is essentially equivalent to, or substitutes for, the print
version.

4.

A licence for 'post on a website' is valid for 12 months from the licence date. This licence does
not cover use of full text articles on websites.

5.

Where 'reuse in a dissertation/thesis' has been selected the following terms apply: Print
rights for up to 100 copies, electronic rights for use only on a personal website or institutional
repository as defined by the Sherpa guideline (www.sherpa.ac.uk/romeo/).

6.

Permission granted for books and journals is granted for the lifetime of the first edition and
does not apply to second and subsequent editions (except where the first edition permission

161

was granted free of charge or for signatories to the STM Permissions Guidelines
http://www.stm-assoc.org/copyright-legal-affairs/permissions/permissions-guidelines/), and
does not apply for editions in other languages unless additional translation rights have been
granted separately in the licence.
7.

Rights for additional components such as custom editions and derivatives require additional
permission and may be subject to an additional fee. Please apply to
Journalpermissions@springernature.com/bookpermissions@springernature.com for these
rights.

8.

The Licensor's permission must be acknowledged next to the licensed material in print. In
electronic form, this acknowledgement must be visible at the same time as the
figures/tables/illustrations or abstract, and must be hyperlinked to the journal/book's
homepage. Our required acknowledgement format is in the Appendix below.

9.

Use of the material for incidental promotional use, minor editing privileges (this does not
include cropping, adapting, omitting material or any other changes that affect the meaning,
intention or moral rights of the author) and copies for the disabled are permitted under this
licence.

10. Minor adaptations of single figures (changes of format, colour and style) do not require the
Licensor's approval. However, the adaptation should be credited as shown in Appendix below.

Appendix — Acknowledgements:
For Journal Content:
Reprinted by permission from [the Licensor]: [Journal Publisher (e.g.
Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE CITATION(Article name, Author(s)
Name), [COPYRIGHT] (year of publication)
For Advance Online Publication papers:
Reprinted by permission from [the Licensor]: [Journal Publisher (e.g.
Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE CITATION(Article name, Author(s)
Name), [COPYRIGHT] (year of publication), advance online publication, day month year (doi:
10.1038/sj.[JOURNAL ACRONYM].)
For Adaptations/Translations:
Adapted/Translated by permission from [the Licensor]: [Journal Publisher (e.g.
Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE CITATION(Article name, Author(s)
Name), [COPYRIGHT] (year of publication)
Note: For any republication from the British Journal of Cancer, the following credit line style
applies:
Reprinted/adapted/translated by permission from [the Licensor]: on behalf of Cancer Research
UK: : [Journal Publisher (e.g. Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE
CITATION (Article name, Author(s) Name), [COPYRIGHT] (year of publication)
For Advance Online Publication papers:
Reprinted by permission from The [the Licensor]: on behalf of Cancer Research UK: [Journal
Publisher (e.g. Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE CITATION (Article

162

name, Author(s) Name), [COPYRIGHT] (year of publication), advance online publication, day
month year (doi: 10.1038/sj.[JOURNAL ACRONYM])
For Book content:
Reprinted/adapted by permission from [the Licensor]: [Book Publisher (e.g. Palgrave Macmillan,
Springer etc) [Book Title] by [Book author(s)] [COPYRIGHT] (year of publication)
Other Conditions:

Version 1.0
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1978-646-2777.

163

164

165

APPENDIX II:

CIRCULATING PANDER CONCENTRATION IS ASSOCIATED WITH
INCREASED HBA1C AND FASTING BLOOD GLUCOSE IN TYPE 2 DIABETIC
SUBJECTS
Note to Reader
This article was previously published in Journal of Clinical & Translational Endocrinology,
2018, 11: 26‐30, and has been reproduced with permission from Elsevier.

166

167

168

169

170

171

